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Abstract 
Here we have improved a semi-quantitative method (Petkune et al., J. Pharm. Pharmacol., 
2011, 63, 9, 1136) for low-level thermodynamically stable polymorph impurity determination 
in the metastable polymorph. Optimization of sample preparation methodology and conditions 
allowed to lower the detection limit down to 0.0005% of thermodynamically stable tegafur β 
polymorph in the metastable α polymorph. Solvent effect on sample preparation have been 
investigated and the nature of solvent and surface interaction have been characterized using 
data from solvent desorption studies. Solvent mediated phase transformations (SMPTs) from 
tegafur α form to β form and theophylline Form II and Form IV have been studied and 
characterized. It was determined that SMPT rate depend linearly on the supersaturation level, 
i.e. difference between equilibrium solubility of two polymorphs in the respective solvent. It was 
revealed that theophylline self-associates in solvents which are good H-bond donors and the 
presence of these aggregates hinder the nucleation and phase transformation. 
 
Polymorphism, Tegafur, Theophylline, Quantitative powder X-ray diffraction analysis, 
Solvent mediated phase transformation. 
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Introduction 
Manufacturing of the active pharmaceutical ingredients (API) requires the highest quality 
standards, due its impact on the life and health of humans. Therefore, a lot of resources are 
devoted to ensure the required quality of the drugs and improve the manufacturing process. 
The majority of small-molecule APIs are typically delivered in the solid dosage form. These 
pharmaceutical solids are often produced as molecular crystals because of their high physical 
and chemical stability and ease of processing. A crystalline drug may exist in more than one 
solid form. Such phenomenon is termed polymorphism, and it is defined as the ability of a 
substance to exist in more than one crystalline structure resulting from different arrangements 
and/or conformations of molecules in the crystal lattice [1]. A crystalline drug may exist also as 
a molecular adduct (drug and a guest component) – solvates, salts and co-crystals. Polymorphic 
forms are chemically identical, however they exhibit differences in properties of pharmaceutical 
interest, such as solubility, dissolution rate, bioavailability, tableting, etc. [2]. Therefore, one of 
the tasks for the pharmaceutical industry is to find and select the solid forms with the optimal 
characteristics for the intended use. Polymorphism is of great interest also in pigment and 
explosive manufacturing. Despite the extensive research in the field of polymorphism, there are 
a lot of unanswered questions concerning the polymorph prediction, polymorph stability 
landscape, formation causes and mechanisms. 
It is a common requirement in the pharmaceutical industry that a manufactured compound 
must be in one, strictly defined crystalline phase, therefore, crystalline phase screening is one of 
the first steps during the drug development. During this step the possibility to form different 
crystalline forms and their relative stability is evaluated. To ensure the stability of the 
commercial product, the thermodynamically stable polymorph in ambient conditions is 
normally chosen for manufacturing. However, due to enhanced dissolution or bioavailability 
profiles, a metastable form might be chosen for manufacturing. To ensure that polymorphs do 
not transform over time, the polymorphic stability must be evaluated with respect to ambient, 
storage, and packaging conditions. [3–5] 
Crystallization of APIs is governed by a combination of thermodynamic and kinetic factors 
[3–6], and it often follows Ostwald’s rule of stages [7], which postulates that crystallization in a 
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polymorphic system progresses from supersaturated state to equilibrium state in stages. Thus, 
according to Ostwald’s rule of stages, the metastable form should crystallize first and then the 
system should move through each possible polymorphic structure before the 
thermodynamically stable polymorph crystallizes. In the majority of cases the 
thermodynamically stable polymorph in given conditions is isolated, however, the solvent used 
for crystallization can affect the crystallization outcome and it might promote the crystallization 
of a specific metastable polymorph. The metastable polymorph will attempt to transform to the 
stable form if possible, and therefore it is important to study polymorphic transformation 
‘reactions’ to determine the factors influencing the outcome of a polymorphic crystallization. 
One type of polymorphic transformation ‘reaction’ drawing attention is solvent mediated 
polymorphic transformation (SMPT) [4,8–10]. This is a process, where the metastable 
polymorph interacts with a bulk solvent phase, and gradually transforms to the more stable 
polymorph by a process of dissolution and crystallization. SMPTs might be useful for 
pharmaceutical industry to produce the thermodynamically stable polymorph if crystallization 
from a solvent gives a metastable polymorph. On the other hand, if a metastable polymorph is 
desired, knowledge of possible SMPTs of the respective system is important, because there 
might be situations when metastable polymorph crystallizes, and through unwanted SMPT 
subsequently transforms to the thermodynamically stable polymorph. 
The aim of this research was to investigate the solvent mediated phase transformations 
(SMPT) in polymorphic systems, and evaluate the potential of SMPT applicability in low-level 
polymorphic impurity quantification. 
Following tasks were set to address this issue: 
1. improve our previously proposed (Petkune et al., J. Pharm. Pharmacol., 2011, 63, 9, 1136) 
method for low-level (less than 1%) thermodynamically stable polymorph impurity 
quantification in a mixture with metastable polymorphic form and evaluate the sample 
preparation conditions effect on the phase quantification; 
2. evaluate the solvent effect on the mechanochemical and classical SMPT of the metastable α 
tegafur to the thermodynamically stable β tegafur; 
3. examine the nature of solvent vapour and tegafur surface interaction; 
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4. apply the knowledge acquired from tegafur α to β SMPT, to determine why 
thermodynamically stable theophylline Form IV can be obtained only by solvent mediated 
transformation in specific solvents, and to find out whether solution prenucleation 
aggregates affect the crystallization result in the case of theophylline. 
Scientific novelty 
1. Parameters affecting semi-quantitative method of low-level (down to 0.0005%) 
thermodynamically stable polymorph impurity determination in the metastable polymorph 
have been evaluated. 
2. It has been shown that phase transition dynamics of α tegafur to β tegafur are in good 
agreement in all SMPTs studied here: solvent drop milling (mechanochemical SMPT), 
classical SMPT, and in samples, that were exposed to 95% solvent relative vapour pressure 
(“solvent vapour mediated phase transformation”). 
3. Solvent desorption from two tegafur polymorphs have been characterized. 
4. The SMPTs from α tegafur to β tegafur and from theophylline Form II to Form IV have been 
examined in detail. The kinetics, phase nucleation and growth aspects of these phase 
transformations have been described. 
5. It has been determined that SMPT rate depend linearly on the supersaturation level, i.e. 
difference between equilibrium solubilities of thermodynamically stable and metastable 
polymorph in the respective solvent. 
6. The correlation between theophylline prenucleation aggregates in the solution and SMPT 
rate and outcome have been established. 
Practical significance 
1. The method, allowing to quantify down to 0.0005% of the thermodynamically stable form in 
bulk metastable form sample, have been proposed. This method has been successfully 
applied in the industrial manufacturing. 
2. The contribution of several parameters in solvent drop milling have been characterized. 
3. The parameters of theophylline Form IV preparation throughout SMPT have been 
established. 
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1. Literature review 
1.1. Polymorphism 
Polymorphism is a well-known phenomenon, which is defined as ability of a compound to 
crystallize into more than one crystalline form that differs with molecule packing arrangements 
and/or conformations within the crystal lattice. The different resulting structures are called 
forms, polymorphs, phases or modifications [1,11]. About two-thirds of organic compounds 
and about 80% of active pharmaceutical ingredients under certain conditions can exist in more 
than one polymorphic form [3,5]. Differences in molecule conformation and/or packing in 
polymorphs results in different physical and physicochemical properties – thermodynamic 
stability, solubility, dissolution rate, melting and sublimation temperatures, etc. [1,3–6,11–15]. 
Polymorphism in elements, such as diamond and graphite forms of carbon, is usually termed 
allotropy [3]. 
Polymorphism can be divided in two groups – packing and conformation polymorphism 
[16,17]. Rigid molecules, without the capability of changing conformation, can give alternative 
crystal structures only by different molecule relative orientation or packing. This is called 
packing polymorphism. Conformational polymorphs, in addition to packing differences, can 
have significant differences between the conformations of the molecules in the polymorphs 
[18,19]. Molecule arrangement and conformation in crystalline solid depend on intramolecular 
and intermolecular interaction, like hydrogen bonging, van der Waals interactions, π-π 
interactions and some other weaker forces [20–26]. 
Term crystalline forms is wider than polymorphism and includes also non-crystalline 
(amorphous) forms of the same compound and solid phases where parent molecule forms a 
crystalline molecular adduct with another molecular species – solvates and co-crystals [3,5,11] 
(see Figure 1.1.). Amorphous forms differ from crystalline forms by the degree of order in solid 
phase. While crystalline forms have long range order, amorphous forms can have only short 
range periodicity and molecule arrangement is disordered [27–29]. Solvates are defined as a 
molecular adducts where solvent molecules are included in to the crystalline structure besides 
host molecules. There is no strict distinction between co-crystals and solvates, but the main 
difference here is that co-crystal forming host molecule is solid in normal conditions [30–36]. 
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Figure 1.1. Classification of solid materials (adapted from [14]) 
1.1.1. Thermodynamics of polymorphs 
Each solid phase has certain relative stability which is defined by the free energy difference - 
∆G [1,3,5]. Only one crystalline phase is thermodynamically stable at a given conditions (with 
the exception of transition points), and all the rest phases are thermodynamically unstable. 
Term metastable phase is used to describe solid phase which can exist outside its 
thermodynamic stability region, and phase transition to thermodynamically stable polymorph 
do no occur or it is very slow. The relative stability is described with Equation 1.1: 
 ∆  = ∆  −  ∆  1.1, 
where enthalpy difference, ∆H, is the lattice energy difference between two solid phases 
resulting from different intermolecular interactions in each polymorph; and entropy difference, 
∆S, arise from different lattice vibrations and structural disorder in the polymorphs. Schematic 
polymorphic system free energy, entropy and enthalpy changes depending on temperature are 
shown in Figure 1.2.A. Over the temperature range in which polymorph can exist, the enthalpy 
of the crystal increases with the rising temperature due to molar volume increase and 
intermolecular interaction weakening. The entropy, initially zero at 0 K for ideal crystal, 
increases due to the increasing population of higher energy levels of lattice vibrations. These 
thermodynamic parameters are different among the various polymorphs at a given temperature 
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(see Figure 1.2.B). Since polymorph free energy dependence on temperature differ from one 
polymorph to another, at some temperature respective polymorph free energy curves cross and 
two polymorphs have equal free energy – they are in equilibrium. This temperature is referred 
as a phase equilibrium temperature. Under the equilibrium temperature polymorphic form I is 
thermodynamically stable (Gform II > G form I), whereas above this point polymorphic form II has 
the lower free energy and is therefore more stable (G form II < G form I). At a given condition only 
one polymorphic form can be thermodynamically stable, and all other polymorphs must be 
thermodynamically unstable. Thermodynamics of polymorphic system shows the relative 
stabilities of polymorphs, but does not indicate anything about phase transition rate. 
 
Figure 1.2. A) Variation in enthalpy, free energy, entropy and term TS with temperature for a 
crystalline phase; B) variation in enthalpy (H) and free energy (G) with temperature for two 
polymorphic forms (adapted from [3]). 
1.1.2. Enantiotropy and monotropy 
As mentioned above, there is an equilibrium point at which two polymorphs have equal 
thermodynamical stability. If this equilibrium point is below the melting point of both 
polymorphs, i.e. each of the polymorphs has a temperature range in which it is stable with 
respect to the other polymorph, the two forms are said to be enantiotropically related. 
Variations in free energy with temperature in enantiotropically related system are given in 
Figure 1.3.A. Form I is thermodynamically stable below equilibrium temperature, whereas form 
II is thermodynamically stable in the temperature region from equilibrium temperature up to 
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melting temperature. If one polymorph is thermodynamically stable with respect to the other 
polymorph in all temperature region below their melting points, the two forms are said to be 
monotropically related. Other polymorph in this case is thermodynamically unstable in all 
temperature-pressure region. Figure 1.3.B illustrates free energy variations in monotropically 
related polymorphs, where form I has the lowest free energy in all temperature region below 
melting temperature. In monotropically related system polymorph equilibrium temperature is 
above melting temperature. 
Isolation of specific polymorphic form requires control over the isolation conditions. The 
isolation of polymorph from enantiotropic system is relatively easy, because it is possible to 
identify and use the conditions at which one polymorph or the other is thermodynamically 
stable and will crystallize. The isolation of the thermodynamically stable polymorph in a 
monotropic system can usually be achieved without great difficulty. Isolation of the unstable 
form, however, requires conditions where desired polymorph is characterized as being most 
metastable. 
The polymorphic systems studied in this work – α and β tegafur; and theophylline Form II 
and Form IV – are enantiotropically related. 
 
Figure 1.3. Variations in enthalpy (H) and free energy (G) with temperature in: A) enantiotropically 
related polymorphs; and B) monotropically related polymorphs (adapted from [3]). 
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1.2. Crystallization 
Crystallization is the most common method of chemical compound isolation from solution, 
and it is governed by a combination of thermodynamic and kinetic factors. It is also the most 
popular method for polymorph isolation, where different polymorphs are obtained by varying 
crystallization methods and conditions. Crystallization method typically used in 
pharmaceutical industry is crystallization from solution (single solvent or solvent mixture), 
using different experimental conditions, such as temperature, initial supersaturation, rate of 
desupersaturation, and rate of agitation. Other methods occasionally used in polymorphic 
crystallizations are crystallization from melt, sublimation, suspendation, etc. [37–41] 
Crystallization from solution is a multi-step process, which includes nucleation, crystal 
growth and Ostwald’s ripening [40–44]. Nucleation and crystal growth are the steps which 
determine the polymorph that will crystallize (discussed further in Section 1.2.1), whereas 
Ostwald’s ripening is a process when crystals tended to achieve minimum total surface energy 
by reducing crystal surface area [37]. This is achieved by dissolution of smallest particles 
(because of higher surface energy) and subsequent dissolved material crystallization on the 
surface of largest particles. Eventually, such crystal agitation should lead to monosized spherical 
particles. 
Crystallization of polymorphs often follows Ostwald’s rule of stages [7], which postulates 
that crystallization in a polymorphic system progresses from supersaturated state to 
equilibrium state in stages. Thus, according to Ostwald’s rule of stages, the metastable form 
should crystallize first and then the system should move through each possible polymorphic 
structure before the thermodynamically stable polymorph crystallizes. In the majority of cases 
the thermodynamically stable polymorph in given conditions is isolated, however, solvent used 
for crystallization can affect the crystallization outcome and it might promote the crystallization 
of a specific metastable polymorph. 
1.2.1. Nucleation and crystal growth 
Crystallization from solution requires supersaturation to initiate crystal formation and 
continue crystal growth. Supersaturation is defined as the ratio of the actual solute 
concentration to the solubility of solute, and it is one of the most important factors affecting 
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crystallization, because it provides the driving force to overcome nucleation activation energy 
and provides molecule transport to nucleation site [43,45–49]. A supersaturated solution is 
thermodynamically unstable and eventually undergoes phase separation process where solute 
molecules self-associates into clusters and can act as centres of crystallization. These molecular 
clusters increase their size by molecule addition and eventually results in nuclei and further in 
crystallites. Classical nucleation theory assumes that the viability of pre-nucleation molecular 
clusters with mean radius r depends on attainment of the critical cluster size (with mean radius 
rc). Critical cluster or critical nuclei is the smallest molecular aggregate capable of independent 
existence in the supersaturated solution. Critical nuclei are too small to be observed directly, 
and therefore their structure is not known, but Mullin have proposed [37] that the structure of 
a critical nucleus could be anything from a diffuse molecule agglomerates to a perfect miniature 
crystal. Term cluster is used to describe thermodynamically unstable molecular aggregates with 
radius (r) lower than critical radius (rc), whereas term nuclei represents thermodynamically 
stable molecular aggregates with r>rc. 
Nucleation in the solution can be either homogenous, where nuclei are forming 
spontaneously in the bulk solution, or heterogeneous, where crystal nucleation is induced by 
the surfaces, interfaces, or by foreign particles. Homogeneous nucleation virtually does not 
occur, because nucleation activation energy in the bulk is higher than activation energy at the 
surface. Therefore, nuclei form heterogeneously at the nucleation sites where activation energy 
is lower – on the surfaces and interfaces. One special case in nuclei formation is seeding, where 
crystals of the solute are already present or are deliberately added to the solution. Added parent 
crystals catalyse the nucleation in the supersaturated solution and therefore nucleation can 
proceed at lower supersaturation levels than required for homogeneous nucleation. 
[39,41,48,50,51] 
Reduction in free energy is the thermodynamic driving force for both heterogeneous and 
homogeneous nucleation [52–55]. The total free energy of molecule cluster (∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵅ�) is the sum 
of a cluster volume free energy (∆ᵀ�ᵀ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�) that favours molecule aggregation and a cluster 
surface free energy (∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵀ�ᵀ�ᵀ�) that favours the dissolution of molecular cluster: 
 ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵅ� = ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵀ�ᵀ�ᵀ� + ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ� = 4ᵪ�ᵅ�2ᵪ� +  
−4ᵪ�3ᵅ�ᵀ� ln ᵪ�
3ᵪ�  
 1.2, 
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 ᵀ�ᵀ� =  
16ᵪ�ᵪ�2
3(ᵅ�ᵀ� ln ᵪ�)2 
 1.3, 
where r is the mean radius of the cluster, k is Boltzmann’s constant, T is absolute temperature, 
γ is the interfacial free energy between the nucleus and the supersaturated solution, σ is the 
supersaturation ratio, v is the molecular volume, and Δᵀ�ᵀ�∗  is the free energy barrier to 
nucleation. Nucleation free energy barrier, Δᵀ�ᵀ�∗, can be used to calculate nucleation rate: 
 
ᵀ� = ᵀ�ᵀ� 
−Δᵀ�ᵀ�∗
ᵅ�ᵀ�   = ᵀ�ᵀ� 
−16ᵪ�3ᵪ�2
3ᵅ�3ᵀ� 3(ln ᵪ�)2  
1.4, 
where A is the pre-exponential factor. Interfacial free energy between the nucleus and the 
supersaturated solution, γ, can be calculated by Mersmann equation: 
 ᵪ� = 0.414ᵅ�ᵀ�  ᵀ�ᵀ�ᵀ�ᵀ� 
2 3⁄ ln  
ᵀ�ᵀ�
ᵀ�∗ 
 1.5, 
where cs is the molar density of the polymorph, c* is the solute concentration, and NA is 
Avogadro’s number. 
The ratio of cluster volume and surface free energy terms in Equation 1.2 define weather 
cluster will grow into nuclei and larger crystals or dissolve back in the solution phase. During 
the initial cluster formation, when r < rc, cluster surface free energy, ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵀ�ᵀ�ᵀ�, is larger than 
cluster volume free energy, ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ� , and cluster is thermodynamically unstable – it has a 
tendency to dissolve. Cluster growth is promoted by supersaturation which provides the 
necessary driving force to overcome the disruptive surface free energy ∆ᵀ�ᵀ�ᵅ�ᵅ�ᵀ�ᵀ�ᵀ�ᵀ�. Eventually, 
the cluster size increases and critical nuclei size is reached (r=rc) at which the surface and 
volume terms are equal and total free energy of the cluster are maximal (see Figure 1.4.A). This 
energy corresponds to nucleation activation energy and molecular aggregate at this point is 
termed critical nuclei or critical cluster. After this stage, when r > rc, cluster becomes viable and 
can be considered as nucleus that eventually grows into a crystal. If cluster does not reach rc it 
dissolves and does not yield a crystal. [5,16] 
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Figure 1.4. A) Cluster free energy change during molecular aggregation depending on cluster/nuclei 
radius; B) Free energy change during polymorph I and II nucleation (adapted from [5]). 
In a solution of polymorphic system (consisting of two polymorphs – thermodynamically 
stable form I and thermodynamically unstable form II) molecular clusters of both polymorphs 
are competing for solute molecules during nucleation [56], and concentration of respective 
nuclei in solution is determined by their free energy. The polymorph with lower free energy 
barrier will crystallize first, thermodynamically unstable form II in this case, because Δᵀ�ᵀ�,ᵀ�ᵀ�
∗ <
Δᵀ�ᵀ�,ᵀ�
∗  (see Figure 1.4.B). Thermodynamically unstable form II grows first because cluster 
formation free energy is lower for this polymorph, however, thermodynamically stable 
polymorph crystallize because formation of this polymorph is energetically favourable. The 
nature of polymorph that eventually crystallizes is determined by the relative nucleation and 
crystal growth rates in respective polymorphic system, however, in most cases nucleation is the 
key step that determines polymorph that crystallizes. Schematic crystallization process of two 
competitive polymorphs is given in Figure 1.5. 
 
Figure 1.5. Schematic representation of two competitive polymorph crystallization (adapted from 
[5]). 
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1.3. Spectroscopic self-association studies 
The information about the prenucleation aggregates are essential to understand the process 
of crystal nucleation and enlighten us on selective polymorph crystallization from specific 
solvents. Furthermore, Hunter et al. [57–59] and Davey et al. [60,61] have showed that there is 
a direct correlation between supramolecular aggregates structure in solution and the solid state 
structure. However, the main obstacle for prenucleation aggregate studies are the fact that there 
are only few methods suitable for such task. The techniques successfully used to study crystal 
emergence in diluted solutions, supersaturated solutions and melts are small angle and wide 
angle X-ray scattering, Raman spectroscopy, mass spectrometry and solution NMR [62–67]. 
Here we used 1H NMR spectroscopy to investigate solution aggregation processes, therefore 
this approach will be discussed in detail.  
NMR spectroscopy is mainly used as a method for organic compound identification and 
characterization; however NMR methods have been demonstrated to be useful for the study of 
molecular aggregation and self-association in solution. The first attempts to use NMR 
spectrometry to examine self-association were more than half century ago [68–70]. Becker et al. 
and Huggins at al. studied the hydrogen bonding in alcohols and phenols. 1H chemical shifts of 
alcohol and phenol hydroxyl group protons were measured over a wide concentration range 
and variation of 1H chemical shifts with concentration was consistent with expectations for a 
system consisting of monomers, dimers, and higher polymers. 
It is possible to use solution NMR measurements to study molecular association because 1H 
chemical shifts are sensitive to changes in the local environment. Hydrogen bonding between 
solute molecules and associate formation affects 1H local environment and a result of this 
interaction is a chemical shift displacement in the NMR spectrum. 
It is generally recognized that dimer and other associate formation and their concentration 
are affected by solution concentration – the more concentrated the solution, the more dimers 
and other associates are present. In order to obtain information about self-association in the 
solution, the dependence of 1H chemical shifts on concentration is analysed. Self-association 
studies of adenosine 5’-triphosphate (ATP) [71]; caffeine [72]; adriamycin and daunomycin 
[73]; chloroquine [74]; actinomycin D [75]; proflavine, Acridine Orange, ethidium bromide, 
actinomycin D [76]; flavin mononucleotide [77]; acridine homodimer and its complex with 
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ethidium bromide [78] and vanillin [79] are a few examples of such an approach. This effect 
also has been used to determine self-association constants, enthalpy and entropy of 
dimerization [72,73,78,80]. 
Most of the previous studies show a decrease in the 1H chemical shifts with concentration 
increase, suggesting that the analysed compounds are involved in self-association processes. 
The reason why 1H chemical shifts are displaced to the lower field for self-associated 
compounds can be explained by the hydrogen bond forming proton deshielding. Upon 
association the hydroxyl group O–H bond (or any other association involved bond) weakens 
and the bond length increases [81–84]. This produces a decrease in the O–H stretching 
frequency and a large deshielding of the O–H proton, resulting in a 1H chemical shift 
displacement to lower field [85]. Hence, the larger the fraction of associated molecules in the 
solution, the more 1H chemical shifts of hydrogen involved in the association will shift to the 
lower fields. There is no clear consistency in the chemical shift displacement upon self-
association in previously mentioned studies and it varies from compound to compound. For 
example: Lam and Kotowycz [71] indicated that the 1H chemical shift displacement with 
concentration changes had a sigmoidal nature for three proton chemical shifts; Abraham and 
Mobli [84] and Bogdan et al. [79] have reported almost linear 1H chemical shift displacement 
upon concentration change; however, in most cases, exponential 1H chemical shift 
displacement upon self-association has been observed. 
In recent years, 1H NMR chemical shift displacement measurements have been used to 
provide information on the structure of prenucleation aggregates in the solution [86]. It is 
possible because the dimer formation and aggregation in solution are the first stages of 
crystallisation and therefore the structure of the supramolecular aggregate, which is formed in 
solution, influences the solid state structure obtained on crystallization [58]. Hunter et al. 
[59,87] showed that the predictions from concentration-dependent changes in 1H NMR 
chemical shifts agreed with the structures of dimers found in the corresponding X-ray crystal 
structures (see Figure 1.6.). The same approach has been successfully used to study ligand 
binding [57,88] and cocrystallization [60]. 
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Figure 1.6. A) Carbamazepine dimer structures in CD3OH and CDCl3 calculated using SHIFTY 
[86]. One molecule of the dimer is overlaid in a fixed position (green) and the positions of the second 
molecule in different structures generated by SHIFTY are shown in violet. B) Comparison of dimer 
motifs found in the X-ray crystal structure of carbamazepine form III (grey molecule) with dimer 
motifs in the solution calculated by SHIFTY (red molecule) (adapted from [59]). 
Other magnetically active nuclei (13C, 15N and others) involved in hydrogen bonding or 
aromatic stacking also show displacement in chemical shifts upon concentration changes. 13C 
NMR spectroscopy has been used to study hydrogen-bonded complexes of pyrimidines and 
purines [89]; self-association of retinoic acid [90]; aromatic stacking interactions of 
supramolecular zipper complexes [91] and to study fundamental aspects of the crystallization 
of glycine [92]. Lam and Kotowycz [71] have used 31P NMR spectroscopy to study adenosine 
5’-triphosphate (ATP) self-association. 
There are several limitations for self-association studies using NMR method. 1H NMR shifts 
only for nonexchangeable hydrogens can be measured. If the proton, involved in the self-
association, easily and completely exchanges with solvent deuterium atoms, no chemical shifts 
of this proton can be measured, as the deuterium atom replacing the proton is not magnetically 
active. However, if the solution concentrations are high and complete deuteration does not 
occur, then 1H NMR shift of exchangeable proton can be observed and measured. Hughes et al. 
[92] have mentioned that the resultant level of deuteration for the exchangeable hydrogens in 
the glycine and D2O system ranged from 91.2% for the 3.6 M solution to 99.9% for the 0.05 M 
solution. It was also observed that the level of deuteration was found to have no significant effect 
on the NMR spectrum. Another limitation is that the NMR method has a limited sensitivity at 
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the low concentrations often necessary for initial self-association studies. This problem cannot 
be solved, therefore other complementary methods, like UV spectrometry are used for self-
association studies. 
It has been reported [93] that compound hydrogen bound association have an effect on the 
UV absorption spectrum and it is possible to use this effect to study molecular association as 
well as self-association [94–96]. The self-association studies by UV spectroscopy use the same 
approach that NMR studies – UV spectra are measured over the concentration range. The 
method is based on the detection of deviation from the Beer-Lambert law with concentration 
changes [94–100]. The variation of apparent molar absorption coefficient as a function of 
concentration can be used to calculate the self-association constants, with the assumption that 
the detected hyperchromic and hypochromic effects result exclusively from the self-association 
of the studied compounds [96]. 
1.4. Solid state reactions and polymorphic transformations 
The most stable phase in given conditions is defined by polymorphic system 
thermodynamics, whereas phase transformations rate from one phase to another is affected by 
kinetic assumptions. Kinetics and thermodynamics of chemical reactions were developed for 
homogeneous systems, where all of the components involved in the reactions are in liquid or 
gaseous state and molecules are evenly distributed in a reaction volume. The homogeneous 
reactions usually occur between freely moving, identical reactant molecules with random 
collisional encounters that are usually unaffected by product formation. 
Solid-state reactions studied here, however, are heterogeneous, and homogeneous reaction 
principles cannot be applied directly. Rate laws describing heterogeneous solid-state reactions 
are more complex than those in homogenous phases, and therefore universal kinetic model that 
could describe most of the solid-state reactions properly is still not developed [101]. 
Technically, polymorphic phase transformations are not solid-state reactions, because no 
chemical bonds are braked or formed, however, solid-state models are used to describe these 
transformations as well, because crystal structure and hydrogen bonding network change 
during polymorphic transformation [102,103]. Kinetic assumptions described in this section 
applies to both – chemical solid-state reaction and polymorphic transformations. 
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1.4.1. General aspects of solid-state reactions 
Reaction rate in classical homogeneous kinetics is expressed as concentration change 
throughout reaction. For first order reaction 
 ᵀ� → ᵀ� 1.6 
reaction rate (v) is defined as 
 ᵪ� = ᵀ�[ᵀ�]
ᵀ�ᵅ�
= − ᵀ�[ᵀ�]
ᵀ�ᵅ�
= ᵅ�[ᵀ�] 1.7, 
where k is first-order reaction constant. If the rate constant k follows Arrhenius behaviour, we 
can write that 
 ᵅ� = ᵀ�ᵀ�−ᵀ�ᵀ� ᵀ�ᵀ�⁄  1.8, 
where A is the pre-exponential factor, Ea is the activation energy, and T is the temperature (K). 
Equation 1.8 describes reaction which has one transition state, however, this is not necessarily 
the case for reactions in solids and polymorphic transformations, because there is no bond 
breaking or formation like in homogeneous reaction. The activation energy for reactions in 
solid-state cannot be interpreted in terms of bond breaking and bond making, therefore 
activation energy for reactions in solid-state are related to the solid phase nucleation, diffusion 
or advance of the product phase, or some other process that may be of a physical nature. Because 
of this, solid-state kinetic reactions and polymorphic transformations are mechanistically 
classified according to reaction limiting step as: nucleation, geometrical contraction, diffusion, 
and reaction order models (see section 1.4.2). [101] 
Term concentration, generally used in homogeneous reactions, is not applicable (it does not 
have any physical meaning) in heterogeneous reactions, because reactions take place on the 
phase contact zone and crystal defects. Therefore reaction rate in solid-state reactions are 
expressed by the fraction of the sample reacted, α, which show what part of starting material 
have transformed to reaction product. The degree of conversion, α, changes from 0 to 1. The 
rate of the reaction may be expressed as dα/dt, and the reaction has gone to completion when 
α=1. Very often weight fraction of starting material or reaction product, w, is also used to 
describe conversion rate. Thickness of the product layer, weight of product, or moles of product 
can be used as well. Solid-state reaction progress throughout phase transformation (kinetic 
curve) usually is plotted in coordinates α-time (Figure 1.7.). [101,103] 
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Figure 1.7. Schematic kinetic curve of solid-state reaction (adapted from [5]). 
The region A in the kinetic curve represents small mass loss, associated with the removal of 
adsorbed gases from the sample. This step is not always observed. Following region B represents 
an induction period where reaction/phase transformation rate is beginning to accelerate. 
Induction time is associated with critical nuclei size reaching time and/or sample heat up. 
Region C represents part of kinetic curve where solid-state reaction/phase transformation is 
progressing at the maximum rate. For most reactions in homogenous phase the initial reaction 
rate is also the maximum rate, because reactant concentration in highest at the beginning of 
reaction, however, heterogeneous solid-state reactions reaches maximal rate eventually. This is 
because solid-state reactions starts in few energetically favoured points – nucleation sites, they 
spreads over the time, thereafter accelerating the reaction. The final part of kinetic curve is 
region D where reaction is starting to slow down as the reaction approaches completion. 
1.4.2. Solid-state kinetic models 
Solid-state kinetic models are theoretical, mathematical descriptions of experimental data 
and usually are expressed as rate equations. Many solid-state kinetics models have been 
developed based on certain mechanistic assumptions, while other models are more empirical 
and may have little mechanistic meaning. Models currently used in solid-state kinetic studies 
are classified according to their rate limiting mechanistic features, such as nucleation, 
geometrical contraction, diffusion, and reaction order. [104] 
Nucleation models. The limiting step in this case is nucleation of resultant phase into the 
starting material. Nucleation occur in nucleation sites, where reaction activation energy is 
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minimized, but when nuclei of resultant phase have formed, phase transformation continues to 
grow with constant speed (weight fraction of resultant phase increases proportionally to surface 
area). 
Geometrical Contraction models. In this case it is assumed that nucleation occurs rapidly on 
the surface of the crystal. The rate of transition is controlled by the resulting reaction interface 
progress toward the centre of the crystal. This means that, transformation rate depends on 
crystal shape. 
Diffusion models. In contrast to homogeneous reactions, where reactant molecules are 
usually readily available to one another, solid-state reactions often occur between crystal lattices 
where molecules that must permeate into lattices are restricted and may depend on lattice 
defects. If reaction rate is controlled by the movement of the reactants to or products from the 
reaction interface, solid-state transformation is called to be diffusion controlled. 
Order-Based models. These models are the simplest models as they are similar to those used 
in homogeneous kinetics. Here reaction order is proportional to resultant phase concentration 
raised to a particular power which is the reaction order. Order-based models are derived from 
the equation 
 ᵀ�ᵪ�
ᵀ�ᵅ�
= ᵅ�(1 − ᵪ�)ᵅ� 1.9, 
where dα/dt is the rate of reaction, k is the rate constant, and n is the reaction order. 
The kinetic models commonly used to describe phase transformations and reactions are 
summarized in Appendix 1. 
1.4.3. Classical monomolecular reaction kinetics 
No induction time has been observed in polymorphic transformation studied, between α and 
β tegafur [105], and its phase transformation kinetic behaviour coincide with classical kinetic 
model. Therefore, let’s take a look at classical monomolecular reaction kinetics as well. 
If reaction follows first order, reaction rate can be expressed through reactant weight fraction 
change over the time dα/dt. If the amount of reactant is represented by its weight (m), then rate 
law is 
 − ᵀ�ᵅ�
ᵀ�ᵅ�
= ᵅ�ᵅ� 1.10. 
Integrated rate law is 
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 ln
ᵅ�0
ᵅ�
= ᵅ�ᵅ� 1.11, 
where m0 represents the weight of reactant at the beginning of reaction. Conversion degree or 
fraction reacted (α) is calculated as 
 ᵅ�0 − ᵅ�
ᵅ�0
= 1 − ᵅ�
ᵅ�0
= ᵪ� 1.12. 
We see that ᵅ�ᵅ�0
= 1 − ᵪ� ; and substituting this in Equation 1.11 we obtain  
 − ln(1 − ᵪ�) = ᵅ�ᵅ� + ᵀ�  1.13, 
where C is constant, corresponding to initial weight fraction of compound studied in initial 
sample [106]. In addition to solid-sate kinetic models, this equation in slightly modified form 
will be used to describe the solid phase transformations between α and β tegafur. 
1.5. Mechanochemistry 
Term mechanochemistry refers to chemical reactions and solid-state processes that are 
initiated by mechanochemical treatment or uses mechanically activated reagents [107,108]. 
Mechanical activation in a ball mill is the most commonly used technique in 
mechanochemistry, due to methods simplicity, relatively low costs, and because of technologist 
interest, since it is one of the most popular shredding methods. Mechanochemical processing 
in ball mill is a combination of two processes – crystal shredding (increase of the surface area) 
and crystal deformation. Since these processes cannot be separated, studies in this field are 
encumbered and crystal shredding and deformation are explored jointly [109–112]. 
The energy in milling system have been categorized into the energy applied and the energy 
required. The energy applied is the energy that is provided by the milling equipment to reduce 
the particle size, whereas energy required is the amount of energy necessary to overcome the 
particle strengths during particle fragmentation. During the milling process, energy applied far 
exceeds the energy required, and the excess energy is usually utilized in the processes that are 
not related to particle size reduction, like, elastic or plastic particle deformation; elastic energy 
dispersion in the milling equipment; friction, noise, heat and vibration in the milling equipment 
[108,112–116]. 
The energy required to reduce particle size vary considerably, as the strength of the material 
is known to vary with particle size. The largest particles tend to be weaker as compared to their 
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smaller counterparts, therefore, it is not surprising that sample mechanical properties may vary 
from particle to particle even for the same size range of a material. This means that there may 
be situations when under the same applied energy, some particles may undergo size reduction 
while others don’t [112]. A gradual decrease in the size of particles subjected to the mechanical 
treatment results in a transition from milling to plastic deformation. This means that besides 
particle size reduction, sample, subjected to mechanochemical treatment, is also 
mechanochemically activated by formation of crystal defects, plastic and linear deformations, 
dislocations, ion and atom vacancies, and interstitial ions. Therefore, mechanical treatment can 
be used to activate the surface of a powder by energy accumulation in the form of defects or 
other structural modifications of a solid, which makes it possible to minimize the activation 
energy or improve steric conditions for its subsequent chemical transformations. The 
accumulated energy is referred as a stress field created in the system. In the single-phase system 
the relaxation of stress field can proceed by several pathways which are accompanied by various 
secondary processes, such as heat liberation, formation of new phases or interfaces, crystal 
defect accumulation, amorphisation or chemical transformations. The factors affecting the 
formation and relaxation of a stress field are summarized in Figure 1.8. [107,113] 
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Figure 1.8. Schematic representation of the factors affecting the formation and relaxation of a stress 
field (adapted from [107]). 
1.5.1. Milling of pharmaceutical powders 
In the pharmaceutical industry, mechanical particle size reduction is a very important 
operation which affects product handling and performance, such as flow, drug stability, 
solubility and dissolution rate [109,110,113,117–122]. Other, maybe even more important 
consequence of the mechanochemical treating, is crystal phase of polymorphic transformation. 
First crystalline phase changes upon milling was observed by Florence et al. [123] in digoxin, 
and Lee and Hersey [124] in methisazone about half century ago. Nowadays, 
mechanochemically induced phase transformations are widespread in fundamental research 
and industry [109,110,118,125–127]. Müller and Polke [128] have reported that human body 
absorbs amorphous materials much more rapidly than crystalline substances, therefore 
solubility and biological activity of poorly soluble pharmaceutical drugs are very often improved 
by drug amorphisation. Lately, besides polymorphic transformation and amorphisation studies, 
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a lot of studies in this area are devoted to pharmaceutical cocrystal formation upon milling 
[129–140]. 
To initiate phase transformation or amorphisation it is necessary to overcome the phase 
transformation energy barrier, which, as discussed previously, is necessary to change the 
molecule arrangement and packing in the crystal lattice. The amount of energy induced in the 
system usually adjust by changing the mechanochemical treatment (milling) time and 
frequency [113,141]. 
It is worth noting that mechanochemically induced polymorphic transformations always 
occur from metastable from to more stable form [142] (amorphous form is not a polymorphic 
form; see Section 1.1). Changes in the crystalline state occur due to mechanically induced 
hydrogen bonding and other intra- and intermolecular interaction changes. However, it is 
common that hydrogen bonding network does not change during the mechanical treatment, 
but only weakens. Such bond weakening leads to highly energetic intermediate state – 
amorphous state, which, depending on the system energetic landscape, might be metastable 
[143]. Very little research has been directed at understanding the mechanism of organic 
cocrystal formation by solid-state milling, mostly, due to lack of methods suitable for such 
studies. However, Etter et al. [144] stated that in solid-state milling “at least one of the 
components should have some volatility at the temperature of the milling experiments, and the 
product dimers should have a stronger intermolecular hydrogen bond than any of the hydrogen 
bonds in the structures of the two starting materials”. The comment regarding volatility, are 
supported by the findings of Rastogi et al. [145,146], that showed that the yield of a solid-state 
cocrystallization may be improved by heating the starting materials before the milling. 
1.6. Solvent-surface interaction 
One of the most popular solvents used in the pharmaceutical industry is water, therefore 
most of the studies in the field are looking at water-solid interactions. Water-solid system will 
be reviewed here, but generally the same rules apply to other solvent systems. 
Water may be introduced into a solid as a result of processing, such as spray-drying, freeze-
drying, aqueous film coating, crystallization, wet granulation, or by exposure to water vapour 
environment at a certain relative humidity [147]. Water molecules can interact with the solid 
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compounds through hydrogen bonding, van der Waals forces, and, if the solid is ionic, through 
cation-water and anion-water interactions [148–151]. Water can interact with crystalline solids 
by sorption at the solid surface, in-corporation into the lattice (hydrate formation), 
deliquescence and capillary condensation (schematically represented in Figure 1.9.). Water 
adsorbs on surfaces in the form of individual molecules, clusters, monolayers and 
multimolecular layers that eventually condense as water. Deliquescence and capillary 
condensation, where the amount of associated water is much larger than in the rest of the 
interactions, may result in a water-soluble compound dissolution in the condensed water. 
Water can dissolve in the solid due to system disorder, as it can act as a plasticizer, penetrate 
the material, thereby facilitating greater solid compound molecule mobility and crystallization 
of the amorphous material. [147] 
 
Figure 1.9. Schematic representation of possible water–solid interactions (adapted from [5]). 
1.6.1. Solvent sorption/desorption  
The physicochemical process where components of one phase are accumulated on two phase 
boundary is called adsorbtion [152]. The adsorption process is sometimes accompanied by 
absorption, i.e. the process where adsorbent molecules penetrates into the bulk of the solid 
phase [153]. The term sorption is used to include both – adsorption and absorption processes 
[154]. Solvent molecules on the solid sample surface adsorb mostly in a monolayer, where 
solvent molecules are interacting with sample surface through hydrogen bonding [155]. 
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However, in the elevated vapour pressures more than one layer of solvent molecules may adsorb 
– up to 4-5 molecular layers below the deliquescence point [156,157]. Water sorption on the 
surface is reversible process, where minor temperature increase or relative vapour pressure 
decrease promotes water desorption from the sample surface. The amount of water sorbed 
depend on the nature of the compound and, most of all, on its crystallinity. Samples with high 
crystallinity can sorb relatively small amounts of vapour due their relatively small surface area, 
whereas amorphous samples can sorb much larger amount of vapour due to large surface area 
and lack of the long range order [158–160]. This effect is sometimes used to characterize sample 
crystallinity [149,161,162]. 
Experimental sorption isotherms – the curves obtained by plotting the weight change of a 
sample versus the relative humidity or water vapour pressure, usually show distinct 
characteristics for every vapour-solid system. The majority of physical adsorption isotherms 
can be classified into five classes (see Figure 1.10.) [5]. The type I isotherms are typical for 
chemisorption, where sorption is limited to a few monolayers of absorbate, and at high 
pressures isotherm plateaus as the pores are filled with absorbate. Type II isotherm is 
characteristic for physical adsorption on nonporous or microporous adsorbent (inflection 
indicates the first monolayer formation). In the sorption process, described by type III isotherm, 
additional adsorption at higher vapour pressures occurs as the adsorbate preferentially interacts 
with the monolayer than with the adsorbent surface (i.e., heat of adsorption < heat of 
liquification). Type IV isotherm is typical for porous surfaces (infection indicates monolayer 
formation), whereas small adsorbate-adsorbant interaction and capillary condensation in 
porous surfaces is observed in sorption processes described by type V isotherm [5]. Sorption 
isotherms IV and V given in Figure 1.10. show hysteresis, which is defined as mismatch between 
sorption and desorption paths. The lower part of hysteresis is observed during vapour pressure 
increase, whereas upper part (dashed line) is observed when vapour pressure is decreased 
[163,164]. The presence of the hysteresis depend on the sample nature, but experiments of 
Kiselev87 and Carman [165] have showed that sample processing in high pressure induced 
hysteresis for samples that here described with type II sorption isotherms. These changes were 
explained by the fact that in increased pressure particles are packed more closely, therefore 
enabling capillary condensation, which is considered as one of the causes why hysteresis is 
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observed. Some other causes of hysteresis are: a) sample surface area change during sorption, 
therefore, the amount of vapour sorbet at given partial pressure changes; b) kinetic factors – 
equilibrium is not achieved during sorption and/or desorption; c) physicochemical 
transformation takes place during sorption/desorption [166]. 
 
Figure 1.10. Types of sorption/desorption isotherms (adapted from [5]). 
Gravimetric vapour sorption methods have been widely used to study the interaction of 
solvent with the pharmaceutical materials [148,167]. The most popular method of vapour 
sorption isotherm construction is DVS (Dynamic vapour sorption). The DVS measures the 
sample mass change over the time at various vapour pressure conditions. The sample mass 
increase here is associated with vapour sorption, while a decrease is due to vapour desorption. 
The vapour pressure around the sample is controlled by mixing saturated and dry carrier gas 
streams, and it is almost exclusively used to study water systems [168,169]. Vapour sorption 
techniques are widely used to investigate solvate formation, particularly hydrates [148,149]. In 
the same way vapour sorption/desorption techniques can be used to study amorphous material 
relaxation to their more stable crystalline state. The amorphous materials typically have a 
greater water vapour sorption capacity than the crystalline material, due to increased void space, 
free energy, and/or surface area, but when the material undergoes an amorphous to crystalline 
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transition, the water sorption capacity drastically decreases [169]. The result of this process is 
an overall sample mass loss as excess water is desorbed during the crystallization. 
Early description of vapour molecule adsorption on a solid surface at a fixed temperature 
was proposed by Langmuir [170]. The equation was stated as: 
 
ᵪ� =
ᵪ�  
ᵅ�
ᵅ�0 
1 + ᵪ�  
ᵅ�
ᵅ�0 
 1.14, 
where θ is the fractional coverage of the surface;  
ᵅ�
ᵅ�0 
 is relative vapour pressure; and α is a 
constant. Brunauer, Emmett and Teller [171–173] extended the Langmuir single layer 
adsorption equation to describe multilayer adsorption. Their model described situation where 
adsorbed molecules in one layer can act as adsorption sites for the molecules in the next layer. 
The proposed equation for the BET model was: 
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 1.15, 
where W – the weight of water adsorbed per unit weight of dry solid at the relative pressure 
 
ᵅ�
ᵅ�0 
; Wm – the weight of water adsorbed corresponding to monolayer coverage; and parameter 
CB is related to the difference between heat of adsorption on the first layer and heat of water 
condensation. [154] 
1.6.2. Solvent additive effect on the solid-state polymorphic transformations 
It is known that several organic and inorganic reactions, as well as cocrystallization and 
polymorphic transformations are more selective and effective in the solid phase, however in 
most of the cases they take place much slower than in solution. In order to combine the best 
features of both reactions types, the approach, where solvent additive is added to the solid-solid 
reaction medium, have been introduced [138,174]. These researches showed that solid-state 
milling kinetics may be considerably enhanced by the addition of a few drops of solvent. In 
addition, this approach can provide a successful means of controlling the polymorphic or 
cocrystallization outcome [135,175]. This process is called “solvent drop grinding” or “liquid-
assisted grinding” [108]. Solvent drop milling have become popular due to its “green” nature – 
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it avoids excessive use of crystallisation solvent, and the yield in these reactions is nearly 100% 
[135,137]. 
The solid-state transformation from ranitidine hydrochloride form 1 to form 2 was 
confirmed to occur via an amorphous phase [117]. Phase transformation was initiated by form 
1 crystal disruption, producing form 2 nuclei. Continued milling produces heat and impact 
energy that propagates the crystallization. Phase transformation via solvent drop milling occur 
similar, with the difference that phase transformation occur through solution not amorphous 
phase. Solvent added dissolves small amount of solid phase and then consequently crystallizes 
in more stable phase. It is possible that both intermediate steps – amorphisation and dissolution 
– are involved in solvent drop milling [102,107,108,135,138,175]. Trask et al. [175] have showed 
that succinic acid β form does not transform to α form upon neat milling (milling without 
solvent additive) and milling with several drops of a polar solvents (water, acetonitrile and 
methanol), whereas milling with several drops of a less polar solvent (toluene, n-hexane and 
heptane) induced the formation of α succinic acid. Similar results were observed when caffeine 
and glutaric acid were ground together. Neat milling and milling with non-polar solvent 
additives (n-hexane, cyclohexane, and heptane) gave cocrystal form I, whereas milling with 
polar solvents (chloroform, dichloromethane, acetonitrile, and water) gave cocrystal form II 
[135]. These experiments show that solvent drop milling outcome is affected by solvent used 
just like in the crystallization from a solution. This confirm the previously stated assertion that 
solvent drop milling is actually a small scale crystallization from solution, where necessary 
energy is supplied by milling. Schematic representation of process occurring during solvent 
drop milling is given in Figure 1.11. Initially solvent adsorbs/absorbs on the surface of starting 
material (Form 1). Starting material Form I dissolve in to the solvent, and eventually, in given 
conditions more stable polymorph 2 nucleates in saturated solution layer. The growth of the 
newly formed Form 2 proceeds by Form 1 dissolution in the adsorbed solvent layer, and 
subsequent crystallization on the form 2 seed crystal. 
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Figure 1.11. Schematic representation of phase transformation during solvent drop milling. 
1.7. Solvent mediated phase transformations (SMPT) 
Solution or solvent mediated polymorphic transformation (SMPT) is a phase transition 
process which takes place through the solution phase where solvent molecules are in contact 
with both crystalline phases and allow the metastable phase molecules to rearrange to form the 
stable phase. SMPT is interpreted as a three-step process – dissolution of the metastable phase, 
nucleation of the stable phase, and growth of the stable phase [45,47]. Schematic representation 
of this process is identical to that given in Figure 1.11., with the difference that during the SMPT 
solid particles are in the bulk solvent. 
The driving force in this process is the difference between the solubilities and dissolution 
rates of both polymorphs, which consequently determines the supersaturation level during the 
crystallization of the thermodynamically stable form. Figure 1.12.A shows solubility profile of 
the dimorphic, monotropic system with the metastable form having the higher solubility. The 
solution with a concentration ci at a temperature Ti is supersaturated with respect to both 
polymorphs at the given temperature and therefore will crystallize. For systems which obey 
Ostwald’s rule of stages (see Section 1.2) the nucleation and growth of the metastable Form 1 
will occur first, but it is expected that even in such cases nuclei of the thermodynamically stable 
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Form 2 will appear and promote the growth of Form 2 and dissolution of Form 1. The 
nucleation and crystal growth process will cause the supersaturated solution concentration fall. 
If only Form 1 nucleates, the solubility drop will be limited by the Form 1 solubility c1, whereas, 
if polymorph 2 also nucleates, the concentration may fall below the Form 1 solubility to 
approach the Form 2 solubility, c2. When the solution concentration drops below the Form 1 
solubility c1, dissolution of metastable Form 1 starts to take place and solution concentration 
subsequently rises towards the solubility of Form 1. This dissolution-crystallization process is 
the SMPT. It is considered that the higher the initial supersaturation ᵪ�ᵅ� =
ᵀ�ᵅ�−ᵀ�2
ᵀ�2
 , the more likely 
the nucleation of Form 2 will be. [176] 
Schematic concentration and supersaturation profiles of both polymorphs during SMPT 
versus time are given in Figure 1.12.B. The plateau region in this plot corresponds to the SMPT 
step during which the growth and dissolution processes are balanced (it is called steady-state 
[45]). If crystal growth of Form 2 is rate determining step, the plateau concentration lies close 
to the solubility of the metastable Form 1, whereas if the rate determining step is the dissolution 
of Form 1 the plateau concentration lies close to the solubility of Form 2. In the latter case the 
phase transformation occur from the lower supersaturation and hence it often leads to slower 
transformation kinetics than in the growth controlled situation [47,176]. The overall SMPT 
driving force is controlled by the free energy difference between both polymorphs and is not 
affected by the choice of solvent, however, if the growth of the stable phase is the rate controlling 
step, solvent may influence the SMPT rate through its impact on the surface integration 
processes [177]. The phase transformation time together with the magnitude of the plateau 
concentration defines the kinetics and rate-determining step in the phase transformation 
process. [176] 
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Figure 1.12. Thermodynamic and kinetic features of SMPT. A) Solubility curves of monotropically 
related forms 1 and 2; B) Schematic representation of the concentration and supersaturation 
profiles throughout SMPT from form 1 to form 2 (adapted from [176]). 
The solution concentration profile throughout SMPT in conjunction with composition of 
the solid phase gives the information about the limiting step in the respective SMPT. There are 
four principal scenarios possible for SMPTs (see Figure 1.13.). They are described in detail 
elsewhere [178]. Here we note only the key points. In scenario A, the solution concentration 
drops immediately after any noticeable amount of the stable phase has been produced. This 
means that the consumption of supersaturation by crystal growth is fast compared to the overall 
metastable phase dissolution rate. This is denoted as a “dissolution controlled polymorphic 
transformation” [45]. In scenario B, the solution concentration stays at the solubility of the 
metastable form throughout phase transformation and the concentration remains at this level 
until almost no metastable solid form remains in the suspension. In this scenario the rate of 
supersaturation consumption by stable form crystal growth is clearly lower than the overall rate 
of dissolution of the metastable form. This case is denoted as “growth controlled polymorphic 
transformation” [45,47,179,180]. Scenario C is classified as a “nucleation-dissolution controlled 
polymorphic transformation”. Here the solution concentration drops quite rapidly as soon as 
the stable phase starts to form (like in case A), however, the nucleation of the stable form 
exhibits an induction time. Once the thermodynamically stable polymorph have nucleated, the 
rate of transformation is essentially limited by the rate of dissolution. In case D, the overall 
growth rate is clearly slower than the overall dissolution rate. The nucleation of the stable phase 
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holds considerable induction time and solution concentration does not start to decay until most 
of the metastable form has transformed to the stable form. This scenario is called as a 
“nucleation−growth controlled polymorphic transformation” [181,182]. [178] 
 
Figure 1.13. Schematic representation of solution concentration/supersaturation profiles and solid 
state compositions throughout SMPTs. Continues line (−) represents solution concentration 
profile; dotted line (···) represents the fraction of the thermodynamically stable phase; and dashed 
line (−∙−) represents the fraction of the metastable phase. Vertical line indicates the induction time 
for nucleation of the stable phase (adapted from [178]). 
Cases of SMPT have been extensively studied over years [8,178,179,183–192], and the latest 
studies [179,184,193] demonstrate that during a SMPT the nucleation of the stable polymorph 
tends to occur on/at the surface of the existing polymorph. The surface of the starting material 
can act as a nucleation substrate for the thermodynamically stable phase by either decreasing 
the solution-nucleus interfacial energy, by topographical contribution, by a crystal lattice match 
[9] or it can be a consequence of a local lattice disorder or amorphous region that have similar 
molecule arrangement to that of thermodynamically stable polymorph [8]. 
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SMPTs attracts attention also form the pharmaceutical industry, as it is one of the 
possibilities to prepare the thermodynamically stable polymorph [8,10,194]. 
1.8. Characterization of polymorphs 
There are a wide range of analytical techniques available for polymorphic system 
characterization, however, crystallographic and thermal methods are the most popular ones 
and will be looked in more detail. Crystallography provides the most definitive evidence of 
polymorphism – crystal structures, while other methods are used as a complementary 
techniques for the characterization of polymorphs. Solid state NMR provides information 
about magnetic environment of nuclei and molecule mobility, it also gives unique spectra for 
each polymorph; microscopy methods (hot stage microscopy (HSM), scanning electron 
microscopy (SEM), atomic force microscopy (AFM)) allows to characterize crystal shape, size, 
morphology and some processes occurring in crystals; spectroscopic methods (IR and Raman 
spectroscopy) are sensitive to hydrogen bonding and gives unique spectra for each polymorph. 
In order to get as full understanding as possible these techniques are always combined. 
[3,5,12,195,196] 
1.8.1. X-ray diffraction (XRD) 
Diffraction pattern depend on the atom, molecule or ion arrangement into the crystal, and 
since different polymorphs have different molecular packing, each polymorph has unique XRD 
pattern. This makes the XRD the most useful method for distinguishing and identifying 
polymorphs. [197–199] Single crystal X-ray diffraction (SC XRD) is the ultimate method for 
polymorph characterization, because it gives direct information on atom’s position in the 
crystal lattice. However, there is one serious obstacle for SC XRD – the preparation of suitable 
single crystal. Usually it is difficult, sometimes even impossible, to prepare a single crystal of 
desired quality, especially of a metastable polymorph [3,199]. Since most of the organic 
compounds are obtained as a micro-crystalline powders, they are analysed with powder X-ray 
diffraction method (PXRD). Due to simple sample preparation, and the fact that PXRD allows 
to identify the crystalline phases obtained, determine degree of crystallinity, study phase 
transformations, quantify phase mixtures, etc., it is appropriate method for the routine 
characterization of polymorphs and solvates [198,199]. The only disadvantage of PXRD method 
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is that it does not give enough information to solve crystal structure, however, the development 
of the PXRD equipment and the increase of the computational power have led to the 
opportunity to solve crystal structure even from the PXRD data. Though this task is not straight 
forward, the amount of structures solved from the PXRD data are vastly increasing. [200–209] 
Since it is possible to use PXRD method for quantitative phase analysis, PXRD gives the 
ability to study phase transformations, by monitoring disappearance of the starting material 
peaks and emergence of product peaks. In order to obtain representative data, a randomly 
oriented powder sample that will present a substantially random selection of all possible crystal 
faces, providing information regarding all possible atomic or molecular spacing in the crystal 
lattice, is required. In order to minimize the errors introduced by the sample preparation and 
sample inhomogeneity it is recommended to standardize the sample preparation method [210–
213]. There are several approaches for quantitative composition calculation from PXRD data, 
like peak intensity ratio method (can use more than one peak), full profile fitting; and Rietveld 
method [199]. Rietveld method is the most popular and precise method since it takes in to 
account the crystallographic structures of the studied compounds. This is also the disadvantage 
of this method, since not all compounds have determined crystal structures [198,199]. The 
precision of quantitative PXRD analysis is from several percent with peak intensity ratio 
method up to 0,1% with Rietveld method [214–219]. 
1.8.2. Thermal methods 
Thermal analysis methods utilise the fact that a thermally induced change in the sample is 
accompanied by significant heat flow. In differentially scanning calorimetry (DSC), the 
instrument measures the required heat flow to sustain the temperature of the sample and 
reference material the same. The resulting thermogram shows a measure of heat flow as a 
function of temperature. In differentially thermal analysis (DTA), heat loss or gain resulting 
from physicochemical changes occurring in a sample is recorded as a function of temperature 
as the substance is heated at a uniform rate. Enthalpic changes observed by DSC and DTA 
methods are caused by phase transitions. Most of them (fusion, boiling, sublimation, 
vaporization, solid-solid transition, and solvent loss) generally produce endothermic effect, 
whereas crystallization produces exothermic effect [220]. The endothermic and exothermic 
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effect observed allows to estimate polymorph relative stability, gives information about solvent 
loss and presence of chemical and physical impurities, etc. DTA and DSC gives somehow 
similar information with the difference that DSC provides thermodynamic data, which can be 
further used to calculate the heat of fusion, heat of crystallization, etc. Therefore, DSC is the 
most popular thermal analysis method in pharmaceutical analysis. [1,3–5,16,195,221,222] 
Another thermal method, usually combined with the previous ones, is thermal gravimetric 
analysis (TGA). TGA measures sample weight changes as a function of temperature. This 
methods is very useful to study processes that are accompanied by weight loss due to 
temperature changes, like, sublimation, desolvation and decomposition. Furthermore, the mass 
loss can be used to establish solvate stoichiometry. Due to ability to use TGA method either in 
thermal or isothermal mode, it is a powerful tool to study the kinetics of various events, such as 
dehydration. The combination of TGA and DSC or DTA allows to explore the nature of any 
thermally induced transitions from both qualitative and potentially quantitative perspectives. 
[3,5,11,220,223] 
1.9. Active pharmaceutical compounds 
1.9.1. Tegafur 
Tegafur, 5-fluoro-1-(tetrahydro-2-furyl)-uracil (see Figure 1.14.A), which was synthetized 
by Hiller et al. [224] as a prodrug of a 5-fluorouracil (Figure 1.14.B), is an antitumor agent 
widely used in the treatment of various cancers, particularly the gastrointestinal and breast 
cancer [225–227]. Over many years the α, β, γ, δ and ε polymorphs of tegafur have been 
reported in the pharmaceutical literature [227–229]. These crystal forms can be prepared as 
follows: α tegafur can be obtained by crystallization from acetone at ambient conditions; β – by 
crystallization from methanol at room temperature under reduced pressure; γ – by heating the 
β tegafur at 130 °C for 1 h, δ – by very slow crystallization from a methanol solution [227], and 
ε form can be crystallized from the thin layer (3 mm) aqueous solution at 4 °C [228]. No tegafur 
solvates have been discovered yet. Only α and β modifications are used for therapeutic purposes, 
therefore our studies focus on these two polymorphs. 
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Figure 1.14. A) Tegafur (5-fluoro-1-(tetrahydro-2-furyl)-uracil); B) 5-fluorouracil 
The β form is thermodynamically stable polymorph at ambient conditions, whereas α tegafur 
is stable at elevated temperatures. Several studies have been devoted to determine α and β 
tegafur equilibrium temperature, and depending on method used, it is from 33 °C to 39 °C 
[230,231]. The α polymorph is stable up to ~130 °C, where the stability region of γ polymorph 
starts. 
Crystal structures of α and β tegafur have been determined and it is known that α tegafur 
(Cambridge Structural Database (CSD) reference code BIPDEJ) crystallize in a triclinic P-1 
space group with cell parameters a=8.994(8) Å, b=16.612(9) Å, c=5.981(5) Å, α=86.40(6)°, 
β=94.06(15)°, γ=80.29(8)°, four formula units in the unit cell, and the cell volume 886.27 Å2. β 
tegafur (CSD reference code BIPDEJ02) crystallize in a monoclinic P21/n space group with cell 
parameters a=11.891(5) Å, b=14.556(2) Å, c=5.062(1) Å, β=99.05(2)°, four formula units in the 
unit cell, and the cell volume 865.25 Å2. The base motif of α and β tegafur crystal structures is a 
tegafur molecule dimer with a ᵀ�2
2(8) motif where tegafur molecules are connected via two N1-
H···O12 hydrogen bonds (Figure 1.15.). The dimers are not identical in both polymorphs, 
because the crystal structure of α tegafur consists of two conformationally different molecules 
(A and B), whereas β tegafur has one molecule in its asymmetric unit and conformation of this 
molecule matches the conformation of molecule B in α tegafur [232]. Dimers in α tegafur are 
formed between conformationally identical molecules, that is, one α tegafur dimer is formed by 
two A molecules, and the second by two B molecules. Tegafur dimers in the α polymorph are 
cross-linked by weak C4-H···O8 and C11-H···O13 hydrogen bonds, whereas in β tegafur dimers 
are stabilized by weak C4-H···O12 and C10-H···F14 hydrogen bonds. It is worth noting that 
tegafur dimers in α form forms between the same enantiomers (there are two enantiomerically 
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and conformationally different dimers), whereas in β tegafur dimers forms between two 
enantiomerically different molecules [232]. 
 
Figure 1.15. Crystal packing of (A)  tegafur and (B)  tegafur. Hydrogen atoms are omitted for 
clarity. 
These two polymorphs have distinctly different crystal morphologies – α polymorph has a 
needle like crystals, whereas β polymorph has prismatic crystals (see Figure 1.16.). α tegafur 
crystal growth along the a axis is promoted by the relatively easy tegafur dimer access to the 
growing surface and the possibility to form multiple weak hydrogen bonds between F14, O13, 
O8 and C4-H, C11-H. Hydrogen bonds in β tegafur are distributed more evenly and they are 
stronger than in α tegafur. The same groups are involved in hydrogen bonding for β tegafur, 
with the difference that instead of C11-H hydrogen, C10-H forms hydrogen bond with fluorine 
atom. Hydrogen bonding in β tegafur enables cross-linked zigzag chains in the b direction, 
however no preferred crystal growth orientation is observed for β tegafur. 
 
Figure 1.16. Photomicrographs of  and  tegafur crystals. 
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1.9.2. Theophylline 
Theophylline, a methyl xanthine derivative (3, 7 dihydro-1, 3-dimethyl-1H-purine-2,6-
dione) (Figure 1.17.), is an oral bronchodilator with anti-inflammatory action that has been 
used for over 70 years to treat pulmonary conditions such as asthma and Chronic Obstructive 
Pulmonary Disease [233]. Theophylline can exist in various polymorphic forms (I, II, III and 
IV) [116,234–241], monohydrate [242–244], dimethyl sulfoxide solvate [245], and as a cocrystals. 
Most of the complexes formed between theophylline and acids (e.g. oxalic acid, malonic acid, 
gentisic acid, sulfathiazole, acetaminophen, etc.) as well as bases (e.g. urea, benzylamine, 
phenobarbital, etc.) have been summarized by Childs et al. [246]. 
Theophylline is one of the pharmaceutically active compounds that have been manufactured 
and used in a metastable crystalline phase (clearly, because of the lack of comprehensive 
knowledge on polymorphic landscape of this compound) [235,237]. Theophylline Form II is 
highly stable metastable polymorph crystallized from majority of solvents at the room 
temperature and therefore was historically considered as thermodynamically stable polymorph, 
until Form IV were presented [237] and proved to be more stable. The fact, that 
thermodynamically stable theophylline polymorph was discovered only lately, most likely, is 
because it does not crystallise directly from any solution, and is obtained only by slow solvent 
mediated transformation (SMPT) from Form II in contact with specific solvents [237]. 
Theophylline Form I has been reported as stable polymorph at higher temperatures, whereas 
Form III is highly metastable and it has been obtained only during the dehydration of monohydrate 
[236,243]. Theophylline monohydrate (referred as Form M) is a monoclinic channel type 
hydrate which has been shown to lose water, either in low humidity or at temperatures above 
353 K, to produce Form II [164,247]. Here we focus exactly on the phase transformation 
between form II and IV. 
 
Figure 1.17. Structure of theophylline (3,7 dihydro-1,3-dimethyl-1H-purine-2,6-dione). 
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The crystal structures of theophylline form II, IV and monohydrate are given in Figure 1.18. 
Theophylline Form II (CSD reference code BAPLOT) crystallize in orthorhombic Pna21 
space group with cell parameters a=24.3301(14) Å, b=3.7707(2) Å, c=8.4850(5) Å, four formula 
units in the unit cell, and the cell volume 778.427 Å2. In the crystal structure of theophylline 
Form II the best hydrogen bond donor (N7-H) bonds to the hydrogen bond acceptor which 
would be expected to be the strongest (N9) [234,248] forming hydrogen bond N7-H···N9. This 
observation is consistent with Etter’s rules [249] that the best hydrogen bond donor tends to 
interact with the best hydrogen bond acceptor. The crystal structure of Form II also has two 
weak bifurcated C8-H···O13 hydrogen bonds. Mentioned hydrogen bonds form second-level 
ᵀ�2
2(8) motif. The resulting crystal structure of Form II consists of theophylline molecules that 
are linked in chains where the planar molecules are stacked along (010). This catemer 
arrangement promotes crystal growth along the molecular chains leading to an elongated 
crystal morphology. 
Theophylline Form IV (CSD reference code BAPLOT03) crystallize in monoclinic P21/n 
space group with cell parameters a=7.70550(10) Å, b=13.0010(2) Å, c=15.7794(3) Å, 
β=103.2240(10)°, eight formula units in the unit cell, and the cell volume 1538.85 Å2. Unlike 
other theophylline anhydrous polymorphs, Form IV has two molecules in its asymmetric unit 
[116]. These molecules form a dimer with a ᵀ�2
2(10) motif and are connected via (N7-H···O13) 
hydrogen bonds. The dimer is discrete and only links to other dimers by weak interactions: C8-
H···N9, C8-H···O11, and by π–π stacking, forming two-dimensional network parallel to the 
(001). Dimer, observed in the Form IV, is similar to the motif observed in the monohydrate and 
in a number of theophylline cocrystals [246,248]. Presence of such dimer motif in the 
thermodynamically stable Form IV and theophylline monohydrate, that is considered to be the 
most stable structure in aqueous environment, may account for the thermodynamic stability of 
this structural motif compared to the chain motif of Form II. 
Theophylline monohydrate M (CSD reference code THEOPH01) crystallize in monoclinic 
P21/n space group with cell parameters a=4.468(2) Å, b=15.355(5) Å, c=13.121(5) Å, 
β=97.792(7)°, four formula units in the unit cell, and the cell volume 891.87 Å2. In a 
theophylline monohydrate two centrosymmetrically related theophylline molecules form a 
dimer through two hydrogen bonds (N7-H···O13) [244]. Theophylline dimers are connected by 
47 
 
water molecules through hydrogen bonds, forming parallel, crosslinked chains, leading to two-
dimensional hydrogen bonded layers, parallel to (10-1) plane. Water molecules are situated in 
the tunnels along the a axis, where they are forming hydrogen bonds to theophylline molecule 
N9 atom. 
In theophylline dimethyl sulfoxide solvate one theophylline molecule is hydrogen bonded to 
one dimethyl sulfoxide molecule through an N7-H···O=S hydrogen bond [245]. The packing 
consists of molecular chains lying parallel to the (010), stacked by π–π interaction between 
pyrimidine and imidazole rings, and weak hydrogen bonds between dimethyl sulfoxide methyl 
groups and theophylline carbonyl group (CDMSO-H···O13). 
The crystal structure of the highly-metastable Form III has not been determined due to its 
metastability. 
 
Figure 1.18. Crystal packing motifs in theophylline Form II, Form IV, theophylline monohydrate 
and DMSO solvate. 
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2. Experimental 
2.1. Materials 
Commercial samples of α and β tegafur (>99%) were supplied by JSC Grindeks (Latvia). 
Samples of α and β tegafur were confirmed to be polymorphicly pure. The entire batches of α 
and β tegafur used in experiments were ground separately for 3 min to ensure required sample 
homogeneity and avoid preferred crystal orientation effects. Anhydrous theophylline was 
purchased from commercial sources and was certified >99% pure. Theophylline was confirmed 
to be Form II and was used as received. Organic solvents of analytical grade were purchased 
from commercial sources and used without further purification (for solvent characterization 
see Appendix 2). Deionized water (electrical conductivity <0.1 µS) was prepared by Adrona, 
Crystal 5 (Latvia). 
2.1.1. Preparation of theophylline crystalline forms 
Theophylline Form IV. Theophylline Form IV was prepared as described elsewhere [237]. 
An excess amount of anhydrous theophylline (~1.0 g) was added to 25 mL of methanol and 
stirred at 600 rpm for 14 days at 23±1 °C (this and further experiments were performed in air-
conditioned laboratory, because temperature deviations during the day hindered Form IV 
nucleation). Solid phase was filtered through Buchner funnel under reduced pressure. The 
polymorphic form of dry residue was confirmed using PXRD. 
Theophylline Form I. Anhydrous theophylline Form II (~1.0 g), ground in mortar with 
pestle for 3 min, was transferred to Petri dish, covered by glass slide and heated at 268±1 °C for 
2 h. Sample was cooled to room temperature and polymorphic form was confirmed using 
PXRD. 
Amorphous theophylline. The excess amount of anhydrous theophylline (~5.0 g) was added 
to 250 mL of water and was left to stir overnight. Solid phase was filtered off and a clear solution 
was spray dried using a Buchi mini spray dryer B-290 (Buchi Labortechnik AG, Switzerland). 
A top spray method was used with the inlet temperature set at 120 °C, the outlet at 70 °C and 
the pressure at 6 bar. Crystallinity of the material obtained was examined using PXRD. 
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Theophylline monohydrate. The excess amount (~3.0 g) of anhydrous theophylline was 
dissolved in ~100 mL of warm water (~70 °C) and was left to stir overnight. The precipitated 
solid phase was filtered, air dried and crystalline phase obtained was confirmed using PXRD. 
2.2. Characterization methods 
2.2.1. Powder X-ray diffraction 
PXRD samples of tegafur were recorded with a Bruker D8 Advance and Bruker D8 Discover 
powder X-ray diffractometers (Bruker AXS, Germany), equipped with a PSD LYNXEYE 
detectors. The measurements were performed with Cu K radiation (1.54180 Å) at room 
temperature. The following conditions were used: step-scan mode with a step size of 0.02°; scan 
speed: 0.2 s/0.02°; 2θ range: 3.0°−30.0°; voltage: 40 kV; current: 40 mA; divergence slit: 0.6 mm; 
anti-scattering slit: 8 mm. The powder samples were packed into glass holders and pressed by a 
glass slide to ensure coplanarity of the powder surface with the surface of the holder. 
Theophylline samples were analysed with a Rigaku Miniflex (Rigaku, Japan) powder X-ray 
diffractometer. Diffraction patterns within the 2θ range of 5° to 40° were recorded at room 
temperature using Cu Kα radiation at 1.54180 Å, with the following measurement conditions: 
tube voltage 30 kV, tube current 15 mA, step-scan mode with 2θ step size 0.02°, and the 
counting time 2 s/step. Diffractometer slits were set as follows: divergence slit – variable; 
scattering slit – 4.2°, receiving slit – 0.3 mm. Powder samples were packed into aluminium 
sample holders with and pressed by a glass slide to ensure co-planarity of the powder surface 
with the surface of the holder. 
Qualitative phase analysis. Reference powder patterns were calculated with Mercury 3.3 
[250] software from CSD crystal structure data. 
Quantitative phase analysis. The quantitative phase analyses were performed using 
fundamental parameter based Rietveld software BGMN (version 1.8.6b) [251] with Profex 
(version 3.1.1) interface. Crystal structure data previously mentioned were used for quantitative 
Rietveld analysis. 
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2.2.2. FTIR spectroscopy 
FTIR spectra were recorded using a Perkin-Elmer Spectrum BX (PerkinElmer Inc., USA) 
spectrometer fitted with a PIKE Technologies MIRacle sampling accessory. MIRacle liquids 
plate was used when spectra of solutions were recorded. The samples were scanned at a 
resolution of 4 cm−1 between 4000 cm−1 and 600 cm−1. Each spectrum consisted of 16 co-added 
scans if not otherwise stated. 
2.2.3. Scanning electron microscopy (SEM) 
SEM imaging was performed using Inspect S SEM (FEI, Holland) or Hitachi S4800 SEM 
(Hitachi, Japan) system. Samples were initially gold coated using a K550X sputter coater 
(EMITECH, UK) and subsequently scanned using an acceleration voltage of 5.0 kV or 2.9 kV 
at a working distance of approximately 10 mm. 
2.2.4. Determination of the surface area 
Surface area was determined by a modified chromatograph “Hrom 3”, detecting the amount 
of argon involved in a monolayer adsorption–desorption process. 
2.2.5. Crystallographic face indexing 
Crystallographic face indexing was undertaken using single crystal X- ray diffractometer 
Nonius Kappa CCD diffractometer (Bruker AXS, Germany) with Mo Kα radiation (0.71073 Å) 
at 60 kV and 30 mA. Data were collected at room temperature. Face indexing was performed 
using Collect software [252]. 
2.2.6. Calculation of crystal morphology 
Predictions of crystal morphology from structure data were done based on Bravais, Friedel, 
Donnay and Harker (BFDH) theory using Mercury 3.3 [250] software. Crystal structures 
necessary for calculations were retrieved from the Cambridge Structural Database. 
2.3. Sample preparation 
2.3.1. Sample preparation for PXRD method calibration 
PXRD calibration was performed using mixtures of 5.0%; 10.0%; 20.0%; 50.0%; 80.0%; 90.0% 
and 95.0% β tegafur in α tegafur (~0.3 g total sample weight). The mixtures were weighed using 
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an analytical balance (BOECO, Germany, d=±0.1 mg ) were used and samples were 
homogenized by shaking (10 Hz) for 5 min in a Retsch MM 300 ball mill (Retsch GmbH, 
Germany) without milling balls in the sample vial. The powder samples were packed into glass 
holders and pressed by a glass slide to ensure coplanarity of the powder surface with the surface 
of the holder. Quantitative PXDR analysis were performed as described in section 2.2.1. 
2.3.2. Determination of micro amounts of β tegafur in the α and β polymorph mixture by 
powder X ray diffractometric analysis 
2.3.2.1. Determination of optimal sample preparation conditions 
The mixture of tegafur α and β forms containing 1.5% weight fraction of β form was prepared 
and separated into six samples with mass 0.50 grams of each sample. The analytical weights 
were used. Weighted samples were milled with a ball mill in 50 mL vials at the shaking 
frequency of 15 Hz at 20±2 °C for 3.0, 5.0 and 7.0 minutes with addition a single drop 
(~0.07 mL) or two drops (~0.15 mL) of water for each milling time. Water was added to the 
sample before milling. 
PXRD patterns of prepared samples were recorded as described in section 2.2.1. 
2.3.2.2. Sample preparation 
Pure α and β polymorphs of tegafur were milled separately for 2.0 minutes in the mortar to 
ensure homogeneity of the sample. The milled β form was weighted in various ratios (1.0%; 
0.50%; 0.25%; 0.10%; 0.050%; 0.010% and 0.0050%, ω/ω) with α form. Total mass of the mixture 
was 0.75 g. Prepared samples were homogenised by shaking for 5.0 minutes in a ball mill 
without milling balls in the sample vial at the shaking frequency of 15 Hz at 20±2 °C. 
The 0.50 g of homogenised sample was weighted for milling, but the rest of the mixture was 
used for the next sample preparation. A drop of water (~0.07 mL) was added to the sample 
before milling. The prepared sample was milled for 5.0 minutes with a ball mill in 50 mL vials 
with the shaking frequency of 15 Hz at 20±2 °C. 
PXRD patterns of prepared samples were recorded as described in section 2.2.1. 
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2.3.3. Optimization of sample preparation conditions for detecting trace amounts of β 
tegafur in α and β tegafur mixture 
2.3.3.1. Determination of optimum milling frequency. 
Mixtures of 2.0%; 1.0%; 0.50%; 0.10%; 0.050%, 0.010%; 0.0050%; 0.0010%; 0.00050% and 
0.00010% β tegafur in α tegafur (3.0 g each) were prepared from a 2.0% stock mixture that was 
diluted to the required concentrations. Samples during preparation were homogenized with a 
ball mill in 50 mL vials for 5 min at 20±2 °C with 15 Hz shaking frequency. The 0.50 g samples 
of homogenized mixtures were each treated with 0.07 mL water and ground in the ball mill at 
7, 10 and 15 Hz shaking frequencies for 5 minutes. 
PXRD patterns of prepared samples were recorded as described in section 2.2.1. 
2.3.3.2. Determination of the optimum added water volume. 
A mixture of tegafur α and β forms containing 1.0% weight fraction of β form was weighed 
and homogenized in the ball mill for 5 min at 20±2 °C, with 15 Hz shaking frequency. The 
0.50 g samples of homogenized mixture were ground in the ball mill with variable water additive 
amounts for 5 minutes at 20±2 °C, with 10 Hz shaking frequency. The added water volume was 
from 0.02 mL to 0.20 mL, with 0.01 mL step size. Micropipette (CAPP, Denmark, d=±2%) was 
used for solvent addition. When the amount of water additive exceeded 0.06 mL, a thick paste 
formed, and it became necessary to dry the samples for 30 minutes after milling. 
PXRD patterns of prepared samples were recorded as described in section 2.2.1. 
2.3.3.3. Sample preparation for recrystallization studies. 
A sample (0.50 g) of tegafur α and β form mixture, containing 1.0 % weight fraction of β 
form, was ground in the ball mill for 5 min at 20±2 °C with 15 Hz shaking frequency, with 
0.20 mL water added just before milling. The obtained thick paste was pressed into glass sample 
holder right after milling, and PXRD pattern was recorded immediately. Consecutive PXRD 
patterns were recorded every 5 min, until no further phase transition was observed (~1 h). 
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2.3.4. Organic solvent effects on phase transition of α and β tegafur upon milling with 
solvent additives 
2.3.4.1. Determination of solvent effect on phase conversion degree during milling 
A sample (10 g) of tegafur α and β form mixture, containing 0.5% weight fraction of β form, 
was prepared from a 5.0% stock mixture that was diluted to the required concentration. Samples 
during preparation were homogenized in a ball mill for 5 min at 20±2 °C with 15 Hz shaking 
frequency. 
The 0.20 g samples of prepared 0.5 % mixture were each treated with 0.025 mL of solvent 
and ground in the ball mill at 10 Hz shaking frequency for 5 minutes. The solvents used in this 
experiment were methanol, ethanol, n-propanol, n-butanol, n-pentanol, n-heptanol, 
isopropanol, benzyl alcohol, ethyl acetate, n-propyl acetate, n-butyl acetate, 1,1-dichloroethane, 
chloroform, acetone, tetrahydrofuran, acetonitrile and toluene. Prepared samples were dried in 
opened milling vessel for 30 min at 20±2 °C after the milling. Dried samples were packed into 
glass holders and PXRD patterns were record. 
2.3.4.2. Determination of α tegafur solubility in the solvents used 
Approximately 0.2 g of α tegafur was added to ~12 mL of solvent in weighing bottle, and the 
prepared mixture was held at 30±1 °C for 48 h in a sealed weighing bottle and stirred 
occasionally to obtain a saturated tegafur solution. The clear, saturated mixture (4.0 mL, 
without any precipitate) was transferred to a tared weighing bottle with a pipet that was also 
held at 30±1 °C. The weighing bottle with the saturated solution was left to evaporate at 
30±1 °C, and then the weighing bottle with the dry residue was weighed on analytical balance. 
PXRD pattern was recorded for the dry residue. Solubility of α tegafur was determined in all the 
previously mentioned solvents. 
2.3.4.3. Determination of solvent vapour effect on phase transition 
Two samples (4 g each) of α and β tegafur mixture with weight ratio 1:1 were prepared. 
Samples were homogenized during the preparation in a ball mill for 5 min at 20±2 °C with 
15 Hz shaking frequency. The prepared homogeneous samples were packed into glass holders 
and PXRD patterns for initial mixtures and pure α and β forms of tegafur were recorded. The 
54 
 
samples were placed in desiccators with 95% relative solvent vapour pressure at 30±0.5 °C, and 
depending on the transition rate, PXRD data were recorded at fixed moments. 
Obtaining 95% relative solvent vapour pressure. To obtain a relative solvent vapour pressure 
of 95%, methanol, ethanol, n-propanol, 2-propanol, n-butanol, n-pentanol, n-heptanol and 
benzyl alcohol solution in glycerol were prepared, and acetone, acetonitrile, ethyl acetate, n-
propyl acetate, n-butyl acetate, chloroform, tetrahydrofuran, 1,2-dichloroethane and toluene 
solution in dimethyl sulfoxide were prepared according to the Raoult’s law 
 ᵀ� =
ᵅ�0 − ᵅ�
ᵅ�0
= ᵅ�
ᵅ�0 + ᵅ�
 2.1, 
where X is the solvent’s mole fraction in solution; po is the vapour pressure of pure solvent; p is 
the solvent’s partial vapour pressure over a solution; n represents the investigated solvent molar 
amount in the solution; no is the moles of glycerol or dimethyl sulfoxide in the solution. 
Temperature control. Desiccators with the prepared solvent solutions were placed in an air 
thermostat (Universal Oven UFB-500, Memmert GmbH, Germany) at 30±0.5 °C 24 hours prior 
to sample insertion. 
2.3.4.4. Solvent sorption studies 
Solvent sorption experiments were performed in weighing dishes at 30 °C by using pure α 
and β tegafur. The 0.20 g samples of pure α and β tegafur were weighed in separate weighing 
dishes with accuracy ±0.1 mg and placed in desiccators with 95% partial pressure of the relevant 
solvents (see section 2.3.4.3). Depending on the sorption rate, samples were weighed at fixed 
moments. 
2.3.4.5. Solvent desorption studies 
Desorption experiments were performed using completely solvent-saturated samples from 
the sorption experiment (described in section 2.3.4.4). The 30±2 mg of solvent-saturated 
samples were quickly placed (in less than 20 seconds) in aluminium sample pan, and desorption 
experiments were performed using a TG/DTA6300 EXSTAR6000 (SII Nanotechnologies, 
Japan) instrument with open aluminium sample pans having internal diameter of 5 mm and 
height of 2.5 mm, under dry nitrogen atmosphere with flow rate of 250 mL/min in isothermal 
conditions at 30 °C. It was observed that desorption rate was highly dependent on mass of the 
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sample, therefore samples with equal mass were used. For fast weighting of the equal amount 
of sample the sample holder each time was filled up to the edge. The following technique 
allowed to prepare the samples with mass 30±2 mg and to reduce the time of weighing. If sample 
weight after this procedure were out of the range, procedure was repeated with fresh solvent-
saturated sample. During the experiment mass of the sample was recorded every 0.5 seconds. 
2.3.5. Organic solvent desorption from two tegafur polymorphs 
2.3.5.1. Sample preparation and fractionation 
A sample (~6 g) of α tegafur was ground in a mortar for 3 min and then gradually sieved 
through sieves with mesh sizes of 150, 75 and 40 µm. Three fractions of α tegafur (~2 g each) 
were obtained with the following particle sizes: 150 – 75 µm; 75 – 40 µm; and less than 40 µm. 
The same procedure was repeated for β tegafur. 
2.3.5.2. Solvent desorption studies 
Samples (~50 mg) of each fraction were placed into separate 2 mL vials and positioned in the 
prethermostated desiccators with 95% relative solvent vapour pressure at 30±0.5 °C (see section 
2.3.4.3) for at least 72 h to obtain completely solvent-saturated samples. Solvent desorption was 
studied as described in section 2.3.4.5. 
2.3.6. Solvent mediated phase transformation between two tegafur polymorphs in several 
solvents 
2.3.6.1. The kinetics of solvent mediated polymorphic transformations 
Acetone, ethanol, i-propanol, toluene, and water solutions (~100 mL) saturated with respect 
to α tegafur were prepared by stirring excess α tegafur for ~3 h at 22±1 °C. The excess tegafur 
was filtered off and the clear solution was used for SMPT. In order to ensure that the solution 
was saturated with respect to α tegafur, PXRD patterns of filtrates were recorded. Solution 
concentration was determined as described in Section 2.3.6.2. 
SMPT kinetics experiments were performed at 22.0±0.1 °C in a thermostated (Grant TC120, 
England, d=±0.1°C;) glass flow-through cell (250 mL) with a magnetic stirrer. 1.0 g of α tegafur 
(used as received) was added to the saturated solution and the solid phase was monitored every 
56 
 
10 min to 2 h throughout the transformation. The stirring of the slurry was stopped for 20 
seconds to allow the suspended solid particles to settle. Solid phase samples (~10 mg) for 
polymorphic composition determination were collected with a metal spoon from the 
suspension. The collected solid phase was quickly filtered through a 2 μm filter paper using a 
glass filter funnel with Buchner flask under reduced pressure. The quantity of β tegafur in the 
sample was monitored and quantified via ex-situ PXRD analysis. The PXRD patterns for dry 
samples were recorded and analysed as described in Section 2.2.1. 
The tegafur concentration in solution was measured every 20 min to 2 h throughout SMPT. 
Samples for solution concentration measurements were gathered at the same time as solid phase 
samples for polymorphic composition determination were collected. Approximately 2 mL of 
saturated solution was filtered through a 0.20 µm syringe filter and then 1.00 mL of clear 
solution was transferred to a preweighed vial with micropipette (±10 µL). The solution was left 
to evaporate at room temperature, weighed and the tegafur solubility was calculated. Two 
parallel experiments were performed. 
2.3.6.2. Tegafur solubility measurements 
An excess amount of the thermodynamically stable β tegafur was added to 15 mL of acetone, 
cyclohexane, ethanol, i-propanol, toluene, and water, and was left to stir overnight at 22±1 °C. 
The saturated solution was filtered through a 0.20 µm syringe filter and then 10.0 mL of clear 
solution was transferred to a preweighed vial. Solution was left to evaporate at room 
temperature, weighed and tegafur solubility was calculated. Solubility of the metastable α 
tegafur was determined identically, except solutions were stirred for ~3 h at 22±1 °C, in order 
to prevent phase transformation to the thermodynamically stable β tegafur. PXRD patterns of 
filtrate were recorded to ensure that the solubility of the desired polymorph was determined. 
Two parallel experiments were performed. 
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2.3.7. The Reluctant Polymorph. Self-association effect on nucleation and solvent 
mediated phase transformation of theophylline 
2.3.7.1. Examination of solution mediated phase transformation 
An excess amount (2.5 g) of anhydrous theophylline Form II (used as received) was added 
to 100 mL of methanol. The suspension was stirred at 600 rpm for 14 days at room temperature 
(23±1 °C) and the following measurements were performed every 7 to 24 h: 
(a) Solution concentration monitoring. Theophylline concentration in the solution was 
measured every 1 h to 1 day. The solution (~1 mL) was filtered through a syringe filter 
of 0.20 μm size, and solution concentration was determined as described in Section 
2.3.7.3. Three parallel solution concentration determination experiments were 
performed. 
(b) Crystallization product from solution. 2 mL of the solution was filtered through 0.20 μm 
syringe filter, transferred to a Petri dish and was left to evaporate at room temperature. 
Crystallized dry residue of three parallel experiments was combined and phase 
composition was examined using PXRD. 
(c) FTIR spectra of the solution. ~0.3 mL of the filtered solution was gathered as described 
above, and the FTIR spectra of solution were recorded immediately after sample 
gathering. 
(d) Phase composition of the solid phase. The stirring of the slurry was stopped 30 seconds 
prior to sample gathering, to allow the suspended solid particles to settle. Solid phase 
sample (10−20 mg) was collected with a metal spoon from the suspension and was 
quickly filtered through Buhner funnel filter under reduced pressure. The solid phase 
was examined using PXRD, FTIR and SEM. 
SMPT was repeated in triplicate. 
SMPT was additionally performed with different starting materials and solvents (given in 
Table 1). Single runs were performed for these experiments. The phase composition of the solid 
phase was monitored every 1 to 7 days, except experiments where Form II and Form IV mixture 
was used; the phase composition in these experiments was monitored every 10 min to 1 h. The 
solvent and theophylline ratio in all SMPT experiments were the same (2.5 g of theophylline 
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and 100 mL of solvent), except SMPT in formic acid, where 15.0 g of theophylline were added 
to 25 mL of formic acid due to high theophylline solubility in formic acid. 
SMPT in methanol-D4 was performed for H1 NMR studies. An excess amount (0.5 g) of 
commercial theophylline Form II was added to 4.0 mL of methanol-D. The suspension was 
stirred at 600 rpm for 10 days at room temperature (23±1 °C). PXRD patterns of solid phase 
and solution H1 NMR spectra (see Section 2.3.7.4) were recorded each day. Stirring was stopped 
1 min prior to sample collection, and: (a) clear solution (~1 mL) was transferred to NMR tube; 
(b) solid phase (10−20 mg) was collected with a metal spoon and quickly filtered through 
Buhner funnel filter under reduced pressure. PXRD and H1 NMR measurements were 
performed immediately after sample collection. Solution from NMR experiment was returned 
back to the reaction vial immediately after recording the NMR spectrum. 
Table 1. Starting materials and solvents used in SMPT 
Starting material Solvent 
Commercial Form II Methanol 
Form II, ground in mortar with pestle for 3 min Methanol 
Lyophilized Form II* Methanol 
Commercial Form II Methanol saturated to theophylline Form IV 
Commercial Form II/Form IV* mixture 
(wII/wIV; 90/10) 
Methanol saturated to theophylline Form II 
Commercial Form II/Form IV* mixture 
(wII/wIV; 90/10) 
Methanol saturated to theophylline Form IV 
Commercial Form II Methanol/water mixture (VMeOH/VH2O; 99/1) 
Commercial Form II Methanol/water mixture (VMeOH/VH2O; 95/5) 
Commercial Form II Methanol/water mixture (VMeOH/VH2O; 80/20) 
Commercial Form II Acetone 
Commercial Form II Acetonitrile 
Commercial Form II Chloroform 
Commercial Form II Formic acid 
Commercial Form II Methanol-D4** 
* Prepared as described in Section 2.1.1. 
** Small scale experiment, Vtotal=4.0 mL 
59 
 
2.3.7.2. Determination of theophylline solubility 
Theophylline Form II and Form IV solubility in acetone, acetonitrile, methanol, chloroform 
and formic acid were determined as follows. An excess amount of theophylline was added to 15 
mL of solvent and was left to stir overnight at 23±1 °C. The saturated solution was filtered 
through a 0.20 µm syringe filter and then 10.0 mL of clear solution was transferred to a 
preweighed vial. Solution was left to evaporate at room temperature, weighed and theophylline 
solubility was calculated. The PXRD pattern of the filtrate was recorded to ensure that the 
solubility of the desired polymorph was determined. Two parallel experiments were performed. 
2.3.7.3. UV/Vis spectroscopic solution concentration monitoring 
Solution concentration throughout SPMTs in methanol was monitored by measurements of 
the UV/Vis absorption at 272 nm using a Perkin-Elmer Lambda 25 UV/Vis spectrophotometer 
(PerkinElmer Inc., USA). Calibration was performed in the concentration region between 
0.2 mM and 0.01 mM (R2=0.99990). For solution concentration determination 20 µL aliquot of 
filtered reaction medium was diluted with 40 mL of methanol. 
2.3.7.4. NMR spectroscopic self-association studies 
1H NMR spectra were recorded as a function of theophylline concentration in the solution. 
Experiments were performed in methanol-D4, chloroform-D, acetone-D6, dimethyl sulfoxide-
D6, deuterium oxide, acetonitrile-D3 and formic acid-D2 Concentration region from nearly 
saturated solutions (1.0 M in formic acid-D2; 0.050 M in methanol-D4; 0.015 M in acetone-D6; 
0.10 M in dimethyl sulfoxide-D6, deuterium oxide, chloroform-D and acetonitrile-D3) to 1 µM 
solutions was covered. Ground anhydrous theophylline Form II was used to prepare the most 
concentrated solution in each solvent and the rest of the solutions were prepared by subsequent 
dilution. Additional samples, where an excess amount of ground theophylline was added to 
deuterated solvents, were prepared to simulate suspensions similar to that examined in SMPT. 
The mass of theophylline added was 120% of the mass necessary to prepare saturated solution 
in the respective solvent. An analytical balance (±0.1 mg) and micropipettes (±1 µL) were used 
for solution preparation. NMR spectra of prepared solutions were recorded right after solution 
preparation, and repeated after 1 and 2 weeks. NMR tubes of prepared solutions were closed 
with lids and sealed with parafilm. Samples were stored at 20.0±0.5 °C between measurements.  
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1H NMR spectra were recorded on a Bruker Avance DRX 400 MHz spectrometer (Bruker 
BioSpin, Germany) using residual solvent as an internal standard. NMR spectra were recorded 
at 26.8±0.5 °C (300.0±0.5 K). 
Theophylline 1H chemical shifts were allocated by 1H-13C HSQC according to literature 
assignments [238]. 1H-13C HSQC experiments were carried out using the standard Bruker 
program hsqcetgpsi2 [253,254]. 
2.3.7.5. In-situ monitoring of crystallization process. 
Two drops (~0.07 mL) of saturated theophylline methanol, acetone, acetonitrile, 
chloroform, water and formic acid solutions from solubility determination experiments 
(section 2.3.7.2) were placed on a FTIR spectrometer liquids plate and spectra of the solution 
were continuously recorded during solvent evaporation/theophylline crystallization. Each FTIR 
spectra showed the average of 16 co-added scans, recorded in 75 s. For acetone solution 4 co-
added scans (recorded in 17 s) were averaged. Spectra were recorded until three continuous 
spectra were identical and no peaks of solvents were visible. The experiment with each solvent 
was repeated in triplicate.  
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3. Results and discussion 
3.1. Quantitative PXRD phase analysis 
Advantages like uniqueness of X-ray powder pattern of compounds, non-destructive nature 
and simplicity make PXRD the most preferred and extensively used technique for 
quantification of polymorphic mixtures [255,256] therefore PXRD were chosen as the most 
appropriate method for phase quantification in this study. The homogenous composition of the 
analysed mixtures and equivalent extinction effects for two polymorphs ensure that the 
diffraction peak intensity of each phase depends linearly on the phase weight fractions in the 
sample [199]. 
PXRD method calibration was performed as described in section 2.3.1, and method 
calibration curve of α and β tegafur mixture is given in Figure 3.1. It is evident that the 
correlation was not completely linear and the calculated content of β tegafur in the samples was 
up to 2% higher than was actually weighed. We believe that this was because of the preferred 
orientation of α tegafur, different degree of crystallinity for both polymorphs and possible 
microabsorption. Nevertheless, experimental data can be described with linear equation 
y=(1.02±0.01)x, with R2 value of 0.9990. The method used was found to be linear in the range 
0 – 100% with limit of detection (LOD) and limit of quantification (LOQ) calculated [215] to 
be 3.0 and 9.2%, respectively. The method was found to be precise with relative standard 
deviation (RSD) of 2.0%. Statistical probability (p) used was p<0.05. Relatively high LOD, LOQ 
and RSD values are because of the fast scan speed (0.2 °/min) used in the experiments. In order 
to maintain consistency, scan speed used for calibration was the same as further used in SMPT 
quantitative analysis. Scan speed of 0.2 °/min was chosen because of the ability to provide fast 
PXRD measurements necessary for kinetic SMPT studies. 
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Figure 3.1. The dependence of calculated β tegafur weight fraction (ωβ calc.) upon the actual β tegafur 
content in the sample (ωβ actual). Statistical probability p<0.05. 
3.2. Determination of micro amounts of β tegafur in the α and β polymorph 
mixture by powder X-ray diffractometric analysis. 
 
Results described in this subsection have been previously partially described in PhD thesis of Sanita 
Skladova “Method improvement of the investigation of phase equilibrium and phase transition kinetics 
with the goal of throughout polymorph screening of the variety of active pharmaceutical ingredients”. 
 
The purpose of this study was to develop a suitable analytical method for determining micro 
amounts of the thermodynamically stable polymorphic form (<1%) in the mixture of 
thermodynamically stable β tegafur and metastable α tegafur. The method used here employed 
controlled polymorphic transformation from metastable α tegafur to the thermodynamically 
stable β tegafur. Thus, the content of thermodynamically stable polymorph in the sample was 
increased by solvent drop milling to the amount that can be determined with the quantitative 
PXRD analysis, and then, the amount of the thermodynamically stable polymorph in the initial 
sample was calculated from calibration data. Schematic representation of experiment design is 
shown in Figure 3.2. Analysed samples were milled for fixed time with the certain milling 
frequency at 20 °C, and the phase transition was stimulated by adding some water to samples 
before milling [135,175]. The calibration line was constructed using the least-square method. 
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Figure 3.2. Schematic representation of experiment design. 
To develop the micro amount quantification method of the thermodynamically stable form 
in the metastable form, six experiments were carried out to establish the acceptable method for 
optimal milling conditions. The samples containing 1.5% weight fraction of β tegafur were 
milled for 3.0, 5.0 and 7.0 minutes after adding a drop (~0.07 mL) or two drops (~0.15 mL) of 
water. The aim of these experiments were to investigate sample preparation conditions in which 
α modification after milling does not completely transit to β form, but the sample consist of 
comparatively high content of α tegafur. The samples that were milled for 5.0 and 7.0 minutes 
had practically the same composition, but in the samples that were milled for 3.0 minutes β 
form content was noticeably lower as it can be seen in Figure 3.3.A. To promote the phase 
transformation of β tegafur to α form, some water – one drop (~ 0.07 mL) or two drops 
(~0.15 mL), was added to the sample before milling. In all experiments the content of β tegafur 
in the samples was significantly higher if a single drop of water was added to the sample before 
milling (see Figure 3.3.B). 
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Figure 3.3. A) Powder X-ray diffraction patterns of the tegafur α and β form mixture containing 
1.5% weight fraction of β tegafur after milling for 3.0; 5.0 and 7.0 minutes; and B) powder X-ray 
diffraction patterns of the tegafur α and β form mixture containing 1.5% weight fraction of β tegafur 
after milling for 5.0 and 7.0 minutes if the phase transition was induced adding a single drop 
(~0.07 mL) or two drops (~0.15 mL) of water. 
Any solvent that does not form solvates or hydrates with analysed polymorphic forms could 
be used to quicken the phase transformation. For the method development as the optimal 
sample preparation conditions were chosen the milling for 5.0 minutes and adding a single drop 
of water. 
Powder X-ray diffraction patterns of calibration samples after milling for 5.0 minutes 
inducing the phase transformation with adding a drop of water to the sample are shown in 
Figure 3.4.A, whereas the dependence of tegafur β form weight fraction after milling upon the 
initial β form content in the sample is shown in Figure 3.4.B. 
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Figure 3.4. A) Powder X-ray diffraction patterns of calibration samples after milling for 5.0 min 
inducing the phase transformation with adding a single drop of water to the sample; and B) the 
dependence of tegafur β form weight fraction after milling upon the initial β form content 
in the sample. 
The calibration factor is equivalent to a linear slope of the linear regression equation. The 
regression line was described by relationship y=ax, taking into account the intersection with the 
origin. If the calibration factor would be calculated from the equation y=ax+b in this case the 
approximated line intersect y-axis at non-zero value and that means positive phase content at 
zero peak intensity (Ipeak≠0, when ω=0), which is physically impossible. The optimal linear slope 
was calculated using MS Excel [257] function Linest. The equation of calibration curve was 
y=(43.0±0.9)x, the correlation coefficient R2=0.996 and the regression residual mean square 
error or the standard deviation Sn, which characterizes the dispersion between the measured (yi) 
and theoretically calculated value (Yi), was 1.5%. 
3.2.1. Conclusions 
The results of this study demonstrate that the quantification of low levels (<1%) of unwanted 
polymorphs in pharmaceuticals can be made using the semi-quantitative, but sensitive X-ray 
diffractometric method. Employed method is based on controlled thermodynamically stable 
polymorph increase by solvent drop milling to the amount that can be determined with the 
quantitative PXRD analysis, and then, the amount of the thermodynamically stable polymorph 
in the initial sample is calculated from calibration data. The content of tegafur β form after 
milling is proportional to the initial β form mass fraction in the sample.  
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3.3. Optimization of sample preparation conditions for detecting trace amounts 
of β tegafur in α and β tegafur mixture 
As shown in Section 3.1, it is possible to determine trace amounts (less than 0.01%) of the 
thermodynamically stable form in mixtures of thermodynamically stable and metastable forms. 
In this section we estimate sample preparation condition impact on proposed quantification 
method. 
It is worth noting, that our first experiments in this direction indicated that phase transition 
did not occur when pure α and β tegafur were ground separately without a solvent, therefore 
the initial sample preparation by milling of pure α and β tegafur did not promote phase 
transition and could not affect the results of quantitative analysis. 
3.3.1. Optimum milling frequency determination. 
Tegafur α and β form mixtures with β form weight fraction from 2.0% to 0.0001% were 
ground at three different milling frequencies: 7 Hz, 10 Hz and 15 Hz to establish an acceptable 
milling frequency. The recorded PXRD patterns (down to ωβ=0.50%) and calibration curves for 
all three milling frequencies are shown in the Figure 3.5. In the higher range of initial β tegafur 
weight fraction (up to ~20%) all of the calibration curves had an exponential nature, but in the 
lower range of β form mass fraction (<2.0%) the calibration curves of samples ground at 7 Hz 
and 10 Hz frequencies could be considered as linear. At the same time, the conversion degree 
curve for samples ground at a 15 Hz frequency maintained an exponential nature also in the 
lower range. Conversion degree dependence on the initial β tegafur weight fraction most likely 
exhibits an exponential nature, because the degree of phase transition is more affected by the 
surface area of β tegafur, thus also the phase boundary area, and less by the initial weight 
fraction of β tegafur. The weight fraction of β tegafur in the sample is not linearly proportional 
to phase boundary area, and therefore the weight fraction after milling does not depend linearly 
on the initial weight fraction of β tegafur. 
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Figure 3.5. A) Powder X-ray diffraction patterns of pure α and β tegafur and calibration samples 
after milling with 10 Hz frequency for 5 min in 20 °C; B) conversion degree depending from initial 
β form weight fraction and milling frequency. 
The calibration factor for samples ground at 7 Hz and 10 Hz frequencies was equivalent to 
the linear slope of the linear regression equation. The liner regression was described as 
previously (see section 3.1). Calibration equation for those samples ground with 7 Hz frequency 
was y=(8.3±0.4)x with correlation coefficient R2=0.97 and standard deviation Sn=1.1%, but for 
samples ground with 10 Hz frequency the calibration equation was y=(35.1±1.1)x with the 
correlation coefficient R2=0.997 and standard deviation Sn=1.4%. 
Experimental points for samples ground with 15 Hz frequency could be described with the 
exponential equation 
 ᵪ�ᵪ�,ᵅ�ᵀ�ᵅ�ᵅ� = ᵪ�ᵪ�,∞(ᵪ�ᵪ�,∞ − ᵪ�ᵪ�,0)ᵀ�
−ᵅ�ᵪ�ᵪ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�ᵅ�  3.1, 
where ᵪ�ᵪ�,ᵅ�ᵀ�ᵅ�ᵅ� was the theoretically calculated weight fraction of β tegafur after milling; ᵪ�ᵪ�,∞ 
was the final weight fraction of β tegafur when the phase transition had ceased; ᵪ�ᵪ�,0 was the 
weight fraction of β tegafur after milling when ᵪ�ᵪ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�ᵅ� = 0; k was the phase transition rate 
constant and ᵪ�ᵪ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�ᵅ� was the weight fraction of β tegafur before milling. The MS Excel [257] 
optimization add-on Solver, based on the least squares method, was used to optimize equation 
3.1 constants. The equation 
 ᵪ�ᵪ� = 96.6(1 − ᵀ�
−12.4ᵪ�ᵪ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�ᵅ� ) 3.2, 
was thus obtained. Experimental point dependence on the initial weight fraction of β tegafur 
(ᵪ�ᵪ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵀ�ᵅ�) was empirical in this case, and the exponential nature of experimental curve may be 
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considered as coincidence. The polymorphic phase transition rate depends on the mass 
transition rate from one phase to another [258], therefore it may be considered that the main 
factor influencing overall phase transition rate is related to the surface properties of both phases. 
If the weight fraction of β tegafur in the sample ground at 15 Hz frequency does not exceed 
0.10%, then it is possible to use a linear regression equation y=(770.0±0.1)x with the correlation 
coefficient R2=0.995 and standard deviation Sn=2.2%. 
In the initial β tegafur weight fraction region from 2.0% to ~0.05% the best correlation was 
achieved, when the samples were ground with 10 Hz frequency, but if lower thermodynamically 
stable form contamination in metastable form must be determined, then the milling frequency 
of 15 Hz is preferred. 
3.3.2. Optimum water additive amount determination. 
Tegafur α and β form mixture with the β form weight fraction of 1.0% was ground with 
various amounts of added water. The conversion degree was determined, depending on the 
volume of added water, and is shown in the Figure 3.6. The sum of two empirical equations 
(Langmuir and Cauchy–Lorentz equations; equation 3.3) was chosen to describe the 
experimental data, because there are no equations in literature that would fit these experimental 
data: 
 ᵪ� = ᵀ�ᵅ�ᵀ�
1 + ᵅ�ᵀ�
+ ᵀ� 1
ᵪ�  
ᵀ�
(ᵀ� − ᵀ�)2 + ᵀ�2 
 3.3, 
where ω is the weight fraction of β tegafur in the samples after milling, V is the volume of added 
water (mL), ᵀ�  is the contribution factor, a is the volume of added water at which the highest 
conversion degree was observed, b is the distribution width ratio, and d and k are empirical 
constants. 
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Figure 3.6. Conversion degree of ground (10 Hz, 5 min at 20 °C) 1.0% β tegafur sample, depending 
on the added water volume. 
Cauchy–Lorentz equation term or another statistical “bell shaped” function was introduced 
into the equation 3.3 to describe the milling efficiency depending on the volume of added water. 
A “bell shaped” statistical distribution term was selected, because surface area determination 
experiments demonstrated (see section 0) that the milling efficiency, and thus also the surface, 
is dependent on the added water volume, matching a statistical “bell shaped” distribution. Thus, 
if no water sorption on the surface of tegafur occurs, the conversion degree depends only on 
the milling efficiency, while that depends on the amount of water added. Langmuir equation 
term was introduced into the equation 3.3 to describe a phase transition occurring in the 
adsorbed water layer on the surface of tegafur, and it is not related to the phase transition 
promoted by milling. 
It was observed that samples with additive volume of less than 0.06 mL were free flowing 
powders after milling, but, when the water additive volume was greater than 0.06 mL, the 
samples formed thick paste and stuck to the milling vessel walls. Water can be considered as a 
lubricant in this process and increasing the volume of water additive above 0.06 mL decreased 
the conversion degree, while at water volumes below 0.06 mL the conversion degree of α tegafur 
to β tegafur increased. 
3.3.3. Phase transition during sample drying. 
The metastable α tegafur transforms to the thermodynamically stable β form during a 
process involving tegafur dissolution in water, and subsequent thermodynamically stable form 
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crystallization due to water additive evaporation. The kinetic curve of this process is shown in 
the Figure 3.7. The highest conversion degree was observed for samples prepared with 0.06 mL 
of water (see section 3.3.2), yet this experiment was performed with 0.20 mL of water, to extend 
the water evaporation time and to enable acquisition of more experimental data. Experiments 
with smaller amounts of water exhibited the same trend, but results were less obvious. The 
kinetic curve can be described with a kinetic equation ᵪ�ᵪ� = 35.8 − 20.7ᵀ�−0.063ᵅ�  (equation 
constants were optimized with MS Excel [257] optimization add-on Solver). Not only an 
increase of β tegafur peak was observed during this process, but there was also a minimal 
increase of α form diffraction peaks indicating increasing crystallinity of α form, or an 
increasing preferred orientation due to the fracture of crystals along certain cleavage planes. As 
can be seen in Figure 3.7., the conversion degree to β tegafur was highly dependent on sample 
drying time; thus for a precise trace amount quantification all samples should be dried for the 
same duration (at least 1 h). 
 
Figure 3.7. β tegafur weight fraction changes during recrystallization process of 1.0% β tegafur 
sample after milling with 10 Hz frequency for 5 min at 20 °C with 0.20 mL water additive. 
3.3.4. Surface area determination. 
Surface areas of unground samples, as well as samples ground without water, and with 
0.06 mL and 0.12 mL of water were determined for estimating the impact of water on milling 
efficiency. The determined surface areas are shown in the Table 2. The surface area of unground 
1.0% β tegafur in mixture with α tegafur was 13.4 m2/g, but the surface area of sample ground 
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with 0.12 mL water was 13.9 m2/g, which indicated that water volume above 0.06 mL did not 
improve milling efficiency, as discussed in section 3.3.2. The surface area of the sample ground 
without water was significantly higher than for the sample ground with a 0.12 mL water 
additive. These differences can be related to different sample dispersion in the milling vessels; 
dry sample after milling was homogenously distributed in the milling vessel, whereas the wet 
sample after milling was located on the mill walls. The maximum surface area, hence the 
maximum milling efficiency, was achieved when phase transition during milling was stimulated 
with a 0.06 mL water additive. 
Table 2. Surface areas of unground, dry ground and with 0.06 mL and 0.12 mL water additive ground 
(5 min, 10 Hz, 20 °C) samples. 
Sample Surface area, m2/g 
unground 13.4 
ground without additive 16.9 
ground with 0.06 mL water additive 18.3 
ground with 0.12 mL water additive 13.9 
 
3.3.5. Conclusions 
Sample preparation condition optimization allowed us to quantify down to 0.0005% of the 
thermodynamically stable β tegafur in α tegafur. The amount of the thermodynamically stable 
form after sample processing was proportional to its initial weight fraction. 
In β tegafur weight fraction range from 2.0% to ~0.05% the best correlation was achieved 
when samples were ground for 5 minutes at 20 °C with 10 Hz frequency. At lower weight 
fraction of β tegafur the milling frequency of 15 Hz was preferred. The optimum results were 
achieved when 0.06 mL of water was added to 0.50 g of tegafur. A sum of Langmuir and 
Cauchy–Lorentz equations could be used to describe the change in conversion degree 
depending on the added water volume. The indirectly determined surface areas and the 
dependence of conversion degree on water additive volume demonstrated that increasing the 
added the water volume above 0.06 mL did not improve milling effectiveness. Conversion 
degree from α tegafur to β tegafur was highly dependent on sample drying time. 
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This method is generally applicable when the sample has phases with similar particle 
properties, and the peak intensity is not particularly dependent on preferred orientation and 
perhaps line broadening effects.  
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3.4. Organic solvent effects on phase transition of α and β tegafur upon milling 
with solvent additives 
In all previously described experiments phase transformation was stimulated using water 
additive, however it is expected that used solvent will affect the efficiency and outcome of 
solvent drop milling just like in any other crystallization. Here we will investigate the effect of 
solvent additive on phase transition of α and β tegafur. 
3.4.1. Solvent effect on the degree of phase conversion during milling 
Initially conversion degrees for samples containing 0.5% of β tegafur in α and β tegafur 
mixture were determined, and a complete conversion to β tegafur occurred when n-propyl 
acetate, acetonitrile, ethyl acetate, 1,2-dichloroethane, acetone, tetrahydrofuran, n-butanol and 
methanol were used as additives (see Table 3). To find out, which of these solvents promotes 
the α tegafur conversion to β tegafur the most, samples containing 0.1% of β tegafur in α and β 
tegafur mixture were examined. None of the solvents promoted complete conversion to β 
tegafur in the case of samples containing 0.1% of β tegafur in α and β tegafur mixture with 
current milling conditions (5 min at 20 °C with 15 Hz shaking frequency). Experiments with 
pure α tegafur were also performed, to find out if there might be any solvents that promote 
phase transition without any β tegafur seeds in the sample. 
Our quantitative composition calculation method was not suitable for quantifying phases 
with weight fraction below 3% after the milling, so the results for samples, where β tegafur peak 
was detected, but was not large enough to quantify, are given as “<3%”. 
The most complete phase transition to β tegafur, for samples containing 0.1% of β tegafur, 
occurred when methanol or 1,2-dichloroethane additive was used – the weight fraction for β 
tegafur increased during milling from 0.1% to 82% and 72%, respectively. The most marked 
decrease in conversion degree between samples with the initial β tegafur content of 0.5% and 
0.1% occurred in those cases, when acetone or n-butanol additive was used – complete 
conversion was detected when samples with the initial β tegafur content of 0.5% were ground, 
but when 0.1% mixture was ground, only a slight increase of β tegafur content was detected (less 
than 5%). 
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Table 3. Conversion degrees of 0.5% and 0.1% β tegafur mixture in α tegafur and pure α tegafur 
during the milling (5 min at 20 °C with 15 Hz shaking frequency), depending on the used solvent 
additive, and corresponding phase transition rates from α tegafur to β in the presence of respective 
solvent vapour. 
 ᵫ�ᵫ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ� ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�, %  
ᵫ�ᵫ�,ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�ᵅ�, % 
Solvent 
0.5% β 0.1% β α 
 
k, days-1 
Methanol HBD 100 82 <3 0.073 
1,2-Dichloroethane AP 100 72 92 0.049 
n-Propyl acetate AP 100 37 - - 
Tetrahydrofuran EPD 100 15 - 1.878 
Ethyl acetate AP 100 13 13 0.042 
Acetonitrile AP 100 6 8 0.194 
n-Butanol HBD 100 3 <3 0.015 
Acetone AP 100 <3 - 2.167 
Benzyl alcohol AA 95 52 25 0.033 
n-Butyl acetate AP 92  - 0.004 
Ethanol HBD 86  - 0.019 
Toluene AA 83  6 0.017 
n-Pentanol HBD 57  - 0.007 
n-Propanol HBD 57  - 0.058 
Chloroform 44  42 0.007 
Water 23  - 0.038 
2-Propanol HBD 31  - 0.007 
n-Heptanol HBD 30  - 0.007 
AP – aprotic polar, AA – aromatic apolar, EPD – electron pair donor, HBD – hydrogen bond donors (for more 
information see Appendix 3). 
 
As we can see, a 1,2-dichloroethane additive promotes almost complete phase transition in 
all cases, even when pure α tegafur is used. Similar situation can be observed when chloroform 
additive is added, only then the conversion proceeds by ~40%. This could be related to a solvent 
structure that promotes only one polymorphic form regardless of whether the seed crystals are 
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added to a sample or not. Conversion of pure α tegafur to β tegafur occurs due to solvent 
structure factors, similar to those in crystallization [259]. Hydrogen bond donor solvents do not 
promote phase transition of pure α tegafur, but both investigated aromatic aprotic solvents 
promote phase transition of pure α tegafur, even though they do not ensure a complete phase 
transition for samples with 0.5% β tegafur additive. 
Changes in conversion degrees are not proportional from one solvent to another when the 
initial weight fraction of β tegafur changes from 0.5% to 0.1%. For example, when acetone 
additive is added to a sample, conversion degree changes form 100% to less than 3%, but when 
methanol additive is added, conversion degree changes form 100% to 82%. There is no clear 
understanding about the causes of these differences, but it could be related to solubility or 
dissolution rates of tegafur in the investigated solvents, or simply due to structural peculiarities 
of each solvent. 
To ensure that phase transition is not stimulated by the water impurity in solvents, Karl 
Fischer titration was performed for all used solvents, and it was determined that water amount 
in the solvents did not correlate with the conversion degree to β tegafur. 
3.4.2. Solvent vapour effect on phase transition 
It is known that solvent vapours accelerate phase transition [105], however it is not known 
if the effect on solid phase transition is the same for solvent vapour and liquid solvent additives. 
For this purpose an atmosphere of solvent vapour with 95% relative pressure was created by 
using the same solvents as in the previous experiments. Phase transition kinetic curves were 
recorded by using PXRD (see Figure 3.8.), and transition rates were calculated as described 
elsewhere [105]. 
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Figure 3.8. β Tegafur weight fraction changes during sample exposure to 95% relative vapour 
pressure of methanol, acetone and ethyl acetate. 
Saturated solvent vapour atmosphere was not used to prevent condensation and sample 
wetting with a condensed solvent. Mixture with a weight ratio of 1:1 was used because no phase 
transition was observed for samples with only 0.5% of β tegafur. 
Phase transition rates for samples exposed to solvent vapour atmosphere with a 95% relative 
pressure are given in Table 3. The general tendency matches the observations from α and β 
tegafur mixture milling experiments – aprotic polar solvents with the smallest molecules are the 
best promoters of this phase transition. Rough correlation between ground sample conversion 
degrees and phase transition rates from α tegafur to β in the presence of solvent vapours 
suggests that solvent role in both types of phase transformations are similar. 
In the case of ethyl acetate and n-propyl acetate there was a very high conversion degree, 
despite the low sorption and phase transition rates in samples exposed to these solvents at 95% 
relative pressure, indicating that the phase transition during the milling procedure is affected 
not just by solvents in gaseous state, but also in their liquid state. 
3.4.3. Conclusions 
The results of these studies demonstrate that the conversion degree of metastable α tegafur 
to the thermodynamically stable β tegafur upon a milling with solvent additive is highly 
dependent on the solvent used. The most complete phase transition to β tegafur occurs when 
methanol or 1,2-dichloroethane additive is used, however only n-propyl acetate, 
tetrahydrofuran and water are suitable for developed quantitative analysis method. Phase 
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transition dynamics of α tegafur to β tegafur is in a good agreement for samples ground in ball 
mill with solvent additive and samples, that were exposed to 95% solvent relative vapour 
pressure.  
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3.5. Organic solvent desorption from two tegafur polymorphs 
Here we try to understand the nature of solvent and surface interaction using data from 
solvent desorption studies. Desorption process of several solvents from both polymorphic 
forms of tegafur was examined to compare solvent-tegafur surface interaction behaviour. As 
seen in section 3.5.2 (see Figure 3.10.), solvent desorption experiment indicated that in most 
cases desorption occurred in two steps. There is no clear understanding on this phenomenon, 
but it could be a case of classical monolayer and multilayer (with possible capillary 
condensation) desorption. Solvent molecule desorption from the top solvent multilayers can be 
associated with the beginning of desorption curve (part I in Figure 3.10.B), where rapid sample 
mass decrease was detected. The next stage, after the initial rapid loss of solvent, in most cases 
appeared exponential and involved solvent monolayer desorption (part II in Figure 3.10.B). 
Following experiments were performed to get some understanding about these processes. 
3.5.1. Surface area and relative sample surface coverage 
Amount of each solvent necessary to form solvent monolayer was calculated using 
determined surface area data (see Table 4), adsorbed solvent mass and solvent molecule 
dimensions [260]. Using mass of solvent, adsorbed during sample storage in 95% relative 
solvent vapour pressure, and theoretical mass of solvent in monolayer, sample surface coverage 
for each sample was calculated. These results are given in Figure 3.9. 
Table 4. Surface areas of α and β tegafur samples depending on particle size. 
Polymorph Particle size, mm Surface area, m2/g 
α 
<40 12.4 
40-75 12.2 
75-150 5.9 
β 
<40 14.8 
40-75 12.8 
75-150 9.2 
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Figure 3.9. Relative sample surface coverage with used solvents in 30 °C, for samples stored in 95% 
relative solvent vapour pressure (madsorbed/mtheoretical). 
If we take a look at sample surface areas (Table 4), it can be seen that the surface areas of 
samples with particle size 40−75 µm and less than 40 µm were almost the same for both 
polymorphs. SEM examinations shows distinct differences in particle size distribution for both 
fractions, therefore similar surface areas for both fractions most likely are due to differences in 
bulk density – fraction with smaller particles forms more dense sample, but fraction with larger 
particles forms less dense sample. These changes in the sample density affects the 
effective/accessible surface area of the sample and the greater bulk density for fraction with 
particle size less than 40 µm causes the apparent reduction of the surface area in the 
experimental measurement. 
From relative sample surface coverage data we see that the amount of acetonitrile, 
tetrahydrofuran, ethyl acetate and acetone adsorbed on the tegafur surface is enough to form at 
least solvent monolayer and that the decrease of sample surface area increases the relative 
sample surface coverage. These calculations shows that amount of acetonitrile adsorbed on the 
surface is enough to form up to 4 solvent molecular layers in the case of 75−150 µm α tegafur 
sample, but adsorbed methanol amount is sufficient to cover up to 10% of the sample surface 
(for samples with particle size 75−150 µm), while adsorbed toluene, ethanol and n-butyl acetate 
covers less than 3% of the sample surface. 
The decrease of particle size from 75−150 µm to 40−75 µm increases the relative sample 
surface coverage by about 20 to 40%, but particle size decrease from 40−75 µm to less than 
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40 µm increases the relative sample surface coverage by about 5 to 15%. We believe that the 
observation that less solvent multilayers formed on the smaller particles if compared to the 
larger particles, is related to previously mentioned differences in the bulk densities. Sample with 
the smallest particles (less than 40 µm) has higher bulk density then the rest fractions and 
therefore effective/accessible surface area of this sample is lower than it would be if all the 
samples had the same density. It is also possible that such results could be due to the effective 
surface area decrease during the solvent adsorption process because of sample recrystallization 
and/or solvent sorption on the previous solvent layers; especially for sample with particle size 
less than 40 µm. 
3.5.2. Solvent desorption studies 
As can be seen from ethyl acetate, acetone and tetrahydrofuran desorption curves (see Figure 
3.10.A), desorption occurs in two steps – at the beginning part of the solvent is desorbed from 
the surface of tegafur, and afterwards desorption progresses throughout the volume of tegafur 
particles. 
 
Figure 3.10. A) Ethyl acetate, acetone and tetrahydrofuran desorption curves from α tegafur; and B) 
example of desorption rate calculation 
Solvent desorption from the surface can be associated with the linear part of desorption 
curve. The next stage, after the initial rapid loss of solvent, appears exponential and involves 
solvent desorption from the entire volume. Solvent surface desorption rates were compared by 
using the average desorption rate equation 
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 ᵪ� = ᵀ�ᵅ�
ᵀ�ᵅ�
 3.4, 
where α is desorption rate, m is sample mass, and t is time. An obstacle to the determination 
of desorption rate was the posed by the observation that the beginning of desorption curve 
cannot be used due to a possible desorption delay. The best way for avoiding this problem could 
be to calculate desorption rate in the middle of a desorption process, using a middle point 
calculated from the sample mass before and after desorption, thereby preventing errors 
stemming from desorption delay and from imprecise end point determination (see Figure 
3.10.B). Solvent desorption rates depending on tegafur polymorphic form, particle size and the 
selected solvent for samples stored at 95% relative solvent vapour pressure are summarized in 
Figure 3.11. (monolayer desorption in Figure 3.11.A. and multilayer desorption in Figure 
3.11.B.). No acetonitrile and tetrahydrofuran monolayer desorption from α and β tegafur were 
observed. 
 
Figure 3.11. Desorption rates of A) acetone, ethyl acetate, n-butyl acetate, ethanol, methanol and 
toluene monolayers; B) acetone, acetonitrile, ethyl acetate and tetrahydrofuran multilayers; 
depending on tegafur polymorphic form and particle size. 
The general trend was that desorption rates increased with increasing particle size and there 
was no distinct difference between desorption rates from both polymorphs. Faster desorption 
from the samples with the larger particles was due to easier solvent removal from the sample 
surface, which is favoured by large volume between particles where solvent can diffuse more 
easily if compared to sample with smaller particles. A lack of major changes between both 
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polymorphs indicated that differences in crystal structure and surface properties had no great 
importance on the solvent desorption rates, therefore the main factor affecting desorption rate 
is sample particle size and morphology. Difference in multilayer solvents desorption rates from 
samples with particle size 40−75 µm and less than 40 µm in most cases was considerably lower 
than those for multilayer solvent desorption rates from samples with particle size 75 to 150 µm 
and 40−75 µm just like the surface areas of the analysed samples. 
Solvent desorption rates from α and β tegafur samples showed that desorption rates of 
acetone, acetonitrile, ethyl acetate and tetrahydrofuran from solvent multilayers were 
approximately 30 times higher than those from solvent monolayers. Further experiments with 
samples stored in 50% relative solvent vapour pressure confirmed that the higher desorption 
rates for tetrahydrofuran, acetonitrile, acetone and ethyl acetate most likely were due to 
multilayer sorption. Thus, at 95% relative solvent vapour pressure the sample surface was 
covered with tetrahydrofuran, acetonitrile, acetone and ethyl acetate as molecular multilayer, 
and the desorption rates for molecules situated at the higher layers were much higher than for 
molecules in direct contact with the surface. However, if samples were stored in the same 
solvents at 50% relative solvent vapour pressure, then monolayer solvent sorption dominated 
and only partial surface saturation above the monolayer occurred. This information was also 
confirmed by sorption results, as the amount of adsorbed solvent at 95% and 50% relative 
solvent vapour pressure differed 1.5−3 times for tetrahydrofuran, acetonitrile, acetone and ethyl 
acetate. This suggests that at 95% relative solvent vapour pressure of acetone, acetonitrile, ethyl 
acetate and tetrahydrofuran, the solvent sorption noticeably exceeded monolayer coverage, but 
for n-butyl acetate, ethanol, methanol and toluene the sorption on the tegafur surface was 
significantly below monolayer coverage. 
Schematically solvent desorption process from the surface and its effect on the desorption 
kinetics are illustrated in Figure 3.12. Section A shows the solvent desorption process, the 
solvent molecules in monolayer having a different interaction energy than the rest of the solvent 
molecules (multilayer molecules), and two separate solvent desorption phases were observed 
(solvent molecules with higher interaction energy than the rest of the molecules are 
schematically represented by filled circles). From the solvents used, acetone and ethyl acetate 
exhibited such a desorption behaviour. Desorption of acetonitrile and tetrahydrofuran differed 
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from the rest of the solvents by the absence of the monolayer desorption part (see Figure 3.12.B). 
This means that all of the adsorbed solvent molecules were energetically equal and the ground 
layer solvent molecule interaction with sample surface was not significantly stronger than 
interaction between the solvent molecules themselves. Our assumption was that this 
phenomenon could be related to solvent ability to form hydrogen bonds and other effective 
intermolecular interactions between solvent and surface, as well as between two solvent 
molecules. Ethanol, n-butyl acetate, methanol, and toluene desorption behaviour is 
schematically illustrated in Figure 3.12.C. These solvents were desorbed in one step like in the 
previously described case; with the difference that in this case it was a monolayer desorption. 
 
Figure 3.12. Schematic depiction of solvent desorption behaviour and solvent molecule position on 
the surface. 
The effect of the particle size and solvent vapour relative pressure on desorption curve are 
summarized in Figure 3.13., by illustrating that solvent relative vapour pressure affects only the 
amount of solvent adsorbed on the surface (Figure 3.13.A), but particle size affects the solvent 
desorption rate, if the same amount of solvent was adsorbed (Figure 3.13.B). 
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Figure 3.13. Schematic representation of A) solvent relative vapour pressure and B) particle size 
effect on solvent desorption curve. 
3.5.3. Sample morphology changes during sample storage 
Tegafur sample morphology studies with scanning electron microscope were performed for 
the β tegafur fraction with particle size of 40 µm and less. Scanning electron micrographs for 
sample before and after the experiment (storage at 95% relative acetone vapour pressure for 
72 h) are shown in Figure 3.14. An accelerating voltage of 2.0 kV was chosen because of the high 
sample charging. 
 
Figure 3.14. Scanning electron micrographs of β tegafur samples with particle size 40 µm and less; 
A) before and B) after sample storage at 95% relative acetone vapour pressure for 72 h. 
Scanning electron micrographs show that the sample before storage in solvent atmosphere 
consisted of small particle (<2 µm) agglomerates, but after storage there were almost no such 
particles. This was due to Ostwald’s ripening – small particles with large surface, thus high 
surface energy, tend to reduce their free energy by reducing the ratio of surface to mass, and 
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this occurs by recrystallization to larger particles. Another difference between samples before 
and after storage in solvent atmosphere can be seen if we take a look at the edges and faces of 
the large particles. The edges of β tegafur particles were quite sharp and well defined before 
storage, but after storage became rounded and hardly visible. Differences could be seen also on 
the surface of large particles – after the sample storage at 95% relative acetone vapour pressure 
the surface of the particles became rough and there are signs that tegafur crystallized from the 
solution (see Figure 3.14.B). This experiment shows that minor changes in sample morphology 
occur during sample storage, and actually sample with slightly different particle size and 
morphology are analysed during the experiment. 
3.5.4. Conclusions 
The results of this study demonstrated that solvent desorption from α and β tegafur did not 
differ significantly between these two phases, and solvent desorption in all cases occurred faster 
from samples with the largest particle size. Structure differences and their surface properties are 
not of great importance on the solvent desorption rates and the main factor affecting desorption 
rate is sample particle size and sample morphology. 
Two different solvent desorption behaviours can be distinguished depending on the solvent 
and surface interaction energy. If the solvent and surface interaction was stronger than 
interaction between solvent molecules, than multilayer and monolayer desorption was 
observed, but, if the adsorbed solvent molecules were of equal energy, then only one desorption 
phase was observed. Solvent desorption rates of acetone, acetonitrile, ethyl acetate and 
tetrahydrofuran multilayers from α and β tegafur were approximately 30 times higher than 
those from solvent monolayers. 
Small tegafur particles recrystallized to larger particles during sample exposure to solvent 
vapour atmosphere, and there were morphological signs of tegafur recrystallization from 
solution on the surface of the particles.  
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3.6. Solvent mediated phase transformation between two tegafur polymorphs in 
several solvents 
In order to gain more fundamental insight on solvent stimulated polymorphic 
transformations – both solvent drop milling and solvent vapour induced phase 
transformations, classical solvent mediated phase transformation (see section 1.7) from 
metastable α tegafur to the thermodynamically stable β tegafur in several popular solvents from 
different solvent classes was studied. 
During our first SMPT kinetics experiments we noticed that the sample drying time had an 
impact on the extent of phase transition – samples, dried at ambient temperature, had increased 
β tegafur content. This was because the thermodynamically stable β tegafur crystallized from 
the saturated tegafur solution that was sampled together with the solid phase, i.e., phase 
transition to β tegafur partially occurred during sample drying, not only during the slurrying. 
In order to avoid this effect, samples for SMPT kinetic experiments were quickly filtered using 
a glass filter funnel with Bunsen flask under reduced pressure. 
The results of the kinetics experiments performed at room temperature (22±1 °C) represent 
a series of plots documenting the composition of the solid phase during the SMPT, as detected 
with the PXRD method. Figure 3.15. shows the composition of the solid phase during the SMPT 
in acetone, ethanol, i-propanol, toluene, and water. These data were used to generate an 
additional data plot where phase transition kinetics curves were normalized to the state where 
a complete transition to β tegafur was observed (Figure 3.16.). This means that the time when a 
complete phase transition was observed was considered as 100%. Using this approach we could 
compare the reaction rate and reaction path in all the solvents used. This figure clearly 
demonstrates that the phase transition models were the same in all the solvents, and the only 
factor that changed was the phase transition rate. An induction time was observed at the 
beginning of phase transitions in all solvents. We cannot clearly assure whether the observed 
delay of the phase transition is an induction time or the time that is necessary for β tegafur 
crystals to grow; however, we believe that this was the limiting step in investigated SMPTs. We 
see that the induction times in all the solvents were proportionally the same – about 10% of the 
phase transition time. It is worth noting that the LOD of our quantitative analysis method was 
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3.0%, therefore the observed induction time might be the time that was necessary to overcome 
this 3.0% range. 
Solution concentration throughout SPMT stayed at the level of α tegafur solubility, and 
started to decay only when all α tegafur transformed to the stable β tegafur (Figure 3.17.). This 
means, that the overall rate of consumption of supersaturation by β tegafur crystal growth was 
lower than the overall rate of α tegafur dissolution. This case is denoted as “nucleation-growth 
controlled polymorphic transformation” [185]. 
 
Figure 3.15. The weight fraction of β tegafur during the SMPT from α tegafur to β tegafur in acetone, 
ethanol, i-propanol, toluene, and water at 22 °C. Line added as a guide. 
 
Figure 3.16. The weight fraction of β tegafur during the SMPT in acetone, ethanol, i-propanol, 
toluene, and water at 22 °C, normalized to the state where the transition to β tegafur is complete. 
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Figure 3.17. Solution concentration (●), and weight fraction of β tegafur in the solid phase (○) 
during the SMPT from α tegafur to β tegafur in acetone at 22 °C. The dashed line (---) represents the 
solubility of α tegafur, continuous line (—) represents the solubility of β tegafur. 
The induction time was followed by a gradual increase of the thermodynamically stable β 
tegafur fraction. SEM analysis of the sample, where β tegafur was first detected using PXRD 
method, revealed that the blocky β tegafur crystal were in contact with the surface of α tegafur 
needle-like crystal side faces (Figure 3.18.). Although it is possible that α and β tegafur crystals 
simply agglomerated together during the sample filtration and drying, the fact that it was not 
possible to separate these crystals without damaging them, indicated that β tegafur, most likely, 
nucleated epitaxially on the surface of α tegafur. Observed epitaxially driven polymorphic 
transformations are common in SMPTs [8,9,179,184,191,193,261]. The surface of the α tegafur 
here acted as a nucleation substrate for the β tegafur by either decreasing the solution-nucleus 
interfacial energy, by topographical contribution or by a crystal lattice match [9]. The surface 
nucleation might have also been a consequence of a local lattice disorder or amorphous region 
that had similarity to crystallizing β tegafur [8]. 
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Figure 3.18. SEM images of the solid phase of SMPT in acetone taken at 60 min. Scale bar 40 µm. 
In order to estimate the nucleation mechanism and understand which α and β tegafur crystal 
faces were in contact, crystal face indexing was performed for both polymorphs. Crystals, where 
β tegafur was in contact with α tegafur (like those in Figure 3.18.), were not suitable for β tegafur 
crystal face indexing, therefore individual β tegafur crystals were indexed. Crystals for β tegafur 
face indexing were collected at 300 min, when individual β tegafur crystals suitable for crystal 
face indexing were in the sample. Appropriate β tegafur crystals were picked out from the phase 
mixture. Face indexing of α tegafur crystals were performed for sample collected at 60 min. 
SEM images showed that β tegafur nucleated on one of the needle-like crystal side faces, 
while crystallographic face indexing of α tegafur crystal (Figure 3.19.A) indicated that these 
faces were {001}, {011} and {010}. A visual comparison of epitaxially nucleated β tegafur crystal 
morphology and indexed crystal morphology (Figure 3.19.B) indicated that crystal face family 
{100}, {110} or {010} must be in contact with α tegafur surface. Intermolecular distance and 
molecule alignment analysis along these faces revealed that there was a good agreement at a 
molecular level between the {110} face of β tegafur and {010} face of α tegafur crystal (Figure 
3.20.), while no match was observed along other crystal faces. Possible lattice match between 
{100}, {110} and {010} face of β tegafur and {001}, {011} and {010} face of α tegafur was examined 
using EpiCalc 5.0 software [262]. The lattice matching calculations indicated that there was no 
lattice matching between any of the studied faces (EpiCalc data can be found in Appendix 4). 
However, it should be taken into account that crystal surface molecules are not static – they 
change their position, arrangement and conformation [37,263], and therefore they could 
arrange into the state, which promoted the growth of β tegafur. This means that the nucleation 
of the β tegafur might be favoured by the surface molecule rearrangement. The {110} surface of 
β tegafur and the {010} surface of α tegafur have similar tegafur molecule arrangement at the 
surface and distances between tegafur dimers are the same for both polymorphs in relevant 
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directions. Because of this, nucleation of β tegafur on {010} face of α tegafur might be initiated 
by minor surface tegafur dimer displacement, conformation change, rotation. The strongest 
hydrogen bond donor and acceptor groups are involved in dimer formation and interactions 
between dimers are relatively weak. These weak interactions at the growing surface are less 
efficient at directing the orientation on an incoming dimer synthon and therefore tegafur 
dimers at the surface are relatively mobile. Figure 3.21. shows, that tegafur dimer arrangement 
similar to that in β tegafur, could be achieved by minor α tegafur surface molecule rotation. 
Such local lattice disorder would spread and eventually thermodynamically stable β tegafur 
would nucleate and continue to grow. 
 
Figure 3.19. Single crystal face indexing of α and β tegafur. 
 
Figure 3.20. Schematic model of β tegafur growing on the α tegafur surface (010). Hydrogen atoms 
are omitted for clarity. 
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Figure 3.21. Schematic representation of tegafur dimer rearrangement on the α tegafur surface to 
initiate the growth of β tegafur. Hydrogen atoms are omitted for clarity. 
In order to quantitatively compare SMPT rates in different solvents, experimental data were 
described with appropriate kinetic model. SEM imaging of the studied SMPT revealed that the 
phase transition took place on the solid phase surface (the phase transition was heterogeneous), 
therefore attempts were made to describe experimental data points with the most common 
solid-state kinetic models [104]. Evaluation of observed phase transformation nature and 
crystal growth morphology indicated that experimental data were in agreement with power 
solid-sate kinetics models. The best correlation was observed when the experimental data points 
were fitted to the power model P2: 
 ᵪ� = (ᵅ�ᵅ�)2 3.5, 
where k is the phase transition rate constant, α is the weight fraction of β tegafur in sample, and 
t is time. The correlation of the experimental data with the theoretical model and phase 
transition rate constants in each solvent are given in Table 5. Rate constants were calculated 
using MS Excel [257] optimization add-on Solver, based on the least squares method [264,265]. 
The power law model P2 used here assumes that the nucleation rate follows the power law, 
while nuclei growth is assumed to be constant [104,266,267]. Nuclei and crystal growth was 
constant, because it took place through crystallization from saturated α tegafur solution. The 
limiting step in nuclei growth was the transport of the tegafur molecule to the crystallization 
zone. Diffusion of tegafur molecules was expected to occur at a constant rate throughout the 
phase transition, because the studied phase transition occurred in solution, which was saturated 
with respect to α tegafur (supersaturation was constant during phase transformation). Taking 
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this into account, nuclei growth rate can be assumed to be constant. This means that the rate-
controlling step in the examined SMPT was the nucleation. There are two scenarios for 
nucleation [267]. The first option is a simultaneous formation of all nuclei; the second option 
is that nucleation occurs stepwise, with nuclei forming over a period of time. SEM imaging 
(Figure 3.18.) shows that β tegafur crystals, observed in the sample where β tegafur was first 
detected, had deviations in the crystal size. This indicates that nucleation in the examined SMPT 
occurred over a period of time. Besides, it is very unlikely that all the nucleation sites would 
have approximately the same reaction (phase transition) activation energy minimum, which 
would be necessary for a simultaneous nucleation. Clearly, nuclei formed first at the nucleation 
sites with the lowest activation energy, and then nucleation gradually spread to the other 
nucleation sites in a rising activation energy order. Since nuclei and crystal growth was constant, 
this nucleation behaviour can be described with a second-order power function. 
Table 5. The P2 model rate constants of SMPT and correlation coefficients, depending on the solvent 
used; the experiment was performed at 22 °C. 
Solvent Rate constant, min-1 Correlation with P2 model, R2 
Acetone 0.028 0.92 
Ethanol 0.023 0.96 
i-Propanol 0.0090 0.92 
Water 0.0065 0.98 
Toluene 0.0056 0.98 
 
The fact that the best experimental and theoretical data correlation was observed for the 2 
dimensional model indicates that the phase transition rate most likely was proportional to the 
surface area of the β tegafur crystals formed [267]. With that said, we can conclude that in the 
examined SMPT β tegafur crystals nucleation corresponds to a second-order power function, 
their growth rate was constant, and the phase transition rate was proportional to the β tegafur 
crystal surface area. 
Despite the fact that solubility and phase transformation kinetic data suggested that this 
phase transformation was limited by nucleation, the correlation between SMPT rate constant 
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and the difference between α and β tegafur solubility in the respective solvent was observed: a 
faster phase transition was observed for the samples slurried in solvents where the difference in 
polymorph solubilities was high (Figure 3.22.). This trend in the SMPT from α tegafur to β 
tegafur was described with equation: 
 ᵅ� = (0.038 ± 0.003)∆ᵅ�ᵅ�ᵅ�. +(0.005 ± 0.001) 3.6, 
where ∆ᵅ�ᵅ�ᵅ�. is difference between α and β tegafur equilibrium solubilities in the respective 
solvent, and k is the rate constant of the SMPT in the same solvent. The correlation coefficient 
was R2=0.97. This correlation means that the driving force in the studied SMPT was excess 
concentration above the equilibrium concentration of β tegafur, i.e. supersaturation with 
respect to β tegafur. 
Supersaturation provided the necessary driving force to overcome the energy barrier to 
promote β tegafur nuclei and crystal growth [5]. In this case supersaturation coincided with the 
difference between α and β tegafur equilibrium solubility in the respective solvent, because the 
solution concentration throughout the phase transformation was fixed at the equilibrium 
concentration of α tegafur. Such solution concentration profile also means that the driving force 
was constant throughout the SMPT. Higher tegafur supersaturation in the solution promoted 
faster phase transformation to the thermodynamically stable β tegafur, because of the increased 
degree of local organization in the solution necessary for crystallization [37], and faster tegafur 
molecule transfer to the crystallization zone (molecules were relatively close). Absolute tegafur 
solubility and the difference between polymorph solubilities depends on the chosen solvent, 
however, the free energy (ΔG) difference between polymorphs does not depend on the solvent 
[176]. This means that the overall driving force of phase transformation was not dependent on 
the chosen solvent, and the SMPT rate depended only on the difference between polymorph 
solubilities (supersaturation). The only SMPT step that might be affected by solvent choice was 
β tegafur nucleation [58,61,268,269]. Tegafur molecules were solvated in the solution, similar 
to the surface of molecular aggregates and crystals. In order to nucleate and continue 
crystallization, tegafur molecules had to be desolvated, and solvent molecules on the nuclei or 
crystal surface had to be replaced by incoming tegafur molecules. This process, most likely, was 
affected by the nature of the solvent and its electron donor/acceptor properties, because strong 
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solute-solvent interaction would inhibit desolvation and therefore nuclei growth, while weak 
solute-solvent interaction would not have a significant impact on nuclei growth. 
 
Figure 3.22. Correlation between SMPT rate constant in acetone, ethanol, i-propanol, toluene, and 
water, and difference between α and β tegafur solubility (Δsol.) in respective solvent. Correlation 
equation y=(0.038±0.003)x+(0.005±0.001); R2 =0.97. 
3.6.1. Conclusions 
The SMPT from α tegafur to β tegafur in acetone, cyclohexane, ethanol, i-propanol, toluene, 
and water at 22 °C is nucleation-growth controlled and it can be described with the P2 power 
model. The rate constants for this process were in the range from 0.028 min-1 to 0.0056 min-1. 
In all the employed solvents an induction time (about 10% of the time required for complete 
phase transition) was observed, indicating that nucleation and/or initial crystal growth was the 
limiting factor for SMPTs performed in saturated solutions. In the examined SMPT the 
nucleation of β tegafur crystals corresponded to second-order power function, nuclei and 
crystal growth rate was constant, and the phase transition rate was proportional to the β tegafur 
crystal surface area. Surface nucleation was observed in studied SMPT. Crystal habit 
investigation indicated that β tegafur nucleated on the {010} face of α tegafur, and the {110} face 
of β tegafur was in contact with α tegafur crystal. The SMPT rate depended linearly on the 
supersaturation level, i.e. difference between α and β tegafur equilibrium solubility in the 
respective solvent.  
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3.7. The Reluctant Polymorph. Self-association effect on nucleation and solvent 
mediated phase transformation of theophylline 
The knowledge acquired during previously described studies were used to study solvent 
mediated phase transformation of pharmaceutically active compound of academic importance 
– theophylline. Theophylline is an active compound that has been manufactured and used in a 
metastable crystalline phase (clearly, because of the lack of comprehensive knowledge of the 
polymorphic landscape of this compound). The fact that the thermodynamically stable 
theophylline polymorph was discovered only recently, is because it does not crystallise directly 
from solution, and is obtained only by slow, solvent mediated transformation (SMPT) from 
Form II in contact with solvent e.g. methanol, 2-propanol or chloroform [237]. Here we try to 
understand why the thermodynamically stable theophylline Form IV can be obtained only by 
solvent mediated transformation in specific solvents, and to investigate the presence of 
prenucleation aggregates which direct the polymorphic outcome of crystallisation. 
Early experiments [270–273] on theophylline self-association provide evidence that 
theophylline does self-associate in aqueous solution and the proposed aggregate is the 
theophylline dimer. The theophylline dimer discussed in these studies is present in the 
thermodynamically stable Form IV, and theophylline monohydrate, Form M, which crystallises 
from aqueous solutions. Theophylline Form II, the polymorph commonly crystallized from 
most non-aqueous solutions, does not contain this dimer motif (crystal structures of 
theophylline polymorphs are discussed in detail in section 1.9.2). Such behaviour raises two 
questions: why does metastable Form II crystallize from non-aqueous solvents; what 
prenucleation aggregates are present in non-aqueous solvents? In order to answer these 
questions, we need to determine (a) does theophylline self-associate in other solvents besides 
water, and, if it does, what is the nature of the association, and (b) since the nucleation of Form 
IV is kinetically slow, does solution aggregation change over time? 
3.7.1. Characterisation of SMPT from theophylline Form II to Form IV 
The SMPT of unprocessed commercial anhydrous theophylline Form II in methanol was 
investigated. Three parallel experiments were performed, but for the sake of clarity only one 
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case is taken as an example of the whole set of experiments to describe and discuss in detail the 
results obtained. 
 
Figure 3.23. Solution concentration (●), and weight fraction of the theophylline Form IV in the solid 
phase (○) during the solution mediated transformation from theophylline Form II to Form IV in 
methanol at 23 °C. The dashed line (---) represents the solubility of theophylline Form II, continuous 
line (—) – solubility of theophylline Form IV. 
During the solvent mediated phase transformation qualitative and quantitative analysis of 
the solid phase were performed using powder X-ray diffractometry (PXRD), Fourier transform 
infrared spectroscopy (FTIR) and scanning electron microscopy (SEM) methods; while the 
solution concentration throughout the transformation was monitored using ultraviolet-visible 
(UV/Vis) spectroscopy. The composition of solid phase determined by PXRD method and 
solution concentration throughout SMPT is presented in Figure 3.23. Results of all three 
experiments showed that the phase transformation from theophylline Form II to Form IV 
showed a considerable induction time which varied from 4 to 6 days while the phase transition 
itself consistently took ~2 days. Such behaviour, that induction time for parallel experiments 
had a great variation, while the phase transition time in all cases was approximately the same, 
suggests that the limiting step for this SMPT is the nucleation of Form IV. The main factors that 
might affect the nucleation and hence the induction time are discussed further. 
The equilibrium saturation of the metastable Form II was reached ~3 h after the theophylline 
addition to methanol. The concentration of the solution remained the same until phase 
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transformation was completed. Solution concentration dropped to the equilibrium saturation 
of the thermodynamically stable Form IV within a few hours of the phase transformation being 
completed, indicating that, once all of the Form II in the sample had dissolved, Form IV 
continued to grow until the solution reached the Form IV equilibrium concentration. This 
shows that the dissolution rate of theophylline Form II was faster than the growth of Form IV 
and dissolution was not the limiting step in the phase transformation. Such a solution 
concentration profile and pronounced induction period indicates that the SMPT was a 
‘nucleation-growth controlled polymorphic transformation’ [185]. The fact that phase 
transformation is also growth limited was confirmed by the time scale of the studied SMPT – 
most of the SMPTs described in the literature take place within a few hours 
[9,176,178,179,184,185,187,274–276], but here phase transformation took ~2 days from the 
moment when Form IV nucleated. This might be due to low supersaturation, which provided 
the necessary driving force to overcome the energy barrier and promoted Form IV 
crystallization [5]. In this case, supersaturation is the difference between the solubilities of Form 
II and Form IV. 
The increase of the Form IV content in the sample exhibited an exponential nature – the 
amount of Form IV increased slowly in the initial stage and then accelerated. Such behaviour 
suggests that the growth of Form IV might be limited by the surface area of Form IV in the 
sample; hence, the rate of SMPT increased as the crystal size (surface area) in the sample 
increased. This assumption was consistent with SEM imaging data, shown in Figure 3.24. 
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Figure 3.24. SEM images throughout SMPT from theophylline Form II to Form IV in methanol at 
23 °C. Inset: time of sample gathering (days), 40 µm scale bar, Form IV indicated with blue colour. 
It is known [237] that theophylline Form II exhibits a needle-like morphology, while Form 
IV crystallizes in hexagonal plate-like crystals. These distinct differences in the crystal shape 
allowed phase transition monitoring using microscopy methods. SEM imaging of the solid 
phase throughout SMPT (Figure 3.24.) revealed that during the first days, while no phase 
transformation was observed, the only apparent change in the solid phase was the agitation and 
Ostwald’s ripening of the theophylline Form II crystals – Form II crystals dissolved mostly from 
the top of the elongated crystals (along c axis) and then recrystallized on the Form II crystal side 
planes (see Figure 3.24., day 1 and day 3). Theophylline Form IV crystals were first observed 
after 5 days, and all observed hexagonal Form IV crystals were approximately the same size: 
~40 µm in diameter and 1−2 µm thick. A similar size for all observed Form IV crystals suggests 
that they nucleated simultaneously or in a very short time interval. Recent studies 
[179,184,191,261] show that surface nucleation dominates in most of SMPTs, however in our 
case there was no clear evidence of such behaviour. Over time Form IV crystals grew 
significantly in 2 dimensions, forming large, plate-like crystals. This growth pattern indicates 
that the growth of the Form IV was governed by the surface of the crystal edges. Eventually, 
breakage of Form IV crystals was observed (day 6), which would lead to increased surface area 
of the edge faces, where crystal growth was fastest, thereby accelerating the crystallization rate 
of Form IV. 
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Preferred Form IV crystal growth directions were determined by the PXRD method. It is 
observed that the PXRD pattern of Form IV crystals after the SMPT have two very intensive 
peaks at 12 and 23° 2θ (Figure 3.25.), suggesting that the sample exhibits preferred orientation. 
Comparison of the pattern with that simulated from the crystal structure revealed that these 
intensive diffraction peaks arise from crystal planes (002) and (004) – the multiple planes of the 
{001} face family. Since plate-like crystals tend to lay down with the dominant faces parallel to 
the PXRD sample holder, the most intense diffraction should occur from this plane. It can 
therefore be concluded that the dominant face in the Form IV crystals obtained during SMPT 
is {001} and crystal growth occurred almost exclusively along this plane. The reason for such 
crystal growth behaviour is that there are no significant intermolecular interactions in the c-
direction of theophylline Form IV, whereas crystal growth along {001} plane is favoured by 
hydrogen bonding and π-π stacking (Figure 3.26.). 
 
Figure 3.25. PXRD patterns of Form IV obtained by SMPT in methanol (—); and simulated from 
crystal structure (---). 
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Figure 3.26. Crystal packing in theophylline Form IV along {001} plane. Hydrogens are omitted for 
clarity. 
Based on morphological observation, Form IV crystal growth perpendicular to {001} was 
observed only when phase transformation was finished – during the SMPT the surfaces of Form 
IV crystal plane {001} were flat (Figure 3.24., day 8.3), whereas 2 days after the SMPT elevations 
on the surface of the Form IV were observed because of crystal agitation (Figure 3.24., day 10). 
The crystal growth rate along {001} was considerably higher than growth rate perpendicular to 
{001} during phase transformation, likely to be because energy released on solution molecule 
attachment to growing crystal edge surface was higher [277]. When phase transformation was 
complete, Ostwald’s ripening [37] took place and crystals tended to achieve minimum total 
surface energy by reducing the crystal surface area. Here, this means that crystals grew 
perpendicular to the large {001} plane at the expense of plate like crystal edges, which dissolved 
more easily [37]. 
Surface nucleation dominates in the majority of SMPTs, therefore experiments with ground 
and lyophilized theophylline as a starting material were performed to evaluate the effect of the 
Form II surface on the nucleation and crystallization of Form IV. There were no significant 
differences in the phase transformation behaviour when ground and unground theophylline 
was used. PXRD and SEM data showed that when the ground Form II was agitated, Ostwald`s 
ripening took place, and crystallization of Form IV followed only after 6 days. If theophylline 
Form IV nucleated on the surface of the Form II, the increase of the Form II surface area in the 
ground sample should reduce the induction time. However, this was not observed, suggesting 
that Form IV did not nucleate on the surface of Form II. When lyophilized theophylline, 
confirmed as a mixture of amorphous theophylline and microcrystalline Form II, was used, no 
phase transition to Form IV was observed within the studied time (90 days). The lyophilized 
material agitated in solution and the crystallinity of Form II increased (Figure 3.27.), but no 
phase transition was detected. It is not clear why crystallinity of the Form II starting material 
should influence the nucleation of Form IV since this is not a surface nucleation process. Later 
experiments on water content (see below) indicate that the ability of amorphous material to 
absorb water might be more important than crystallinity. 
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Figure 3.27. SEM images throughout lyophilized theophylline slurrying in methanol at 23 °C. Inset: 
time of sample gathering (days) and 20 µm scale bar. 
In order to ascertain whether theophylline aggregates present in the methanol solution affect 
the phase transformation, an experiment using methanol solution saturated with respect to 
Form IV as a solution medium was performed. The SMPT held approximately the same 
induction and phase transformation time (5 and 2 days, respectively) as experiments in 
methanol. 
Similar experiments with theophylline Form II and Form IV mixture (wII/wIV; 90/10) as a 
starting material were performed to exclude induction time and observe only phase 
transformation. No induction times were observed in either case, and phase transformation 
rates were the same regardless of solution composition (Figure 3.28.). This means the molecular 
aggregates, if there were any at all, in both saturated solutions were the same and/or they did 
not play a significant role in the phase transformation. If we compare theophylline Form IV 
weight fraction change over the time in these experiments and those, performed with 
commercial Form II as a starting material, we see that phase transformation with theophylline 
Form II and IV mixture as a starting material occurs three times faster. We believe that this 
phase transformation rate mismatch is due to differences in the Form IV crystal active edge 
surface areas for the samples. SEM imaging confirmed that Form IV edge surface area in 
prepared polymorphic mixtures were larger, than in the sample where the same amount of 
Form IV was generated by SMPT. Since this is the region in which growth of Form IV 
dominates, larger surface area leads to faster rate of growth, therefore a faster transformation. 
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Figure 3.28. Weight fraction of the theophylline Form IV in the SMPT from theophylline Form 
II/Form IV mixture (wII/wIV; 90/10) to Form IV, in saturated (○) Form IV and (●) Form II methanol 
solutions at 23 °C. Δ represents the weight fraction of the theophylline Form IV in the solid phase 
during the SMPT from theophylline Form II in methanol at 23 °C. All kinetic curves are fitted to the 
time when weight fraction of Form IV in solid phase was 10%. 
Seton et al. [237] reported that theophylline equilibrium solid phase depends on the water 
activity in the solution, and that Form IV is preferred when water activity in the solution is 
below 0.69 (VMeOH/VH2O, 55/45). To investigate the possibility that water activity affects also the 
phase transformation rate to Form IV, SMPT was observed in solvents samples with different 
water contents. SMPT from theophylline Form II to Form IV, performed in dried methanol 
and methanol/water mixtures with volume ratios (VMeOH/VH2O) 99:1, 95:5 and 80:20, clearly 
showed that increased water in the solution increased the induction time (Figure 3.29.A). Phase 
transformation rate also increased but with a lesser effect – from 1.5 days in dried methanol to 
5 days in methanol/water mixture (VMeOH/VH2O; 95/5). 
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Figure 3.29. Induction and phase transformation times of SMPT from theophylline Form II to Form 
IV at 23 °C depending on used solvent environment. No phase transformation to Form IV was been 
observed in formic acid and methanol/water mixtures with 5% and 20% of water within the studied 
period (40 days). 
These results might explain why fluctuation of induction time were observed in the earlier 
SMPTs. Methanol used in initial experiments was used as received and was taken from different 
batches, therefore the water content (adsorbed from the air) was not the same in all samples. 
Karl Fisher titration showed that batch methanol contained ~0.2% of water, whereas methanol 
dried with anhydrous NaSO4 contained less than 0.1% water. These minor water impurities 
affected the induction time of the SMPT. This might be the reason why phase transformation 
with lyophilized theophylline as starting material was hindered. Theophylline lyophilisation 
resulted in partially amorphous theophylline, which tends to absorb more water from the air 
than crystalline phases [149], and it is possible that the phase transition in this case was slowed 
down by adsorbed water. 
The induction times and transformation times in a range of solvents were measured and 
compared (Figure 3.29.B). We see that phase transition times correlated to induction times – 
the longer the induction time, the slower the phase transformation. This might indicate that 
nucleation and Form IV growth were limited by the same factors. 
It has been shown previously [278] that in the nucleation-growth controlled SMPT between 
α and β tegafur, the phase transformation rate and induction time linearly depends on 
supersaturation level, i.e. difference between solubilities of the polymorphs. Here we do not 
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observe such a correlation. This might be because Form IV nucleation and growth is not 
affected by supersaturation level, perhaps, because the difference in solubilities is small. 
Crystallization always gave Form II, including crystallization from solutions with Form IV 
equilibrium concentration. Even seeding with Form IV, gave Form II and Form IV mixture. 
Induction and phase transition times were longer in solvents (solvent mixtures) which had 
good proton donor groups. Fastest phase transformation and shortest induction time were 
observed in dried methanol, followed by stock methanol, acetonitrile and acetone. Longest 
induction times were observed in proton donor solvents – chloroform and formic acid, and 
previously discussed methanol/water mixtures. In fact, no Form IV has been detected in formic 
acid and methanol/water mixtures 95/5 and 80/20 within the studied period of 90 days. An 
influencing factor might be theophylline molecule and aggregate solvation/desolvation 
behaviour. Theophylline molecules are solvated in the solution, but in order to nucleate Form 
IV and continue its growth, theophylline molecules have to be desolvated, and solvent 
molecules on the nuclei or crystal surface be replaced by incoming theophylline molecules. 
Taking in to the account that induction time was several days and phase transformation was 
very slow, we can assume that solute-solvent interaction in studied SMPT was strong compared 
to solute-solute interaction and thus the desolvation process inhibited Form IV nucleation and 
growth. 
In order to further understand how the solvent environment affects SMPT rate and 
induction time, NMR spectroscopy was used to investigate for prenucleation aggregates in the 
solution.  
3.7.2. Theophylline self-association studies 
To understand solution chemistry and ascertain possible aggregation of theophylline 
molecules in solution, the influence of theophylline solution concentration on 1H NMR 
chemical shift displacement was analysed. 1H NMR experiments were carried out in seven 
solvents (methanol-D4, chloroform-D, acetone-D6, dimethyl sulfoxide-D6, deuterium oxide, 
acetonitrile-D3 and formic acid-D2). These solvents were chosen because: (a) it is known that 
in dimethyl sulfoxide and water theophylline crystallizes as solvates and the crystal structures 
of these solvates are not similar; (b) they have different H-bond donor/acceptor properties: 
105 
 
acetone, acetonitrile and dimethyl sulfoxide are H-bond acceptor; chloroform is H-bond donor; 
water, methanol and formic acid are both – H-bond donor and acceptor; and (c) from formic 
acid theophylline crystallizes into Form II with no subsequent transformation observed. 
The concentration range covered in this experiment was the same for all solvents – from 
saturated to 1 µM theophylline solution. The number of scans for NMR spectra acquisition was 
adjusted depending on solution concentration. Theophylline solutions with lower 
concentrations were not studied because the NMR spectra acquisition time, necessary to obtain 
spectra with acceptable signal/noise ratio, would be unreasonably long. 
The theophylline used in the experiment had natural 1H/2H abundances and therefore the 
most acidic imidazolium group proton (N7-H) took part in proton exchange with the 
deuterated solvent deuterium atoms. As a result, the imidazolium group proton was visible in 
the NMR spectra in solvents where only partial proton exchange took place - chloroform-D, 
dimethyl sulfoxide-D6 and acetonitrile-D3. Methyl group protons and alkene group proton 
(C8-H) did not showed any effect on proton exchange. 
If there are multiple structures that have different thermodynamic stabilities and perturb the 
1H NMR chemical shifts in different ways, the shapes of the dilution curves differ for different 
signals. While this does not rule out the possibility of multiple structures, the data can be treated 
as a simple two state equilibrium, and the complexation-induced changes in chemical shift are 
assumed to relate to a single specific aggregate structure [87]. Since the solubility of the 
theophylline in all selected solvents except formic acid is low (>0.06 M) multiple aggregate 
structures are not expected. 
No chemical shift displacement upon concentration changes were observed in methanol-D4, 
acetone-D6, dimethyl sulfoxide-D6 and acetonitrile-D3. This means that no self-association 
takes place in these solvents, or theophylline undergoes dimerization or other self-association 
at concentrations lower than those covered in the experiment, i.e. below 1 µM, and other 
agglomerates do not form in the concentration region studied. It is unlikely that self-association 
occurs at such low concentrations, and it is probable that solvated theophylline monomers were 
the main species in the solution.  
1H NMR dilution studies in chloroform-D, deuterium oxide and formic acid-D2 showed 
large concentration-dependent changes in chemical shifts. In the chloroform-D all chemical 
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shifts were displaced to lower fields as concentration increased (Figure 3.30.A). In deuterium 
oxide methyl groups 1H chemical shifts were displaced to higher field while the alkene group 
proton (C8-H) chemical shift was displaced to the lower field (Figure 3.30.B). Imidazolium 
group proton (N7-H) chemical shift was not observed in the deuterium oxide due to proton 
exchange. In formic acid-D2 alkene group proton (C8-H) chemical shift was displaced to higher 
field, whereas imidazolium group proton (N7-H) chemical shift was displaced to lower field 
(Figure 3.30.C). Minor methyl groups 1H chemical shift displacement to higher and field were 
observed as concentration increased. The pattern and magnitude of chemical shift changes are 
completely different in all solvents, indicating that aggregates present in these solutions are 
different. It is likely the associate existing in the deuterium oxide is the theophylline dimer 
which is also present in the crystal structure of theophylline monohydrate (Figure 3.31.A). The 
associates in chloroform-D solution might be the asymmetric dimer corresponding to Etters 
rule (Figure 3.31.B), π-π stacked dimer or some associate involving solvent molecules. It is also 
possible, that chemical shift displacement is reflecting the average structure of multiple 
aggregates. Since theophylline solubility in formic acid is noticeably higher than in other 
solvents (more than 30 times), it is possible that associates present in formic acid-D2 were 
oligomers and not dimers. Data shows that theophylline concentration at which self-associates 
were formed were different in each solvent. In deuterium oxide theophylline formed self-
associates at 10-4 M solution, in chloroform at 10-3 M solution, and in formic acid-D2 at 10-2 M 
solution.  
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Figure 3.30. Theophylline chemical shift displacement depending on chloroform-D (A); deuterium 
oxide (B); and formic acid-D2 (C) concentration. Chemical shifts are indicated as: methyl group C10 
protons (●); methyl group C12 protons (○); alkene group proton (C8-H) (Δ); and imidazolium 
group proton (N7-H) (▲). 
 
Figure 3.31. Theophylline dimer present in crystal structures of monohydrate, Form IV and most 
cocrystals (A); and the preferred theophylline dimer according to Etters rules (B). 
No change in chemical shift displacement was observed with time (>20 days) in any studied 
solvents. Small scale SMPT performed in methanol-D4 showed the same – solution 
composition did not change over time; hence, no aggregates are formed or disarranged during 
slurrying indicating that this is not the reason for long induction times. 
Theophylline dimers/aggregates formed in solvents which are good proton donors [279]. 
These were the solvents where SMPT exhibited longest induction times and phase transition 
rates (we should mention that SMPT in water does not occur, because theophylline 
monohydrate is the most stable crystalline form in aqueous environments). Such correlation 
implies that the presence of theophylline dimers or aggregates in the solution hinders the 
nucleation and growth of Form IV. It is likely that the reason why good proton donors inhibit 
phase transformation and extend induction time is the formation of solvent molecule stabilized 
theophylline dimers/aggregates. Trask et al. [248] have suggested that the theophylline dimer 
motif is favoured by the presence of a competing strong hydrogen bond donor in the system (in 
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this case formic acid, chloroform or water in methanol/water mixture). The strongest hydrogen 
bond donor in theophylline solution forms a hydrogen bond with the system’s most basic group 
– theophylline imidazole group nitrogen (N9). This bond fulfils the ‘best-donor–best-acceptor’ 
rule and consequently permits theophylline dimer formation by secondary hydrogen bonding 
(N7-H···O13). Such solvated theophylline dimer should be the most stable aggregate in the 
solution, since it uses the system’s best donors and acceptors. This explains why increasing 
water in the methanol sample increased induction time and extended phase transformation 
time. The increase of water in methanol/water mixture increased the level of hydrated 
aggregates in the solution, and the more solution theophylline molecules were bound in these 
dimers, the more formation of Form IV was hindered. 
Solvated theophylline aggregates inhibit nucleation and growth of Form IV, either because 
they are not the correct structure to nucleate Form IV or because these associates need to be 
desolvated or disarranged in order to crystallize. If the solute solvent bonds are stronger than 
the weak inter dimer interactions in the solid structure, then the desolvation process is 
unfavourable and therefore phase transition is slow. 
3.7.3. FTIR studies of theophylline crystallization from saturated solutions 
It is known [3,5,256,280,281] that FTIR spectra of polymorphs and their solutions are 
different. Parveen et al. [64] have shown that FTIR spectroscopy can be used to show a direct 
relationship between molecular self-associates in solution and motifs in the subsequently 
crystallised solid phases. Here we use FTIR spectroscopy to monitor theophylline crystallization 
from acetone, acetonitrile, chloroform, methanol and water. FTIR spectra of saturated 
theophylline solution were continuously recorded during solvent evaporation and subsequent 
– theophylline crystallization. FTIR spectra of both theophylline polymorphs studied in this 
work are clearly different and therefore suitable for such an experiment (Figure 3.32.). However, 
due to low theophylline solubility in the selected solvents, only the strongest carbonyl group 
stretching bands were visible in the initial spectra. 
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Figure 3.32. FTIR spectra of theophylline Form II (—) and Form IV (---), showing carbonyl group, 
alkene group hydrogen bond and imidazolium group hydrogen bond stretching band assignment. 
It is known [282] that hydrogen bonding lengthens and weakens the C=O bond, therefore 
the carbonyl group stretching band is observed at a lower frequency; thus the stronger the 
hydrogen bonding, the lower the stretching frequency. This rule can be clearly seen in the case 
of theophylline. Carbonyl group C2=O11, which is not involved in the hydrogen bonding in 
either polymorph (there are only weak interactions with theophylline methyl group hydrogens), 
have an identical band position in the FTIR spectra (1706 cm−1) and the stretching frequency is 
higher than that of C6=O13 carbonyl group. In Form IV, the carbonyl group C6=O13 is 
involved in strong hydrogen bonding with the best hydrogen bond donor (N7-H) and this 
results in a stretching frequency of 1640 cm−1; while in Form II, the C6=O13 group is involved 
in two weak bifurcated C8-H···O13 hydrogen bonds, stretching band is observed at 1664 cm−1. 
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Figure 3.33. FTIR spectra of carbonyl group stretching band region during theophylline 
crystallization from saturated solutions upon solvent evaporation at room temperature. Colour 
gradient shows FTIR spectra changes throughout crystallization (red – saturated solution, blue – 
crystallization product). FTIR spectra of solid theophylline Form II (dashed line) and IV 
(continuous line) are added for comparison purpose. Acetone carbonyl group stretching band is 
marked with ▲. 
Figure 3.33. illustrates the carbonyl group stretching band position and intensity changes 
during theophylline crystallization from saturated Form II solutions during solvent 
evaporation. 
The stretching bands of other groups/bonds expected to take part in self-association – alkene 
group hydrogen bond and imidazolium group hydrogen bond – were not visible in solution 
FTIR spectra due to low theophylline solubility in the chosen solvents, and they were observed 
only when all the solvent had evaporated. During the solvent evaporation the intensities of all 
theophylline bands increased because of increasing theophylline concentration in the solution. 
An exception to this was the final part of crystallization from saturated methanol solution, 
where theophylline carbonyl group intensities decreased. For clarity these spectra are shifted by 
y axis. Crystallization from acetone, acetonitrile, chloroform, methanol and formic acid gave 
theophylline Form II, and water produced theophylline monohydrate. Intensive water OH 
bending band was overlapping with both theophylline carbonyl group stretching bands, 
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therefore the crystallization experiment from saturated water solution was not suitable for 
studies. 
The strongest carbonyl group stretching bands in theophylline solution spectra were 
observed in concentrated solution, whereas weaker spectral bands appeared only when 
theophylline crystals emerged. In all solvents the most distinct changes in theophylline band 
positions and intensities were observed at the moment when solid theophylline emerged. This 
was due to fact that, before the crystallization FTIR spectra represented mostly solvated 
theophylline and theophylline associates, whereas during the crystallization, spectra were 
reflecting the average spectra of solvated theophylline, multiple theophylline associates and 
crystalline theophylline. The ratio of these species changed during the 
evaporation/crystallization and therefore, the band position of functional groups involved in 
these processes also changed. Finally, when all solvent have evaporated, FTIR spectra of 
crystalline theophylline was observed. 
The position of C2=O11 carbonyl group stretching band in methanol, acetonitrile and 
chloroform solutions were the same (1706 cm−1) and it coincided with the position of this group 
in both polymorphs, therefore we can conclude that this group was not involved in strong 
hydrogen bonding in the solution (similar to crystalline theophylline) and the nearby 
environment of this group was similar to that in both polymorphs. The position of this 
stretching band in acetone solution cannot be determined, as acetone carbonyl group stretching 
bands overlaps with this carbonyl group stretching band. The position of C2=O11 carbonyl 
group stretching band does not change during the crystallization from methanol solution, 
whereas during the crystallization from acetonitrile and chloroform solutions the band shifted 
to 1720 cm−1 indicating a change in bonding. The final position of this group stretching band 
does not match that in the solid Form II. FTIR spectra did not change within 5 h. Such band 
shift to higher frequency indicates that hydrogen bonding was weaker in the crystallized 
material than in solution. Crystallizations from both solvents were repeated in larger scale. 
PXRD showed that crystallization products were Form II, and FTIR spectra of obtained material 
coincided with Form II spectra. The reason why C2=O11 carbonyl group stretching band 
position in FTIR in-situ experiment does not match the position of this band in Form II spectra 
might be related to theophylline crystallization manner from acetonitrile and chloroform. No 
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distinct theophylline crystals were observed on the FTIR spectrometer liquids plate after solvent 
evaporation, meaning that theophylline crystalized as a thin film. Such crystallization behaviour 
might promote monolayer product along {100} plane, where this carbonyl group is on the 
surface and it is not involved in any hydrogen bonding. Consequently, C2=O11 carbonyl group 
stretching band would be shifted to higher frequency for such crystallization product.  
In saturated formic acid solution position of C2=O11 carbonyl group stretching band was 
1696 cm−1 and during the crystallization it gradually shifted to the position of this carbonyl 
group in crystalline theophylline. This happened because in the solution this carbonyl group 
was involved in hydrogen bonding with formic acid proton, whereas during the crystallization 
this hydrogen bond was disarranged. 
Unlike C2=O11 carbonyl group, the position of the C6=O13 carbonyl group stretching 
bands were not the same in the methanol solution and crystallized material. In the methanol 
solution the carbonyl group C6=O13 stretching band was observed at 1656 cm−1, i.e. in between 
the stretching bands of this carbonyl group in solid Form II and Form IV. This suggest that the 
associates (dimers, aggregates, solvated entities) in the solution were not the same as in the solid 
phases and that the hydrogen bonding in the solution was stronger than that in the Form II and 
weaker than that in Form IV. From 1H NMR experiment we know that there was no 
theophylline self-association in methanol, therefore we can conclude that the association 
causing band shift must be hydrogen bonding between the carbonyl group and methanol -OH 
group proton. The changes of the C6=O13 stretching band position were observed at the final 
part of the crystallization and the band position shifted from 1656 to 1664 cm−1, which is the 
position of this band in theophylline Form II. 
In chloroform, analogous C6=O13 carbonyl group stretching band shift were observed, with 
the only difference that initially this band had two maxima – at 1656 cm−1 and 1648 cm−1. The 
band at 1656 cm−1 corresponds to solvated theophylline species, analogous to those in 
methanol, whereas the band at 1648 cm−1 most likely corresponds to the dimer detected by 
NMR measurements. A similar situation was observed when theophylline crystallized from 
formic acid; with the difference that in saturated formic acid solution a wide band in this region 
was observed. The wider carbonyl group stretching band must be a result of multiple associates. 
The concentration of saturated formic acid solution was ~100 times higher than the 
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concentration of saturated chloroform solution, therefore it was expected that associates 
formed were more complex than dimers and with some diversity. Upon crystallization these 
agglomerates were disarranged and desolvated, and the final position of C6=O13 carbonyl 
group stretching band matched the position of Form II. 
Minor changes in the position of the C6=O13 carbonyl group stretching band were observed 
when theophylline crystallized from acetone solution. This suggests that theophylline hydrogen 
bonding did not change significantly upon crystallization from acetone, at least as regards to 
this carbonyl group. The position of C6=O13 carbonyl group stretching band remained the 
same during the crystallization from acetonitrile. Such behaviour points out, that this 
theophylline carbonyl group does not form hydrogen bonds in acetone and acetonitrile 
solutions, neither to solvent molecules, nor to other theophylline molecules. It is 
understandable – acetone and acetonitrile are not proton donor solvents. However it was 
expected that these solvents would compete with the basic theophylline imidazole group 
nitrogen (N9) to form a hydrogen bond with the most acidic theophylline proton (N7-H). NMR 
experiments showed that theophylline molecules in the acetone and acetonitrile solution are 
monomeric and self-association does not occur in these solvents, meaning that species with 
solvated (N7-H) group dominated in acetone and acetonitrile. 
The same FTIR in-situ crystallization experiment was repeated with saturated Form IV 
solution in methanol and identical results were obtained, suggesting that there are the same 
associates in the solution regardless of to which polymorph the solution is saturated. 
3.7.4. Conclusions 
The SMPT from theophylline Form II to Form IV is a very slow nucleation-growth 
controlled polymorphic transformation. Form IV nucleation is homogenous and slow. 
Nucleation of and therefore induction of the phase transformation is hindered by solution 
aggregates. Form IV crystals grow along the {001} direction, forming plate-like crystals. SMPT 
induction times correlate to phase transition times in studied solvents, indicating that 
nucleation and Form IV growth is limited by the same factors. Theophylline self-associates in 
solvents which are good H-bond donors i.e. chloroform, water and formic acid. There are the 
same molecular aggregates in the solutions saturated with respect to Form II and Form IV. The 
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theophylline aggregates present in solution do not change over time and therefore the long 
induction time of Form IV is not dependent on solution processes. NMR and FTIR data suggest 
that the nature of solution aggregates is solvent dependent, most likely linked to hydrogen 
bonding character of the solvent.  
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4. Conclusions 
1. Sample preparation conditions and detection limit of previously published (Petkune et al., 
J. Pharm. Pharmacol., 2011, 63, 9, 1136) semi-quantitative method for low-level 
thermodynamically stable polymorph impurity determination in the metastable 
polymorph have been improved. Detection limit was lowered down to 0.0005% of 
thermodynamically stable tegafur β polymorph in the metastable α polymorph. 
2. In β tegafur weight fraction range from 2.0% to approximately 0.05%, the best correlation 
was achieved when 0.50 g samples were ground for 5 min at 20 °C with 10 Hz frequency. 
At lower weight fraction of β tegafur, the milling frequency of 15 Hz was preferred. The 
optimum results were achieved when 0.06 mL of water was added to 0.50 g of tegafur. 
3. It has been shown that a sum of Langmuir and Cauchy–Lorentz equations could be used 
to describe the change in conversion degree depending on the added water volume. The 
determined surface areas and the dependence of conversion degree on water additive 
volume demonstrated that increasing the added water volume above 0.06 mL did not 
improve milling effectiveness. 
4. Conversion degree of β tegafur was highly dependent on sample drying time, and the 
recrystallization process could be described with a kinetic equation ᵪ�ᵪ� = 35.8 −
20.7ᵀ�−0.063ᵅ�. 
5. Phase transition dynamics of β tegafur to α tegafur is in a good agreement for samples 
ground in ball mill with solvent additive and samples, that were exposed to 95% solvent 
relative vapour pressure. 
6. Solvent desorption from α and β tegafur do not differ significantly and solvent desorption 
in all cases occur faster from samples with the largest particle size. Structure differences and 
their surface properties are not of great importance on the solvent desorption rates and the 
main factor affecting desorption rate is sample particle size and sample morphology. 
7. Two different solvent desorption behaviours can be distinguished depending on the solvent 
and surface interaction energy. If the solvent and surface interaction was stronger than 
interaction between solvent molecules, than multilayer and monolayer desorption was 
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observed, but, if the adsorbed solvent molecules were of equal energy, then only one 
desorption phase was observed. 
8. Solvent desorption rates of acetone, acetonitrile, ethyl acetate and tetrahydrofuran 
multilayers from α and β tegafur were approximately 30 times higher than those from 
solvent monolayers. 
9. Small tegafur particles recrystallized to larger particles during sample exposure to solvent 
vapour atmosphere, and there were morphological signs of tegafur recrystallization from 
solution on the surface of the particles. 
10. The SMPT from α tegafur to β tegafur in acetone, cyclohexane, ethanol, i-propanol, 
toluene, and water at 22 °C is nucleation-growth controlled and it can be described with 
the P2 power model. The rate constants for this process were in the range from 0.028 min−1 
to 0.0056 min−1. In all the employed solvents an induction time (about 10% of the time 
required for complete phase transition) was observed, indicating that nucleation and/or 
initial crystal growth was the limiting factor for SMPTs performed in saturated solutions. 
11. Surface nucleation was observed in studied SMPT from β tegafur to α tegafur. Crystal habit 
investigation indicated that  tegafur nucleated on the {010} face of α tegafur, and the {110} 
face of β tegafur was in contact with α tegafur crystal. 
12. The SMPT rate from β tegafur to α tegafur depended linearly on the supersaturation level, 
i.e. difference between α and β tegafur equilibrium solubility in the respective solvent. 
Similar correlation was observed in mechanochemical SMPT. 
13. Studied SMPT from theophylline Form II to Form IV is very slow nucleation-growth 
controlled polymorphic transformation. Form IV nucleation is homogenous and Form IV 
crystals grow along {001} face, forming plate-like crystals. SMPT induction times correlate 
to phase transition times in studied solvents, indicating that nucleation and Form IV 
growth is limited by the same factors. 
14. Theophylline solution phase studies revealed that phase transformation to Form IV occur 
faster in weak hydrogen bond donor or aprotic solvents, where theophylline exists as a 
monomers. Good hydrogen bond donor solvents – chloroform, water and formic acid – 
promotes theophylline self-association which hinders phase transformation to Form IV. 
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Appendix 1. Solid state kinetic models 
Table A.1. Solid-state integral expressions g(α) for the most often used solid-state kinetic models 
[103,104,283–286]. 
Model Differential form ᵅ�(ᵫ�) = (ᵼ�ᵅ�)(
ᵅ�ᵫ�
ᵅ�ᵅ� ) Integral form ᵅ�(ᵫ�) = ᵅ�ᵅ� 
Nucleation models   
Power law (P2) 2ᵪ�1/2 ᵪ�1/2 
Power law (P3) 3ᵪ�2/3 ᵪ�1/3 
Power law (P4) 4ᵪ�3/4 ᵪ�1/4 
Avrami-Erofeyev (A3/2)   
Avrami-Erofeyev (A2) 2(1 − ᵪ�)(− ln(1 − ᵪ�))1/2 (− ln(1 − ᵪ�))1/2 
Avrami-Erofeyev (A3) 3(1 − ᵪ�)(− ln(1 − ᵪ�))2/3 (− ln(1 − ᵪ�))1/3 
Avrami-Erofeyev (A4) 4(1 − ᵪ�)(− ln(1 − ᵪ�))3/4 (− ln(1 − ᵪ�))1/4 
Prout-Tompkins (B1) ᵪ�(1 − ᵪ�) ln (ᵪ�/(1 − ᵪ�)) + ᵀ�ᵀ� 
Geometrical contraction models   
Contracting area (R2) 2(1 − ᵪ�)1/2 (1 − (1 − ᵪ�)1/2) 
Contracting volume (R3) 3(1 − ᵪ�)2/3 (1 − (1 − ᵪ�)1/3) 
Diffusion models   
1-D diffusion (D1) 1/2ᵪ� ᵪ�2 
2-D diffusion (D2) (− ln(1 − ᵪ�))−1  (1 − ᵪ�) ln(1 − ᵪ�)  + ᵪ� 
3-D diffusion – Jander (D3)  3(1 − ᵪ�)2/3/2(1 − (1 − ᵪ�)1/3)  1 − (1 − ᵪ�)1/3 
2 
Ginstling-Brounshtein (D4) (3/2((1 − ᵪ�)−1/3 − 1) 1 − (2ᵪ�/3) − (1 − ᵪ�)2/3 
Reaction-order models   
First-order (F1)  (1 − ᵪ�) −ln (1 − ᵪ�) 
Second-order (F2) (1 − ᵪ�)2 (1 − ᵪ�)−1 − 1 
Third-order (F3) (1 − ᵪ�)3 0.5((1 − ᵪ�)−2 − 1) 
 
Appendix 2. Characterization of solvents used 
Table A.2. Characterization of solvents used. 
Solvent Purity Manufacturer 
Acetone >99.5% Penta, Fisher Scientific 
Acetonitrile >99.9% Fluka, Fisher Scientific 
Benzyl alcohol >99% Alfa Aesa 
1-Butanol >99.5% Penta 
Butyl acetate >99% Alfa Aesa 
Chloroform >99% Alfa Aesa, Fisher Scientific 
Cyclohexanol >99% Alfa Aesa 
1,1-Dichloroethane >98% Реахим 
Dichloromethane 99.7% Alfa Aesa 
Dimethylsulfoxide >99%, USP Penta 
1,4-Dioxane >99.9% Sigma-Aldrich 
Ethanol 99.97% LABSCAN 
Ethyl acetate >99.5% Penta 
Glycerine >98%, Ph. Eur. Penta 
Isobuthanol >99% Alfa Aesa 
Isopropyl acetate >99% Alfa Aesa 
Methanol >99.8% Fluka, Fisher Scientific 
N,N-Dimethylformamide >98% Penta 
1-Heptane >98% Реахим 
1-Hexane >98% Реахим 
Nitromethane >98% Merck 
1-Propanol >99.5% Penta 
2-Propanol >99.5% Alfa Aesa 
Tetrahydrofuran >99.5% Hempur 
Toluene >98% Реахим 
Water Deionised in the laboratory using Crystal 5, conductivity <0.2 μS 
Acetone-D6 99.9% Cambridge Isotope Laboratories 
Acetonitrile-D3 99.8% Apollo Scientific 
Chloroform-D 99.8% Euriso-top 
Deuterium oxide 99.96% BDH Chemicals 
Dimethyl sulfoxide-D6 99.9% Cambridge Isotope Laboratories 
Formic acid-D2 98%, <5% D2O Cambridge Isotope Laboratories 
Methanol-D4 99.8% Cambridge Isotope Laboratories 
 
Appendix 3. Solvent classes 
Classifications:  A – K-nearest neighbour (KNN) classification; 
B – Counter-propagation artificial neural networks (CP-ANN-1) classification; 
C – Counter-propagation artificial neural networks (CP-ANN-2) classification (see original publication [287]). 
 
Class:   1 – aprotic polar (AP); 
2 – aromatic apolar or lightly polar (AALP); 
3 – electron pair donors (EPD); 
4 – hydrogen bond donors (HBD); 
5 – aliphatic aprotic apolar (AAA). 
Table A.3. Solvent classification using the k-nearest neighbour classification method [287]. 
ID Solvent A B C ID Solvent A B C ID Solvent A B C 
1 acetic acid 4 4 4 52 diethylene glycol 4 4 4 103 nitrobenzene 1 1 1 
2 acetic anhydride 1 1 1 53 dietyl ether 3 3/5 3 104 nitroethane 1 1 1 
3 acetone 1 1 1 54 di-isopropyl ether 5 5 3 105 nitromethane 1 1 1 
4 acetonitrile 1 1 1 55 1,2-dimethoxyethane 3 1/3 3 106 n-octane 5 5 5 
5 acetophenone 2 2 2 56 N,N-dimethylacetamide 1 1 1 107 1-octanol 4 4 4 
6 acetylacetone 2 1 1 57 N,N-dimethylaniline 1 1 1 108 n-pentane 5 5 5 
7 2-aminoethanol 4 4 4 58 3,3-dimethyl-2-butanone 1 1 1 109 1-pentanol 4 4 4 
8 aniline 1 1 1 59 N,N-dimethylformamide 1 1 1 110 2-pentanol 4 4 4 
9 anisole 2 2 2 60 2,4-dimethylpyridine 1 1 1 111 3-pentanol 4 4 4 
10 benzaldehyde 2 2 2 61 2,6-dimethylpyridine 1 1 1 112 2-pentanone 1 1 1 
11 benzene 2 2 2 62 dimethylsulfoxide 1 1 1 113 3-pentanone 1 1 1 
12 benzonitrile 1 1 1 63 2,6-dimethyl-4-heptanone 1 1 1 114 pentyl acetate 1 1 1 
13 benzyl alcohol 2 2 2 64 2,4-dimethyl-3-pentanone 1 1 1 115 phenetole 2 2 2 
Table continues in next page 
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Table A.3. continuation 
ID Solvent A B C ID Solvent A B C ID Solvent A B C 
14 bromobenzene 2 2 2 65 1,4-dioxane 1 1 3 116 Phenol 2 2 2 
15 1-bromobutane 3 3 3 66 diphenyl ether 2 2 2 117 3-picoline 1 1 1 
16 bromoethane 3 1/3 3 67 di-n-propyl ether 5 5 3 118 4-picoline 1 1 1 
17 1-butanol 4 4 4 68 DMEU 1 1 1 119 piperidine 4 4 4 
18 2-butanol 4 4 4 69 DMPU 1 1 1 120 1-propanol 4 4 4 
19 2-butanone 1 1 1 70 ethanol 4 4 4 121 2-propanol 4 4 4 
20 n-butyl acetate 1 1 1 71 ethyl acetate 1 1 1 122 n-propylamine 4 4 4 
21 n-butylamine 4 4 4 72 ethyl benzoate 2 2 2 123 propyl formate 1 1 1 
22 butyronitrile 1 1 1 73 ethyl formate 1 1 1 124 propylene carbonate 1 1 1 
23 carbon disulfide 2 2/5 5 74 ethyl propionate 1 1 1 125 propionitrile 1 1 1 
24 carbon tetrachloride 5 4 4 75 ethylenediamine 4 4 4 126 Pyridine 1 1 1 
25 chlorobenzene 2 2 2 76 ethylene glycol 4 4 4 127 pyrrolidine 4 4 4 
26 1-chlorobutane 3 3 3 77 fluorobenzene 2 2 2 128 quinoline 1 1 1 
27 chloroform 4 4/1/3 3 78 formamide 4 4 4 129 Styrene 2 2 2 
28 1-chloropropane 3 3/1 3 79 furfuryl alcohol 1 2/4 2 130 Sulfolane 1 1 1 
29 2-chloropropane 3 3/1 3 80 glycerol 4 4 4 131 tert.-butyl alcohol 4 4 4 
30 m-cresol 2 2 2 81 n-heptane 5 5 5 132 tert.-butyl methyl ether 3 5/3 3 
31 cyclohexane 5 5 5 82 HMPTA 1 1 1 133 TEGDME 1 1/3 3 
32 cyclohexanol 4 4 4 83 n-hexane 5 5 5 134 1,1,2,2-tetrachloroethane 1 3 1 
33 cyclohexanone 1 1 1 84 1-hexanol 4 4 4 135 tetrachloroethylene 5 4/2 5 
34 cyclohexene 2 5/2 5 85 iodobenzene 2 2 2 136 tetraethylene glycol 4 4 4 
35 cyclopentane 5 5 5 86 iodoethane 3 1/3 3 137 tetrahydrofuran 3 3 3 
36 cyclopentanone 1 1 1 87 isobutyl alcohol 4 4 4 138 1,1,3,3-tetramethyl urea 1 1 1 
37 cis-decaline 5 5 5 88 iso-octane 5 5 5 139 Toluene 2 2 2 
38 n-decane 5 5 5 89 mesitylene 2 2 2 140 tributylamine 3 3 3 
39 DEGDEE 3 3/1 3 90 methanol 4 4 4 141 1,1,1-trichloroethane 1 1 1 
40 DEGDME 1 1/3 3 91 methyl acetate 1 1 1 142 trichloroethylene 1 1 1 
Table continues in next page 
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Table A.3. continuation 
ID Solvent A B C ID Solvent A B C ID Solvent A B C 
41 dibenzyl ether 2 2 2 92 methyl benzoate 2 2 2 143 triethylamine 3 3 3 
42 di-n-butyl ether 5 5/3 3 93 2-methyl-2-butanol 4 4 4 144 triethylene glycol 4 4 4 
43 m-dichlorobenzene 2 2 2 94 3-methyl-1-butanol 4 4 4 145 trifluoroacetic acid 4 4 4 
44 o-dichlorobenzene 2 2 2 95 3-methyl-2-butanone 1 1 1 146 2,2,2-trifluoroethanol 4 4 4 
45 1,2-dichloroethane 1 1 1 96 methyl formate 1 1 1 147 trimethylene glycol 4 4 4 
46 1,1-dichloroethane 1 1 1 97 4-methyl-2-pentanone 1 1 1 148 2,4,6-trimethylpyridine 1 1 1 
47 1,1-dichloroethylene 1 1 1 98 2-methoxyethanol 4 4 4 149 m-xylene 2 2 2 
48 Z-1,2-dichloroethylene 1 1 1 99 N-methylacetamide 1 1 1 150 o-xylene 2 2 2 
49 dichloromethane 1 1 1 100 N-methylformamide 1 1 1 151 p-xylene 2 2 2 
50 diethylamine 4 4 4 101 N-methyl-pyrrolidin-2-one 1 1 1 152 Water 4 4 4 
51 diethyl carbonate 1 1 1 102 morpholine 1 4/1 4      
 
Table A.4. Solvent groups based on cluster analysis of following solvent property parameters, 
hydrogen bond acceptor propensity, hydrogen bond donor propensity, polarity/dipolarity, dipole 
moment, and dielectric constant [288]. 
Group Solvents 
Group 1 n-Dodecane (0.0), n-decane (0.1), Cyclohexane (0.1), n-octane (0.1), n-hexane (0.2), n-
heptane (0.2), cis-decalin (0.2), n-pentane (0.2), carbon tetrachloride (0.3), 
tetrachloroethene (0.3) 
Group 2 Ethyl acetate (0.2), diethyl sulfide (0.4), propyl ethanoate (0.6), methyl benzoate (0.8), 
methyl ethanoate (0.8), butyl ethanoate (1.1), tetrahydrofuran (1.4), methyl tertiary-butyl 
ether (1.6), diethyl ether (1.9), ethyl formate (2.3), diisopropyl ether (2.8), methyl 
methanoate (2.8), dibutylether (3.1), dimethyl disulfide (3.5) 
Group 3 2-methyl-1-propanol (0.3), 2-butanol (0.5), 1-butanol (0.9), 2-methoxyethanol (1.1), 1-
pentanol (1.3), 2-propanol (2.8), 2-methyl-2-propanol (4.0), 1-propanol (4.1), 1-octanol 
(6.6), ethanol (8.4), morpholine (9.0), butylamine (11.9), methanol (16.2) 
Group 4 m-Xylene (0.1), p-xylene (0.1), benzene (0.1), mesitylene (0.2), carbon disulfide (0.3), 
toluene (0.3) 
Group 5 2-hexanone (0.0), cyclopentanone (0.8), 2-pentanone (1.1), pyridine (1.2), 4-methyl-2-
pentanone (1.2), cyclohexanone (1.5), 4-methylpyridine (2.2), 2-heptanone (2.5), 3-
pentanone (2.7), acetophenone (3.4), butanone (4.1), 2,4-dimethylpyridine (4.7), acetone 
(6.4), 2,6-dimethylpyridine (7.0) 
Group 6 N,N-dimethylacetamide (0.8), N,N-dimethylformamide (1.3), N-methyl-2-pyrrolidone 
(6.3), dimethylsulfoxide (8.3) 
Group 7 1-iodobutane (0.4), chlorobenzene (0.6), fluorobenzene (0.8), 1,1,1-trichloroethane (0.9), 
dibromomethane (1.0), diiodomethane (1.0), 1,2-dibromoethane (1.4), chloroform (1.6), 
iodobenzene (1.7), anisole (2.0), bromoform (2.1), ethyl phenyl ether (2.1), 
dichloromethane (2.7), trichloroethene (2.9), 1,1-dichloroethane (3.8), o-dichlorobenzene 
(3.9), 1,2-dichloroethane (3.9) 
Group 8 Acetic acid (0.1), propanoic acid (2.8), pentanoic acid (3.5), m-cresol (6.2) 
Group 9 Propanenitrile (1.0), benzonitrile (4.7), acetonitrile (5.4), butanenitrile (6.0), nitromethane 
(6.3) 
Group 10 Benzyl alcohol (2.8), aniline (2.8) 
Group 11 Triethylamine (0.4), 1,4-dioxane (0.4) 
Group 12 Formic acid (4.9), ethylene glycol (4.9) 
Group 13 Diethylamine 
Group 14 Glycerol 
Group 15 Water 
The Euclidean distance of each solvent to the centre of the corresponding group is provided 
in the parentheses. 
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Appendix 4. EpiCalc calculations for potential lattice match 
Table A.5. EpiCalc calculation for potential lattice matching between {100}, {110} and {010} face of 
β tegafur and {001}, {011} and {010} face of α tegafur. V/V0 is the dimensionless potential energy 
parameter used to measure the goodness-of-fit. 
α face (hkl) β face (hkl) V/V0 
010 100 0.9941 
010 110 0.9675 
010 010 0.9836 
001 100 0.9908 
001 110 0.9925 
001 010 0.9902 
011 100 0.9985 
011 110 0.9923 
011 010 0.9908 
 
The value of V/V0 indicates the goodness-of-fit between the substrate lattice and the 
overlayer lattice, where V/V0=1 indicates that there is no match between lattice points, V/V0=0.5 
– a partial match (for non-hexagonal substrate), and V/V0=0 – complete matching of the lattice 
points or crystal faces.  
 
The default setting for overlayer dimensions (25 x 25) and the orientation angle (60° with a 
step size of 0.25°) was used to test α and β tegafur lattice match. 
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Determination of trace amounts of b tegafur in commercial
a tegafur by powder X-ray diffractometric analysisjphp_1319 1136..1140
Sanita Petkune, Raitis Bobrovs and Andris Actin¸š
The Faculty of Chemistry, University of Latvia, Riga, Latvia
Abstract
Objectives The main objective of this work was to develop a suitable analytical technique
for determining trace amounts of the thermodynamically stable solid form in bulk samples
of metastable form, to a sensitivity of 0.005%–1.0%. Tegafur (5-fluoro-1-(tetrahydro-2-
furyl)-uracil) a and b crystalline forms were used as a model for this problem.
Methods The trace content of the thermodynamically stable b polymorphic form in
tegafur samples was increased by promoting phase transition from the bulk of thermody-
namically metastable a form to b form, and achieving sufficient b form content for a
quantitative powder X-ray diffractometry (PXRD) analysis. The phase transition was stimu-
lated by adding water to the samples and then grinding in controlled conditions (tempera-
ture, time, grinding speed). A calibration line was constructed using the least squares
method.
Key findings By using a solvent that does not form hydrates with the analysed poly-
morphs, it was possible to promote the phase transformation from metastable form to the
thermodynamically stable form. After sample preparation, the thermodynamically stable
solid form content in the analysed mixture had increased proportionally to the initial weight
fraction (0.005%–1.0%) of the stable form seed crystals in the samples, and the coefficient
of proportionality was 43.0  0.9, with a standard deviation Sn = 1.5%.
Conclusions A simple, sensitive, semi-quantitative analytical method was developed for
the low-level determination of the thermodynamically stable polymorphic form in mixtures
of thermodynamically stable and metastable polymorphs.
Keywords drug polymorphism; powder X-ray diffraction; semi-quantitative analysis of
trace amounts; tegafur
Introduction
The impact of crystal polymorphic transformations on drug product performance is well
recognized in the pharmaceutical industry. Various crystal structures of a given substance
often exhibit different physical properties.[1]
To ensure product stability, the polymorph most stable in ambient conditions is normally
chosen for development into the final dosage product. Recently, however, metastable forms
have been utilized due to enhanced dissolution or bioavailability profiles.[2] Sometimes
metastable polymorphic forms may be inadvertently generated due to the stress produced by
temperature, mechanical treatment and moisture during processing or storage of the drug
product.[3] Contamination by polymorphic impurities can influence both the stability and
performance of the final product and during the last decade the requirements for identifica-
tion, specification and control of active pharmaceutical ingredient polymorphs have become
a part of the quality assurance process.[4] Therefore it is necessary to develop quantification
methods for measuring low level contamination with undesired crystalline phases.[1] A
multitude of analytical techniques is available to quantify crystal forms in mixtures but those
methods have not been routinely applied to quantify low amounts of one polymorph in the
presence of another.[5] FT-infrared spectroscopy has been used to determine polymorph
content down to 1–5%.[6,7] Powder X-ray diffraction (PXRD) has been employed to deter-
mine low-level polymorph impurities with the minimum quantifiable level of 1–2.5%.[6,8,9]
Solid-state NMR spectroscopy has also been applied to the detection of polymorph traces,[8]
though solid-state NMR methods involve significant sample preparation or analysis time.
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Due to the growing quality requirements directed at active
pharmaceutical substances there is a demand for a rapid and
simple quantification of unwanted solid forms at low levels
(<1%).[10]
Advantages like the non-destructive nature, simplicity and
ambient temperature measurements of either drug substances
or final dosage forms make PXRD the most preferred and
extensively used technique for quantification of polymorphic
mixtures.[4] In addition, PXRD is one of the most sensitive
methods for detection of low-level solid forms, therefore
PXRD was chosen as the most appropriate method for phase
quantification in this study.
The purpose of this study was to investigate the quantifi-
cation of low-level polymorphic impurities and to establish
an analytical method with a detection limit below 1% for the
determination of the thermodynamically stable polymorphic
form in mixtures with a metastable polymorphic form. The
a and b forms of tegafur (5-fluoro-1-(tetrahydro-2-furyl)-
uracil), a cancer chemotherapy drug,[11] were selected as the
model system for this study. Our low-level determination
technique was based on a new approach to the sample prepa-
ration process, which included a solvent-promoted stimula-
tion of phase transition from a thermodynamically metastable
form to the stable form. The conditions were selected to
increase the stable form content to a level high enough to
enable the quantification of mixture with PXRD. Conse-
quently, a new, sensitive semi-quantitative PXRD analytical
method was developed for detection of trace amounts (0.005–
1.0% weight fraction) of thermodynamically stable polymor-
phic impurity in a metastable commercial product. Since the
ever-growing quality requirements for active pharmaceutical
ingredients tend to increase the expense of quality assurance,
our contribution of a simple, rapid and low-cost analytical
technique will be useful to the pharmaceutical industry as a
part of quality control for active pharmaceutical ingredients.
Materials and Methods
Materials
The a and b forms of pharmaceutical-grade tegafur were
obtained from JSC Grindeks (Riga, Latvia).
Optimization of sample preparation
A mixture of tegafur a and b forms containing 1.5% weight
fraction of the b form was prepared and separated into six
samples of 0.50 g. An analytical balance (BOECO, Hamburg,
Germany) of 0.0001 g accuracy was used. Weighted
samples were ground at 20°C with a Retsch MM300 shaker
(Retsch GmbH, Haan, Germany) at a shaking frequency of
15 Hz for 3, 5 and 7 min with the addition of one or two drops
(~0.07 ml or ~0.15 ml, respectively) of water before each
grinding operation. Water was added to the samples before
grinding to ensure faster phase transition.
Sample preparation
Pure a and b polymorphs of tegafur were ground in a mortar
separately for 2 min, to ensure sample homogeneity. The
ground b form was weighed and mixed in various ratios (1.0,
0.50. 0.25, 0.10, 0.050, 0.010 and 0.0050% w/w) with the
ground a form. The total mass of each mixture was 0.75 g.
The prepared samples were homogenized at 20°C by shaking
in a Retsch MM300 shaker for 5 min at a shaking frequency
of 15 Hz.
In each case 0.50 g of homogenized sample was weighted
for wet grinding, but the rest of the mixture was used for the
next sample preparation. A drop of water (~0.07 ml) was
added to each sample before grinding. The prepared samples
were ground for 5 min at 20°C with a Retsch MM300 shaker
with shaking frequency 15 Hz.
Two parallel samples were prepared and analysed for each
mixing ratio of a and b tegafur.
Powder X-ray diffractometric analysis
Samples were analysed with a powder X-ray diffractometer
Bruker D8 Advance (Bruker AXS, Karlsruhe, Germany). The
divergence and scattering slits were set at 1.0 mm, and the
receiving slit was set at 0.6 mm. Diffraction patterns within
the 2q range of 9° to 13° were recorded at room temperature
using CuKa radiation at 1.54180 Å, with the following mea-
surement conditions: tube voltage 40 kV, tube current 40 mA,
step-scan mode with the step size 2q = 0.02°, and the counting
time 10 s/step.
Powder samples were packed into glass holders with
~150 mg weight capacity and pressed by a clean glass slide
to ensure coplanarity of the powder surface with the surface
of the holder. Obtained diffractograms were analysed with
DIFFRACplus EVA (version 9.0) software.
Quantitative analysis of tegafur a and b
form mixtures
A full profile analysis was used for quantitative analysis, in
which all points of X-ray patterns were used for quantification
of tegafur a and b forms. Experimental points were saved as
*.raw file format and then converted to *.uxd file format,
which can be used for quantification. In MS Excel worksheet
columns were created for 2q angles (step size 0.02°), intensi-
ties of pure tegafur a and b forms (counts/s), intensities of the
analysed tegafur a and b form mixture (counts/s), theoreti-
cally calculated intensities of the mixture (counts/s) and least
square values of differences between theoretically calculated
and experimental intensities. Reflex intensities for pure a and
b forms and intensities of analysed mixtures were copied from
previously prepared *.uxd files. Theoretical intensities were
calculated using Equation 1.
I Q I I= ⋅ ⋅ + ⋅ −( )( )β β α βω ω1 (1)
where I is the theoretical intensity in the analysed sample
(counts/s); Ia, Ib are the intensities of pure tegafur a and b
forms, prepared using the same method as the sample (counts/
s); wb is the weight fraction of tegafur b form in the sample;
Q is a normalization coefficient. This coefficient must be close
to 1, and it was established to prevent errors related to the
sample preparation.
The weight fraction of tegafur b form wb was calculated
using MS Excel add-in Solver. The minimum values of least
square sums were found by optimizing the normalization
coefficient Q and weight fraction wb, by using Equation 2.
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Results and Discussion
It has been reported that tegafur b form is stable at tempera-
tures under 34–39°C, while tegafur a form is stable at higher
temperatures.[12] The X-ray patterns of tegafur a and b forms
in 2q interval from 9° to 13° are shown in Figure 1.
It is evident that the b form diffraction reflex at 2q = 12.2°
overlapped with the strongest a form reflex, which was twice
as intensive as the rest of a form reflexes, but full profile
analysis allowed us to use this area for quantification. The
homogenous composition of the analysed mixture and the
normalization coefficient close to 1 ensured that the reflex
intensities of each phase were linearly dependent on phase
weight fractions in the sample. Therefore it was possible to
use a calibration line.
Six experiments were carried out to establish the optimal
grinding conditions for reproducible multiplication of the
thermodynamically stable phase content in the samples. The
samples containing 1.5% weight fraction of b tegafur were
treated with a drop (~0.07 ml) or two drops (~0.15 ml) of
water and subsequently ground for 3, 5 and 7 min. The aim of
these experiments was to investigate sample preparation con-
ditions in which a modification after grinding does not com-
pletely transform to the b form, but the sample still contains a
reasonably high content of a tegafur. The samples that were
ground for 5 and 7 min had practically the same composition,
but the samples that were ground for 3 min had a noticeably
lower fraction of the b form (Figure 2a). To promote the phase
transformation of b tegafur to the a form, one drop (~0.07 ml)
or two drops (~0.15 ml) of water was added to the sample
before grinding. In all experiments the content of b tegafur in
the samples was significantly higher if a single drop of water
was added to the sample before grinding (Figure 2b).
Any solvent that does not form solvates or hydrates with
analysed polymorphic forms could be used to promote the
phase transformation. We chose water (one drop for each
0.50 g sample), followed by grinding for 5 min.
Powder X-ray diffraction patterns of calibration samples
after this optimized treatment are shown in Figure 3.
Our developed method was found to be linear in the range
of 0.005–1.0% weight fraction of b form in the initial mixture.
The relationship between tegafur b form initial and final
weight fraction after grinding is shown in Figure 4.
The calibration factor was equivalent to the slope of the
linear regression equation. The regression line was described
by the function y = ax, taking into account the intersection
with the origin. If the calibration factor would be calculated
from the equation y = ax + b, then the approximated line
would intersect the y-axis at a non-zero value, meaning posi-
tive phase content at zero peak intensity (Ipeak  0, when
w = 0), which is physically impossible. The optimal linear
slope was calculated using MS Excel function Linest. The
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Figure 1 Powder X-ray diffraction patterns of tegafur a (- - -) and b
(—) form.
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Figure 2 (a) Powder X-ray diffraction patterns of the tegafur a and b form mixture containing 1.5% weight fraction of b tegafur after grinding for
3, 5 and 7 min. (b) Powder X-ray diffraction patterns of the tegafur a and b form mixture containing 1.5% weight fraction of b tegafur after grinding
for 5 and 7 min if the phase transition was induced adding a drop (~0.07 ml) or two drops (~0.15 ml) of water.
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equation for the calibration curve was y = (43.0  0.9)x, the
correlation coefficient R2 = 0.996, and the regression resi-
dual mean square error or the standard deviation Sn, which
characterized the dispersion between the measured (yi) and
theoretically calculated value (Yi), was 1.5%.
The detection and quantitation limits were calculated
from standard deviation through Equation 3 and Equation 4,
respectively, as recommended by the ICH guideline:[13]
Limit of detection LOD S Sn( ) = 3 3. (3)
Limit of quantitation LOQ S Sn( ) = 10 (4)
where Sn is the standard deviation of the response and S is the
slope of the calibration curve.
The calculated LOD was 0.12%, and the calculated LOQ
was 0.35%. However, taking into account that these LOD and
LOQ values were calculated from standard deviation, and the
standard deviation was determined as deviation from the
linear calibration slope, we could not expect low LOD and
LOQ values. The developed quantitation method was based
on crystal seeding and solvent-promoted phase transition that
led to relatively high statistical deviation. During the devel-
opment process we determined that the PXRD method
allowed detection of the analytical signal if b tegafur weight
fraction was as low as 0.005% (i.e. 24 times smaller than
the LOD). Despite the large dispersion of experimental data
points, the developed sample preparation method allowed
rapid and simple determination of trace amounts as low as
0.005%, that so far have been difficult to achieve with any
known method of polymorphic form analysis. The essence of
this method is in the sample processing phase, while the
subsequent quantitative analysis of prepared mixtures could
be done not only with PXRD, but any other quantitative tech-
nique that allows the construction of a calibration curve.
Through this method it becomes possible to quantify trace
amounts of thermodynamically stable polymorphic impurities
in bulk drug samples. In addition to active pharmaceutical
ingredients, this method is generally able to detect trace
amounts of polymorphic impurities in final dosage forms, but
as the dosage forms contain excipients affecting the grinding
efficiency, it is necessary to construct new calibration plots for
each analysed object.
Conclusions
This study demonstrates that very low levels (0.005–1.0%) of
unwanted polymorphs in pharmaceuticals can be determined
by using a sensitive semi-quantitative method. This trace
polymorph analysis is based on a new approach to sample
preparation, including solvent-promoted stimulation of phase
transition from a thermodynamically metastable form to the
stable form. The method was developed for model mixtures
of a and b tegafur. The optimal grinding time for tegafur a
and b phase analysis at 20°C was 5 min, if the shaking fre-
quency was 15 Hz. The phase transition was facilitated by
the addition of a single drop of water to each 0.50 g sample.
The content of tegafur b form after the sample preparation
was linearly proportional to the initial b form weight frac-
tion in the sample, and the coefficient of proportionality
was 43.0  0.9, while the standard deviation Sn was 1.5%.
Through this method it becomes possible to quantify trace
amounts of stable polymorph impurities in thermodynami-
cally metastable bulk drug samples.
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Figure 3 Powder X-ray diffraction patterns of calibration samples
after inducing the phase transformation with adding a drop of water to
the sample and grinding for 5 min.
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Figure 4 The dependence of tegafur b form weight fraction after grind-
ing upon the initial b form content in the sample.
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ABSTRACT: We report a semiquantitative method for determining trace amounts (<1%) of
thermodynamically stable forms in polymorphic mixtures, focusing on sample preparation ef-
fects on solid phase transitions. Tegafur [5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-
2,4-dione] was used as a model material in this study. The amounts of the thermodynamically
stable $ tegafur were increased to levels detectable by powder X-ray diffractometry by grind-
ing the samples in a ball mill in the presence of water. The limit of detection for this method
was as low as 0.0005% of $ tegafur in " and $ tegafur mixtures. The amount of $ tegafur
after sample preparation was found to be proportional to the initial weight fraction of $ tega-
fur. The sum of Langmuir and Cauchy–Lorentz equations was used to describe the change
in conversion degree due to the added water volume, where Langmuir equation described
water sorption during the sample preparation and Cauchy–Lorentz equation described the
grinding efficiency. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association
J Pharm Sci
Keywords: polymorphism; polymorph contamination; trace amount detection; semi-
quantitative analysis; tegafur; X-ray powder diffractometry; milling; solid state; thermody-
namics
INTRODUCTION
About two-thirds of organic compounds and about
80% of active pharmaceutical ingredients under cer-
tain conditions can exist in more than one polymor-
phic form. Polymorphism is defined as the ability of
a drug compound to crystallize into more than one
different crystalline form that differs with molecule
packing arrangements and/or conformations within
the crystal lattice.1–4 The often encountered differ-
ences in stability, solubility, and bioavailability of ac-
tive pharmaceutical ingredient polymorphs require a
control over solid phase composition of these prod-
ucts. It is a common requirement in Pharmacopeia
monographs that active pharmaceutical ingredients
in drugs must exist in one fixed crystalline form.
The most thermodynamically stable form is usu-
ally chosen for pharmaceutical use, but sometimes
a metastable form has better solubility or bioavail-
ability, and is selected for manufacturing.5 In this
case, it becomes very important that the final manu-
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factured product is free from the thermodynamically
stable form because even trace amounts can facilitate
a phase transition to the unwanted thermodynam-
ically stable form. Therefore, methods for detecting
the stable form in trace amounts (<1%) are necessary
to ensure kinetic stability of metastable solid phar-
maceutical ingredients.
As shown in a previous publication,6 it is possi-
ble to determine trace amounts (<0.01%) of the ther-
modynamically stable form in mixtures of thermody-
namically stable and metastable forms. Our aim for
this work was to determine sample processing im-
pact on phase quantification. The amount of the ther-
modynamically stable form was increased by grind-
ing the sample with water additive in a way similar
to literature precedents.7–11 The increased amount of
the stable form could then be determined with X-ray
diffractometry, which was selected as the most appro-
priate method for phase quantification. Also infrared,
Fourier transform Raman, solid-state nuclear mag-
netic resonance spectroscopy, and thermal analysis
methods can be used for phase analysis.1,2
Accurate measurement of intensity, height, and
plotted area of diffraction peaks is most important
for obtaining reliable and reproducible results and
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calibration curves.12 Nature of the samples, instru-
ment and sample preparation parameters, type of
sample holders, sample rotation, particle size, pow-
der packing, and dominant orientation are also cru-
cial factors that affect diffraction peak intensities and
areas, thus influencing quantification results.12–14
Tegafur [5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahyd-
ropyrimidine-2,4-dione] was chosen as a model ma-
terial in this study because it does not form
hydrates and solvates that could gradually loose as-
sociated solvent during sample preparation, and thus
affect phase quantification. Tegafur is an antitumor
agent, widely used in the treatment of various ma-
lignancies, particularly gastrointestinal and breast
cancers.15 Over years, ", $, (, *, and g forms of tegafur
have been reported in pharmaceutical literature,15–17
but only " and $ modifications are used for therapeu-
tic purposes.
MATERIALS AND METHODS
Materials
Commercial samples of " and $ tegafur were supplied
by JSC Grindeks (Riga, Latvia).
Sample Preparation
The entire batches of "- and $-tegafur used in experi-
ments were ground separately for 3 min to ensure re-
quired sample homogeneity and avoid preferred crys-
tal orientation effects.
Determination of Optimum Grinding Frequency
Mixtures of 2.0%, 1.0%, 0.50%, 0.10%, 0.050%,
0.010%, 0.0050%, 0.0010%, 0.00050%, and 0.00010%
$ tegafur in " tegafur (3.0 g each) were prepared from
a 2.0% stock mixture that was diluted to the required
concentrations. Samples during preparation were ho-
mogenized in a Retsch MM300 ball mill (Retsch
GmbH, Haan, Germany) for 5min at 20◦C, with 15Hz
shaking frequency. The analytical balance (BOECO,
Hamburg, Germany) had an accuracy of ±0.0001 g.
The samples of homogenized mixtures (0.50 g) were
each treated with 0.07 mL water and ground in the
ball mill at 7, 10, and 15 Hz shaking frequencies for
5 min.
Determination of the Optimum Added Water Volume
A mixture of tegafur " and $ forms containing 1.0%
weight fraction of $ form was weighed and homoge-
nized in the ball mill for 5 min at 20◦C, with 15 Hz
shaking frequency. The 0.50 g samples of homoge-
nized mixture were ground in the ball mill with vari-
able water additive amounts for 5 min at 20◦C, with
10 Hz shaking frequency. The added water volume
was from 0.02 to 0.20 mL, with 0.01 mL step size.
When the amount of water additive exceeded 0.06mL,
a thick paste formed, and it became necessary to dry
the samples for 30 min after grinding.
Sample Preparation for Recrystallization Studies
A sample (0.50 g) of tegafur " and $ form mixture,
containing 1.0%weight fraction of $ form, was ground
in the ball mill for 5 min at 20◦C with 15 Hz shak-
ing frequency, with 0.20 mL water added just before
grinding. The obtained thick paste was pressed into
glass sample holder right after grinding, and powder
X-ray diffraction (PXRD) pattern was recorded. Con-
secutive PXRD patterns were recorded every 5 min,
until no further phase transition was observed (∼1 h).
Determination of Surface Area
Three samples of tegafur " and $ formmixture (0.50 g
each), containing 1.0% weight fraction of $ form, were
ground in the ball mill for 5 min at 20◦C, with 10 Hz
shaking frequency. The first sample had no added wa-
ter, the second had 0.06mL of water, and the third had
0.12 mL of water. Water was added just before grind-
ing. The samples were removed from grinding vessels
immediately, and were dried at ambient temperature
for 3 h. Surface area determination requires a 1–2 g
sample; therefore, three parallel samples for each vol-
ume of added water were ground in the ball mill and
then combined to obtain the required sample mass.
Surface area was determined by a modified chro-
matograph “Hrom 3,” detecting the amount of ar-
gon involved in a monolayer adsorption–desorption
process.
PXRD Analysis
Samples were analyzed with a Bruker D8 Advance
powder X-ray diffractometer (Bruker AXS, Karlsruhe,
Germany), equipped with a PSD LYNXEYE detector.
Measurements were performed with CuK radiation
(1.54180 A˚) at room temperature. The following con-
ditions were used: step-scan mode with a step size of
0.01◦; scan speed: 0.2◦/min; 2θ range: 9.0◦–12.7◦; volt-
age: 40 kV; current: 40 mA; divergence slit: 0.6 mm;
scattering slit: 8 mm.
Powder samples were packed into glass holders
with a weight capacity of approximately 150 mg
and pressed by a clean glass slide to ensure copla-
narity of the powder surface with the surface of the
holder. The obtained diffractograms were analyzed
with DIFFRACplus EVA (ver. 9.0) software (Bruker
AXS, Karlsruhe, Germany).
Quantitative Analysis of α and β Polymorph Mixture
Individual diffraction peaks area method was used
in tegafur " and $ form quantification. The areas of
the plotted diffraction peaks were calculated by using
the computer program TOPAS 3 (Bruker AXS, Karl-
sruhe, Germany), and weight fractions of $ form were
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Intensity (counts)
Figure 1. Powder X-ray diffraction patterns of tegafur "
and $ forms.
calculated by using the Eqs. 1–3:
T$;% = Smixture; 9.6S$; 9.6 × 100% (1)
T";% =
⎡
⎣Smixture; 12.1 −
(
Smixture; 9.6 × S$; 12.1S$; 9.6
)
S"; 12.1
⎤
⎦× 100%
(2)
T$norm;% = T$;%T$;% + T";% × 100% (3)
where T$;%, T";% are weight fractions of " and $ forms;
S$;9.6, S$; 12.1 are diffraction peaks plot areas for pure
$ form at 9.6◦ and 12.1◦; Smixture; 9.6, Smixture; 12.1 are
the diffraction peaks plot areas at 9.6◦ and 12.1◦ for
the analyzed mixture; S"; 12.1 is the diffraction peaks
plot area of pure " form at 12.1◦; and T$norm;% is a nor-
malized weight fraction of the $ form. Weight fraction
calculations for " and $ forms differ because the most
intensive " form diffraction peak at 12.1◦ is overlap-
ping with a $ form diffraction peak (see Fig. 1).
RESULTS AND DISCUSSION
Chemical composition uniformity of tegafur poly-
morphs ensures that each phase’s diffraction peaks
intensity is linearly dependent on phase weight
fraction in mixture; therefore, it is possible to
use calibration line method for quantitative tega-
fur " and $ phase analysis.12,18 To determine trace
amounts of the thermodynamically stable polymor-
phic form in mixtures of thermodynamically stable
and metastable forms, the amount of thermodynam-
ically stable form need to be reproducibly multiplied
to a degree that allows its quantification with PXRD.
Our first experiments in this direction indicated that
phase transition did not occur when pure "- and $-
tegafur were ground separately without a solvent;
therefore, the initial sample preparation by grinding
of pure "- and $-tegafur did not promote phase tran-
sition and could not affect the results of quantitative
analysis.
Optimum Grinding Frequency Determination
Tegafur " and $ form mixtures with $ form weight
fraction from 2.0% to 0.0001% were ground at three
different grinding frequencies: 7, 10, and 15 Hz to
establish an acceptable grinding frequency. The low
intensity "-tegafur diffraction peak at 2θ 10.1◦ may
mask the $ form peak at 2θ 9.6◦ (see Fig. 2); hence,
the quantification of very small amounts of $-tegafur
may be distorted. To minimize the influence of this
" form diffraction peak, the $ form diffraction peak
area at 2θ 9.6◦ was calculated in the 2θ region from
9.0◦ to 10.0◦.
The recorded X-ray patterns and calibration curves
for all three grinding frequencies are shown in the
Figure 3. In the higher range of initial $-tegafur
weight fraction (up to ∼20%), all of the calibration
curves had an exponential nature, but in the lower
range of $ form mass fraction (<2.0%), the calibra-
tion curves of samples ground at 7 and 10 Hz frequen-
cies could be considered as linear. At the same time,
the conversion degree curve for samples ground at a
15 Hz frequency maintained an exponential nature
also in the lower range. Conversion degree depen-
dence on the initial $-tegafur weight fraction most
likely exhibits an exponential nature because the de-
gree of phase transition is more affected by the sur-
face area of $-tegafur, thus also the phase boundary
area, and less by the initial weight fraction of $-
tegafur. Theweight fraction of $-tegafur in the sample
is not linearly proportional to phase boundary area,
and therefore, the weight fraction after grinding does
not depend linearly on the initial weight fraction of
$-tegafur.
The calibration factor for samples ground at 7 and
10 Hz frequencies was equivalent to the linear slope
of the linear regression equation. The regression line
was described by the relationship y = ax, taking into
account the intersection with the origin. If the cali-
bration factor would be calculated from the equation
y = ax + b, in this case, the approximated line would
intersect y axis at nonzero value and that wouldmean
positive phase content at zero peak intensity (Ipeak =
0, when ω = 0), which is physically impossible. The
optimal linear slope with minimized slope error and
standard deviation Sn was calculated using MS Excel
function Linest.
Calibration equation for those samples groundwith
7 Hz frequency was y = (8.3 ± 0.4)x with correlation
coefficient R2 = 0.97 and standard deviation Sn =
1.1%, but for samples ground with 10 Hz frequency,
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Intensity (counts)
Figure 2. Powder X-ray diffraction patterns of pure "- and $-tegafur and calibration samples
with initial $ form weight fraction from 0.10% to 0.005% after grinding with 7 Hz frequency for
5 min in 20◦C.
the calibration equation was y = (35.1 ± 1.1)x with
the correlation coefficient R2 = 0.997 and standard
deviation Sn = 1.4%.
Experimental points for samples groundwith 15Hz
frequency could be described with the exponential
equation
T$,theor = T$;∞(T$;∞ − T$;0)e−kT$;initial (4)
where T$, theor was the theoretically calculated weight
fraction of $-tegafur after grinding, T$; ∞ was the fi-
nal weight fraction of $-tegafur when the phase tran-
sition had ceased, T$; 0 was the weight fraction of $-
tegafur after grinding when T$; initial = 0, k was the
phase transition rate constant, and T$; initial was the
weight fraction of $-tegafur before grinding. The MS
Excel Solver optimization software, based on the least
squaresmethod, was used to optimize Eq. 4 constants.
The following equation was thus obtained.
T$ = 96.6(1 − e−12.4T$;initial ) (5)
Experimental point dependence on the initial
weight fraction of $-tegafur (T$;initial) was empirical in
this case, and the exponential nature of experimental
curve may be considered as coincidence. The polymor-
phic phase transition rate depends on the mass tran-
sition rate from one phase to another19; therefore, it
may be considered that the main factor influencing
overall phase transition rate is related to the surface
properties of both phases.
If the weight fraction of $-tegafur in the sample
ground at 15 Hz frequency does not exceed 0.10%,
then it is possible to use a linear regression equation
y= (770.0± 0.1)xwith the correlation coefficientR2 =
0.995 and standard deviation Sn = 2.2%.
In the initial $-tegafur weight fraction region from
2.0% to approximately 0.05%, the best correlation
was achieved, when the samples were ground with
10 Hz frequency, but if lower thermodynamically sta-
ble form contamination in metastable form must be
determined, then the grinding frequency of 15 Hz is
preferred.
Optimum Water Additive Amount Determination
Tegafur " and $ form mixture with the $ form
weight fraction of 1.0% was ground with various
amounts of added water. The conversion degree was
Intensity (counts)
a b
(%)
y
R
y
R
Figure 3. (a) Powder X-ray diffraction patterns of pure " and $ tegafur and calibration samples
after grinding with 7 Hz frequency for 5 min in 20◦C and (b) conversion degree depending from
initial $ form weight fraction and grinding frequency.
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Figure 4. Conversion degree of ground (10 Hz, 5 min at
20◦C) 1.0% $-tegafur sample, depending on the added water
volume.
determined, depending on the volume of added water,
and is shown in the Figure 4. The sum of two empir-
ical equations (Langmuir and Cauchy–Lorentz equa-
tions; Eq. 6) was chosen to describe the experimental
data because there are no equations in literature that
would fit these experimental data:
T = dkV
1 + kV + f ×
1
B
[
b
(V − a)2 + b2
]
(6)
where T is the weight fraction of $-tegafur in the sam-
ples after grinding, V is the volume of added water
(mL), f is the contribution factor, a is the volume of
added water at which the highest conversion degree
was observed, b is the distribution width ratio, and d
and k are empirical constants.
Cauchy–Lorentz equation term or another statis-
tical “bell shaped” function was introduced into the
Eq. 6 to describe the grinding efficiency depending
on the volume of added water. A “bell shaped” statis-
tical distribution term was selected because surface
area determination experiments demonstrated (see
section Surface Area Determination) that the grind-
ing efficiency, and thus also the surface, is dependent
on the added water volume, matching a statistical
“bell shaped” distribution. Thus, if no water sorption
on the surface of tegafur occurs, the conversion de-
gree depends only on the grinding efficiency, which
depends on the amount of water added. Langmuir
equation term was introduced into the Eq. 6 to de-
scribe a phase transition occurring in the adsorbed
water layer on the surface of tegafur, and it is not
related to the phase transition promoted by grinding.
It was observed that samples with additive volume
of less than 0.06mL were free flowing powders after
grinding, but when the water additive volume was
greater than 0.06 mL, the samples formed thick paste
t
(%)
Figure 5. $-Tegafur weight fraction changes during re-
crystallization process of 1.0% $-tegafur sample after grind-
ing with 10 Hz frequency for 5 min at 20◦C with 0.20 mL
water additive.
and stuck to the grinding vessel walls. Water can
be considered as a lubricant in this process, and in-
creasing the volume of water additive above 0.06 mL
decreased the conversion degree, whereas at water
volumes below 0.06 mL, the conversion degree of $-
tegafur to "-tegafur increased.
Phase Transition During Sample Drying
The metastable phase " transforms to the thermody-
namically stable phase $ during a process involving
tegafur dissolution in water, followed by crystalliza-
tion (this process proceeds until the eventual evapo-
ration of the added water). The kinetic curve of this
process is shown in the Figure 5. The highest conver-
sion degree was observed for samples prepared with
0.06 mL of water (section Optimum Water Additive
Amount Determination), yet this experiment was per-
formed with 0.20 mL of water to extend the water
evaporation time and to enable acquisition ofmore ex-
perimental data. Experiments with smaller amounts
of water exhibited the same trend, but results were
less obvious. The kinetic curve can be described with a
kinetic equation T$ = 35.8 − 20.7 × e−0.063t (equation
constants were optimized with MS Excel Solver). Not
only an increase of $-tegafur signal was observed dur-
ing this process, but therewas also aminimal increase
of " form diffraction peaks indicating increasing crys-
tallinity of " form, or an increasing preferred orienta-
tion due to the fracture of crystals along certain cleav-
age planes. As can be seen in Figure 5, the conversion
degree of $-tegafur was highly dependent on sample
drying time; thus, for a precise trace amount quan-
tification, all samples should be dried for the same
duration (at least 1 h).
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Table 1. Surface Areas of Unground, Dry Ground, and with
0.06 and 0.12 mL Water Additive Ground (5 min, 10 Hz, 20◦C)
Samples
Sample Surface Area (m2/g)
Unground 13.4
Ground without additive 16.9
Ground with 0.06 mL water additive 18.3
Ground with 0.12 mL water additive 13.9
Surface Area Determination
Surface areas of unground samples, as well as sam-
ples ground without water, and with 0.06 and 0.12mL
of water were determined for estimating the impact of
water on grinding efficiency. The determined surface
areas are shown in the Table 1. The surface area of un-
ground 1.0% $-tegafur in mixture with "-tegafur was
13.4 m2/g, but the surface area of sample ground with
0.12 mL water was 13.9 m2/g, which indicated that
water volume above 0.06 mL did not improve grind-
ing efficiency, as discussed in section Optimum Water
Additive Amount Determination. The surface area of
the sample ground without water was significantly
higher than for the sample ground with a 0.12 mL
water additive. These differences can be related to dif-
ferent sample dispersion in the grinding vessels; dry
sample after grinding was homogenously distributed
in the grinding vessel, whereas the wet sample after
grinding was located on the mill walls. The maximum
surface area, hence the maximum grinding efficiency,
was achieved when phase transition during grinding
was stimulated with a 0.06 mL water additive.
CONCLUSIONS
We found that it is possible to determine down to
0.0005% of the thermodynamically stable form mixed
within a metastable form by using tegafur model ma-
terial. The amount of the thermodynamically stable
form after sample processing was proportional to its
initial weight fraction.
In $-tegafur weight fraction range from 2.0% to ap-
proximately 0.05%, the best correlation was achieved
when samples were ground for 5 min at 20◦C with
10Hz frequency. At lower weight fraction of $-tegafur,
the grinding frequency of 15Hzwas preferred. The op-
timum results were achieved when 0.06 mL of water
was added to 0.50 g of tegafur. A sum of Langmuir and
Cauchy–Lorentz equations could be used to describe
the change in conversion degree depending on the
added water volume. The indirectly determined sur-
face areas and the dependence of conversion degree
on water additive volume demonstrated that increas-
ing the added water volume above 0.06 mL did not
improve grinding effectiveness. Conversion degree of
$-tegafur was highly dependent on sample drying
time, and the recrystallization process could be de-
scribed with a kinetic equation T$ = 35.8 − 20.7 ×
e−0.063t.
This method is generally applicable when the sam-
ple has phases with similar particle properties, and
the peak intensity is not particularly dependent on
preferred orientation and perhaps line broadening
effects.
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Solvent  effects  on   tegafur  (5-ﬂuoro-1-(tetrahydro-2-furyl)uracil)  phase  transition  to   tegafur  during
grinding  with  solvent  additive,  as well  as  phase  transition  in samples  exposed  to  95%  relative  solvent
vapor  pressure  has  been  studied  in  this  research.  Samples  containing  0.5%  and 0.1%  of  tegafur  in    and
 tegafur  mixture,  as  well  as  samples  of pure  tegafur  were  ground  with  different  solvent  additives,
and  conversion  degrees  depending  on the  solvent  were  determined  using  PXRD  method.  Samples  with
 and   tegafur  weight  fraction  of  1:1 were  exposed  to 95%  relative  solvent  vapor  pressure,  and  phase
transition  rates  were  determined.  Solubility  of   tegafur,  solvent  sorption  and  desorption  behavior  on  olymorphism
egafur
orption
esorption
olubility
-ray powder diffractometry
and   tegafur  have  been  examined.
It was found  that the  conversion  degree  of  tegafur  to  tegafur  mainly  depends  on  solubility  of  
tegafur  in  the  relevant  solvent,  and  the  conversion  degree  to  tegafur  is  higher  in  such  solvents,  where
solubility  of   tegafur  is higher.  The  samples  ground  in  a ball  mill  with  solvent  additive  had  a  trend  of
phase  transition  dynamics  from    tegafur  to  tegafur  similar  to the  samples  exposed  to 95%  relative
solvent  vapor  pressure.. Introduction
Polymorphism is a well-known phenomenon, which is deﬁned
s ability of a compound to crystallize into more than one crystalline
orm that differs with molecule packing arrangements and/or con-
ormations within the crystal lattice (Brittain, 2009; Hilﬁker, 2006;
ippagunta et al., 2001). Most of active pharmaceutical ingredients
xhibit polymorphism, therefore it is a common Pharmacopoeia
equirement that active pharmaceutical ingredients in drugs must
xist in one, ﬁxed crystalline form. The thermodynamically sta-
le form is usually chosen for pharmaceutical use, but recently,
etastable forms are manufactured more often due to enhanced
issolution or bioavailability proﬁles and patent concerns (Brittain,
009).
It is known that grinding can promote phase transition
Boldyrev, 2006; Chieng et al., 2006; Lin et al., 2006; Otsuka and
aneniwa, 1986) of polymorphs, and solvent additive acceler-
tes the process even more (Shan et al., 2002; Trask et al., 2004,
005). In our previous experiments (Petkune et al., 2011) we devel-
ped a semi-quantitative analytical method for determining trace
mounts of the thermodynamically stable polymorphic form in the
ixture of thermodynamically stable and metastable polymorphic
∗ Corresponding author. Tel.: +371 26465235.
E-mail address: raitis.bobrovs@gmail.com (R. Bobrovs).
378-5173/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.ijpharm.2013.01.009© 2013 Elsevier B.V. All rights reserved.
modiﬁcations, where the amount of the thermodynamically stable
form was  increased by grinding samples with a solvent additive.
However, there is a lack of research on how solvents affect phase
transition of polymorphs during the grinding.
The purpose of this study was to investigate the effect of sol-
vent additive on phase transition of  and  tegafur and to take a
look at possible causes that could affect phase transition during the
grinding.
Tegafur (5-ﬂuoro-1-(tetrahydro-2-furyl)-uracil) (see Fig. 1) 
and  modiﬁcations were selected as a model material in this study.
Tegafur is an antitumor agent widely used in the treatment of
various malignancies, particularly gastrointestinal and breast can-
cers (Uchida et al., 1993). Over years , , ,  and  forms of tegafur
have been reported in pharmaceutical literature (Actin¸sˇ et al., 2006;
Needham et al., 2006; Uchida et al., 1993), but only  and  modi-
ﬁcations are used for therapeutic purposes.
2. Materials and methods
2.1. Materials
Commercial samples of  and  tegafur were supplied by JSC
Grindeks.
Used solvents – methanol, ethanol, n-propanol, 2-propanol,
n-butanol, n-pentanol, n-heptanol, benzyl alcohol, ethyl acetate,
n-propyl acetate, n-butyl acetate, 1,2-dichloroethane, chloroform,
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cetone, tetrahydrofuran, acetonitrile and toluene were supplied
y Merck and used without any further puriﬁcation. All of the used
eagents had a reported purity >98%.
.2. Methods
.2.1. Sample preparation
The entire batches of  and  tegafur used in experiments were
round separately for 3 min  to ensure the required sample homo-
eneity and to avoid preferred crystal orientation effects.
.2.2. Determination of solvent effect on phase conversion degree
uring grinding
A sample (10 g) of tegafur  and  form mixture, containing
.5% weight fraction of  form, was prepared from a 5.0% stock
ixture that was diluted to the required concentration. Samples
uring preparation were homogenized in a Retsch MM300 ball mill
Retsch GmbH, Germany) for 5 min  at 20 ◦C with 15 Hz shaking fre-
uency. The analytical balance (BOECO, Germany) had an accuracy
f ±0.0001 g.
The 0.20 g samples of prepared 0.5% mixture were each treated
ith 0.025 mL  of solvent and ground in the ball mill at 10 Hz shak-
ng frequency for 5 min. The solvents used in this experiment were
ethanol, ethanol, n-propanol, n-butanol, n-pentanol, n-heptanol,
sopropanol, benzyl alcohol, ethyl acetate, n-propyl acetate, n-butyl
cetate, 1,1-dichloroethane, chloroform, acetone, tetrahydrofuran,
cetonitrile and toluene. Prepared samples were dried in opened
rinding vessel for 30 min  at 20 ◦C after the grinding. Dried samples
ere packed into glass holders with a weight capacity of ∼150 mg
nd PXRD patterns were record.
.2.3. Determination of  ˛ tegafur solubility in the solvents used
Approximately 0.2 g of  tegafur was added to ∼12 mL  of solvent
n weighing bottle, and the prepared mixture was held at 30 ◦C for
8 h in a sealed weighing bottle and stirred occasionally to obtain
 saturated tegafur solution. The clear, saturated mixture (4.0 mL,
ithout any precipitate) was transferred to a clean, tared weighing
ottle with a pipet that was also held at 30 ◦C. The weighing bot-
le with the saturated solution was left to evaporate at 30 ◦C, and
hen the weighing bottle with the dry residue was weighed on ana-
ytical balance (BOECO, Germany, d = ±0.0001 g). PXRD pattern was
ecorded for the dry residue. Solubility of  tegafur was  determined
n all the previously mentioned solvents.
.2.4. Determination of solvent vapor effect on phase transition
Two samples (4 g each) of  and  tegafur mixture with weight
atio 1:1 were prepared. Samples were homogenized during the
reparation in a ball mill for 5 min  at 20 ◦C with 15 Hz shaking
requency. The prepared homogeneous samples were packed into
lass holders and PXRD patterns for initial mixtures and pure  and
forms of tegafur were recorded. The samples were placed in des-
ccators with 95% relative solvent vapor pressure at 30 ± 0.5 ◦C, andharmaceutics 443 (2013) 193– 198
depending on the transition rate, PXRD data were recorded at ﬁxed
moments.
Obtaining 95% relative solvent vapor pressure. To obtain a rela-
tive solvent vapor pressure of 95%, methanol, ethanol, n-propanol,
2-propanol, n-butanol, n-pentanol, n-heptanol and benzyl alco-
hol solution in glycerol were prepared, and acetone, acetonitrile,
ethyl acetate, n-propyl acetate, n-butyl acetate, chloroform, tetra-
hydrofuran, 1,2-dichloroethane and toluene solution in dimethyl
sulfoxide were prepared according to the Raoult’s law (Eq. (1))
X = po − p
po
= n
no + n (1)
where X is the solvent’s mole fraction in solution; po is the vapor
pressure of pure solvent; p is the solvent’s partial vapor pressure
over a solution; n represents the investigated solvent molar amount
in the solution; no is the moles of glycerol or dimethyl sulfoxide in
the solution.
Temperature control. Desiccators with the prepared solvent solu-
tions were placed in an air thermostat (Memmert, Universal Oven
UFB-500) at 30 ± 0.5 ◦C 24 h prior to sample insertion.
2.2.5. Solvent sorption studies
Solvent sorption experiments were performed in weighing
dishes at 30 ◦C by using pure  and  tegafur. The 0.20 g samples
of pure  and  tegafur were weighed in separate weighing dishes
with accuracy ±0.0001 g and placed in desiccators with 95% partial
pressure of the relevant solvents (see Section 2.2.4). Depending on
the sorption rate, samples were weighed at ﬁxed moments.
2.2.6. Solvent desorption studies
Desorption experiments were performed using completely
solvent-saturated samples from the sorption experiment
(described in Section 2.2.5). The 30 ± 2 mg  of solvent-saturated
samples were quickly placed (in less than 20 s) in aluminum
sample pan, and desorption experiments were performed using a
TG/DTA6300 EXSTAR6000 instrument with open aluminum sample
pans having internal diameter of 5 mm and height of 2.5 mm,
under dry nitrogen atmosphere with ﬂow rate of 250 mL/min
in isothermal conditions at 30 ◦C. Desorption rate was highly
dependent on mass of the sample; therefore samples with equal
mass were used. The highest possible mass (30 ± 2 mg) was  placed
into each sample pan to minimize the error of sample weighing
and to reduce the time of weighing (the sample holder was  simply
ﬁlled up to the edge). Mass changes were recorded every 0.5 s.
2.2.7. Karl Fischer titration
The water amount in solvents was  quantiﬁed by a volumetric
Karl Fischer titrator Metrohm 836 Titrando with one-component
system using HYDRANAL – Composite 5 (Fluka, Germany) as titrat-
ing solution. The mixture was calibrated against pure water.
The volume of solvents used in Karl Fischer titration was  5.0 and
1.0 mL  depending on the expected water content in solvents.
The water content (ωH2O) of sample was calculated using the
following equation:
ωH2O =
VKF · Weq · 100
Wsample
(2)
where VKF is the consumption of titrant (mL), Weq is the titer of
titrant (mg  H2O/mL) and Wsample is the weight of sample (mg).
2.2.8. PXRD analysis
Samples were analyzed with a Bruker D8 Advance powder X-raydiffractometer (Bruker AXS, Karlsruhe, Germany), equipped with a
PSD LYNXEYE detector. Measurements were performed with CuK
radiation (1.54180 A˚) at room temperature. The following condi-
tions were used: step-scan mode with a step size of 0.02◦; scan
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Table 1
Conversion degrees of 0.5% and 0.1%  tegafur mixture in  tegafur and pure 
tegafur during the grinding (5 min at 20 ◦C with 15 Hz shaking frequency), depending
on  the used solvent additive.
Solvent ω after grinding (%)
ω initial (%) 0.5%  0.1%  
Methanol HBD 100 82 <3
1,2-Dichloroethane AP 100 72 92
n-Propyl acetate AP 100 37 –
Tetrahydrofuran EPD 100 15 –
Ethyl acetate AP 100 13 13
Acetonitrile AP 100 6 8
n-Butanol HBD 100 3 <3
Acetone AP 100 <3 –
Benzyl alcohol AA 95 52 25
n-Butyl acetate AP 92 –
Ethanol HBD 86 –
Toluene AA 83 6
n-Pentanol HBD 57 –
n-Propanol HBD 57 –
Chloroform 44 42
2-Propanol HBD 31 –
n-Heptanol HBD 30 –Fig. 2. Powder X-ray diffraction patterns of  and  tegafur.
peed: 0.2◦/min; 2 range: 8.0–13◦; voltage: 40 kV; current: 40 mA;
ivergence slit: 0.6 mm;  anti-scattering slit: 8 mm.
Powder samples were packed into glass holders with a weight
apacity of ∼150 mg  and pressed by a clean glass slide to ensure
oplanarity of the powder surface with the surface of the holder.
he obtained diffractograms were analyzed with DIFFRAC.EVA (ver.
.0) software.
.2.9. Quantitative analysis of  ˛ and  ˇ polymorph mixtures
Majority of peaks in PXRD patterns of  and  tegafur is over-
apping, therefore only the most intensive, non-overlapping peaks
re used for quantiﬁcation (see Fig. 2).
The peaks at 2 = 12.1◦ for  tegafur and at 9.6◦ for  tegafur were
sed for quantiﬁcation with the individual peak area method. The 
egafur peak at 2 = 12.1◦ was used for quantiﬁcation even though
t is overlapping with a peak of  tegafur, because it is twice as
ntensive as the rest of the peaks for  tegafur and, thus, introduces
he smallest error in quantitative analysis, even if the area of 
egafur peak at 2 = 12.1◦ is subtracted from the total of mixture
eak areas.
The areas of the plotted peaks were calculated by using the
omputer program TOPAS 3, and weight fractions of  form were
alculated by using the Eqs. (3–5):
;% =
Smixture;9,6
S;9,6
× 100% (3)
;% =
(
Smixture;12,1 −
(
Smixture;9,6 × S;12,1/S;9,6
)
S;12,1
)
× 100%
(4)
 norm;% =
ω;%
ω;% + ω;%
× 100% (5)
here ω;%, ω; % are weight fractions of  and  forms; S; 9.6,
; 12.1 are peak plot areas for pure  form at 9.6◦ and 12.1◦;
, S are the peak plot areas at 9.6◦ and 12.1◦mixture; 9.6 mixture; 12.1
or the analyzed mixture; S; 12,1 is the peak plot area of pure 
orm at 12.1◦, and ω norm; % is a normalized weight fraction of the
 form.AP, aprotic polar; AA, aromatic apolar; EPD, electron pair donor; HBD, hydrogen
bond donors.
3. Results and discussion
3.1. Solvent effect on the degree of phase conversion during
grinding
Initially conversion degrees for samples containing 0.5% of 
tegafur in  and  tegafur mixture were determined, and a com-
plete conversion to  tegafur occurred when n-propyl acetate,
acetonitrile, ethyl acetate, 1,2-dichloroethane, acetone, tetrahydro-
furan, n-butanol and methanol were used as additives (see Table 1).
To ﬁnd out, which of these solvents promotes the  conversion to
 tegafur the most, samples containing 0.1% of  tegafur in  and
 tegafur mixture were examined. None of the solvents promoted
complete conversion to  tegafur in the case of samples containing
0.1% of  tegafur in  and  tegafur mixture with current grinding
conditions. Experiments with pure  tegafur were also performed,
to ﬁnd out if there might be any solvents that promote phase tran-
sition without any  tegafur seeds in the sample.
Our quantitative composition calculation method was not suit-
able for quantifying phases with weight fraction below 3% after
the grinding, so the results for samples, where  tegafur peak was
detected, but was not large enough to quantify, are given as “<3%”.
The most complete phase transition to  tegafur, for sam-
ples containing 0.1% of  tegafur, occurred when methanol or
1,2-dichloroethane additive was used – the weight fraction for 
tegafur increased during grinding from 0.1% to 82% and 72%, respec-
tively. The most marked decrease in conversion degree between
samples with the initial  tegafur content of 0.5% and 0.1% occurred
in those cases, when acetone or n-butanol additive was  used –
complete conversion was detected when samples with the initial
 tegafur content of 0.5% were ground, but when 0.1% mixture was
ground, only a slight increase of  tegafur content was detected
(less than 5%).
As we  can see, a 1,2-dichloroethane additive promotes almost
complete phase transition in all cases, even when pure  tegafur is
used. Similar situation can be observed when chloroform additive
is added, only then the conversion proceeds by ∼40%. This could be
related to a solvent structure that promotes only one polymorphic
form regardless of whether the seed crystals are added to a sample
or not. Conversion of pure  tegafur to  tegafur occurs due to
solvent structure factors, similar to those in crystallization (Allesø
et al., 2008). Hydrogen bond donor solvents do not promote phase
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Table 2
Solubility of  tegafur, solvent vapor sorption on the  and  tegafur, and phase
transition rates depending on the used solvent.
Solvents Solubility
(g/100 mL)
Sorption (×10−3 mol/g) k (days−1)
 
Tetrahydrofuran EPD 7.46 32.9 41.8 1.878
Acetonitrile AP 6.07 14.2 9.5 0.194
Acetone AP 5.11 18.4 69.5 2.167
Methanol HBD 4.86 2.5 2.3 0.073
Ethyl acetate AP 2.98 7.6 5.8 0.042
Ethanol HBD 2.78 0.75 3.3 0.019
1,2-Dichloroethane AP 2.43 8.4 4.6 0.049
n-Propyl acetate AP 1.62 0.90 0.62 –
n-Butanol HBD 1.16 1.5 1.9 0.015
n-Pentanol HBD 1.15 0.75 1.5 0.007
n-Butyl acetate AP 1.09 1.0 0.75 0.004
n-Propanol HBD 0.83 0.58 1.3 0.058
2-Propanol HBD 0.69 2.5 1.5 0.007
n-Heptanol HBD 0.59 2.5 1.1 0.007
Toluene AA 0.42 0.71 1.3 0.017
Chloroform AP0,0 EPD0,0 HBD 0.20 2.7 2.5 0.007
Benzyl alcohol AA – 1.2 1.2 0.033
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ransition of pure  tegafur, but both investigated aromatic aprotic
olvents promote phase transition of pure  tegafur, even though
hey do not ensure a complete phase transition for samples with
.5%  tegafur additive.
Changes in conversion degrees are not proportional from one
olvent to another when the initial weight fraction of  tegafur
hanges from 0.5% to 0.1%. For example, when acetone additive is
dded to a sample, conversion degree changes form 100% to less
han 3%, but when methanol additive is added, conversion degree
hanges form 100% to 82%. There is no clear understanding about
he causes of these differences, but it could be related to solubility
r dissolution rates of tegafur in the investigated solvents, or simply
ue to structural peculiarities of each solvent.
To ensure that phase transition is not stimulated by the water
mpurity in solvents, Karl Fischer titration was performed for all
sed solvents, and it was  determined that water amount in the
olvents did not correlate with the conversion degree to  tegafur.
The rest of the experiments were performed to ﬁnd out is there
ny relationship between conversion degree of  tegafur to  tega-
ur, solubility of  tegafur, solvent sorption and desorption behavior
n  and  tegafur.
.2. Determination of  ˛ tegafur solubility in several solvents
Solubility of  tegafur in a series of solvents (see Table 2) was
etermined to clarify, whether the conversion degree of tegafur
epends on  tegafur solubility in a particular solvent. Solubility
as determined only for  tegafur was, because in the investigated
amples  tegafur was present in large excess, and also the sol-
bility of  and  tegafur differ minimally at 30 ◦C, because it is
lose to the polymorphic transition temperature (∼36 ◦C) (Uchida
t al., 1993). Solubility of  tegafur in benzyl alcohol could not be
etermined, because this solvent did not evaporate completely and
ormed a thick paste of tegafur and some decomposition products.
It is evident that  tegafur dissolves better in polar solvents,
nd its solubility in nonpolar solvents is very low because of the
ack of possibilities to form hydrogen bonds between solvent and
egafur molecules. From solubility data we can see that there is no
elation between the type of solvents used (aprotic polar, electron
air donors or hydrogen bond donors) and solubility of  tegafur,
xcept that solubilities in aromatic apolar solvents were very low.0 1 2 3 4 5
Fig. 3. Ethyl acetate, acetone and tetrahydrofuran desorption curves from  tegafur.
Experimental data strongly suggests that the conversion degree
of  tegafur to  tegafur mainly depends on solubility of  tegafur
in the particular solvent – upon increase of solubility, the conver-
sion degree also increases. Most likely this is due to the fact that
phase transition occurs in solution, which is formed on particle
surface. The outer layer of tegafur particles dissolves in the sol-
vent, and seed crystals of  tegafur encourage crystallization of the
thermodynamically stable polymorph.
3.3. Solvent sorption studies
From experimental data it can be seen (see Table 2) that the sol-
vent sorption on  and  tegafur did not differ signiﬁcantly, and
the highest sorption was  observed for solvents, in which  tegafur
solubility was the highest. The greatest sorption was observed for
tetrahydrofuran, acetone and acetonitrile, but the lowest sorption
was with alcohols and toluene. The general trend is that aprotic
polar solvents with small molecules were better absorbed on tega-
fur surface, and that could be related to the fact that small molecules
with electron donor groups are suitable for hydrogen bond forma-
tion with the NH moiety of tegafur, thus promoting an interaction
between solvent and tegafur. In all cases except acetone, sorption
of aprotic polar solvents on  tegafur was  greater than sorption on
 tegafur, and in most cases hydrogen bond donors absorbed better
on  tegafur. Aromatic non-polar solvents exhibited low sorption
potential, and the differences between sorption on  and  tegafur
were minor.
3.4. Solvent desorption studies
As can be seen from ethyl acetate, acetone and tetrahydrofuran
desorption curves (see Fig. 3), desorption occurs in two  steps –
at the beginning part of the solvent is desorbed from the surface
of tegafur, and afterwards desorption progresses throughout the
volume of tegafur particles.
Solvent desorption from the surface can be associated with the
linear part of desorption curve. The next stage, after the initial
rapid loss of solvent, appears exponential and involves solvent
desorption from the entire volume. Solvent surface desorption
rate was compared by using the average desorption rate equation
 ˛ = dm
dt
(6)
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Fig. 4. Example of desorption rate calculation.
here  ˛ is desorption rate, m is sample mass, and t is time. An
bstacle to the determination of desorption rate was the posed by
he observation that the beginning of desorption curve cannot be
sed due to a possible desorption delay. The best way for avoiding
his problem could be to calculate desorption rate in the middle
f a desorption process, using a middle point calculated from
he sample mass before and after desorption, thereby preventing
rrors stemming from desorption delay and from imprecise end
oint determination (see Fig. 4). Desorption rates for both tegafur
olymorphs are shown in Table 3. Most rapid desorption from
 tegafur was observed in the case of tetrahydrofuran, acetone,
thyl acetate and acetonitrile – the same solvents that sorbed the
ost on  tegafur. The desorption rates of these four solvents
rom  tegafur were surprising, especially because sorption
f tetrahydrofuran and acetone on  tegafur is even greater
han on  tegafur. One of the possible interpretations on this
henomenon could be that  and  tegafur surfaces interact
ifferently with the investigated solvents. A similar situation was
bserved with n-butyl acetate, but in that case the desorption rate
as greater for  tegafur. Desorption rates of toluene, n-propanol,
-butanol and chloroform did not differ signiﬁcantly from  to
 tegafur.
.5. Solvent vapor effect on phase transitionIt is known that solvent vapors accelerate phase transition
Petkune et al., 2012; Trask et al., 2004), however it is not known if
he effect on solid phase transition is the same for solvent vapors
able 3
olvent desorption rate from  and  tegafur.
Solvent dm/dt (g/min)
 
Tetrahydrofuran EPD0,0 AP 958 36
Acetone AP 885 8
Ethyl acetate AP 612 23
Acetonitrile AP 437 27
Toluene AA 239 261
n-Propanol HBD 118 135
Chloroform AP 38 76
n-Butyl acetate AP 9 129
n-Butanol HBD 4 7
P, aprotic polar; AA, aromatic apolar; EPD, electron pair donor; HBD, hydrogen
ond donors.Fig. 5.  Tegafur weight fraction changes during sample exposure to 95% relative
vapor pressure of methanol, acetone and ethyl acetate.
and liquid solvent additives. For this purpose an atmosphere of sol-
vent vapor with 95% relative pressure was created by using the
same solvents as in the previous experiments. Phase transition
kinetic curves were recorded by using PXRD, and transition rates
were calculated as described in Petkune et al. (2012) (see Fig. 5).
Saturated solvent vapor atmosphere was not used to prevent
condensation and sample wetting with a condensed solvent. Mix-
ture with a weight ratio of 1:1 was  used because no phase transition
was observed for samples with only 0.5% of  tegafur.
Phase transition rates for samples exposed to solvent vapor
atmosphere with a 95% relative pressure are given in Table 2.
The general tendency matches the observations from solubility
and sorption studies – aprotic polar solvents with the smallest
molecules are the best promoters of this phase transition. Sorption
data indicates that phase transition is faster when solvent sorption
on the thermodynamically stable  tegafur is greater than that on
 tegafur.
In the case of ethyl acetate and n-propyl acetate there was  a
very high conversion degree, despite the low sorption and phase
transition rates in samples exposed to these solvents at 95% relative
pressure, indicating that the phase transition during the grinding
procedure is affected not just by solvents in gaseous state, but also
in their liquid state.
4. Conclusions
The results of this study demonstrate that the conversion degree
of metastable  tegafur to the thermodynamically stable  tega-
fur upon a grinding with solvent additive is highly dependent on
the solvent used. The most complete phase transition to  tegafur
occurs when methanol or 1,2-dichloroethane additive is used. The
conversion degree of  tegafur to  tegafur mainly depends on the
solubility of  tegafur in the relevant solvent, and the conversion
degree to  tegafur is higher in those solvents, in which the solu-
bility of  tegafur is higher. The conversion degree of  tegafur to
 tegafur does not correlate with the presence of trace water in the
investigated solvents.
Phase transition dynamics of  tegafur to  tegafur is in a good
agreement for samples ground in ball mill with solvent additive
and samples,that were exposed to 95% solvent relative vapor pres-
sure. The highest solvent vapor sorption is observed for solvents,
in which the solubility of  tegafur is the highest. Solvent sorp-
tion on both of the tegafur polymorphs does not differ signiﬁcantly.
The highest desorption rate from  tegafur is observed for solvents
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a  b  s  t  r  a  c  t
Desorption  behavior  of  8 different  solvents  from   and   tegafur  (5-ﬂuoro-1-(tetrahydro-2-furyl)uracil)
has  been  studied  in  this  work.  Solvent  desorption  from  samples  stored  at 95%  and  50% relative  solvent
vapor  pressure  was  studied  in isothermal  conditions  at 30 ◦C. The  results  of  this  study  demonstrated  that:
solvent  desorption  rate  did  not  differ  signiﬁcantly  for both  phases;  solvent  desorption  in all  cases  occurred
faster  from  samples  with  the  largest  particle  size;  and  solvent  desorption  in  most  cases  occurred  in  two
steps.  Structure  differences  and their  surface  properties  were  not  of  great  importance  on the  solvent
desorption  rates  because  the  main  factor  affecting  desorption  rate  was  sample  particle  size  and  sample
morphology.  Inspection  of the  structure  packing  showed  that  solvent  desorption  rate  and amount  of  sol-
vent  adsorbed  were  mainly  affected  by  surface  molecule  arrangement  and  ability  to  form  short  contactsolvent–surface interaction
olvent vapor
olvent monolayer
between  solvent  molecule  electron  donor  groups  and freely  accessible  tegafur  tetrahydrofuran  group
hydrogens,  as  well  as  between  solvents  molecule  proton  donor  groups  and  ﬂuorouracil  ring  carbonyl
and  ﬂuoro  groups.  Solvent  desorption  rates  of acetone,  acetonitrile,  ethyl  acetate  and  tetrahydrofuran
multilayers  from   and  tegafur  were  approximately  30  times  higher  than  those  of  solvent  monolayers.
Scanning  electron  micrographs  showed  that  sample  storage  in solvent  vapor  atmosphere  promotes  small
llizattegafur  particles  recrysta
. Introduction
Pharmaceutical compounds are mostly produced in deﬁned
rystalline forms that are commonly crystallized from solutions.
ost of the crystalline pharmaceutical ingredients possess the abil-
ty to form more than one crystalline form, and this property of
ubstances is called polymorphism. Polymorphs usually have dif-
erent, precisely known dissolution rates and bioavailability, but
rystal size and shape can affect these properties. Therefore, the
rystal shape is monitored during drug manufacturing process and
 lot of work in the area of crystal engineering has been devoted to
ontrolling the crystal habit and determination of crystal properties
Brittain, 2009; Hilﬁker, 2006; Vippagunta et al., 2001).
The solvent used for the crystallization of an organic compound
an have a large effect on the resulting crystal shape and morphol-
gy (Lahav and Leiserowitz, 2001; Schöll et al., 2006; Stoica et al.,
004; Weissbuch et al., 2005); therefore solvent effects on crys-
al surface have been comprehensively studied, and two theories
bout solvent and surface interaction effects on crystal growth have
een developed. One of them suggests that favorable interactions
etween solvent and speciﬁc crystal faces leads to reduced interfa-
ial tension, causing phase transitions and crystal growth at speciﬁc
irections (Bennema and Gilmer, 1973; Bourne and Davey, 1976).
∗ Corresponding author. Tel.: +371 67372576.
E-mail addresses: raitis.bobrovs@lu.lv, raitis.bobrovs@gmail.com (R. Bobrovs).
378-5173/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.ijpharm.2013.09.008ion  to larger  particles.
© 2013 Elsevier B.V. All rights reserved.
The second theory postulates that solvent adsorption on speciﬁc
faces inhibits their growth as removal of adsorbed solvent creates
an additional energy barrier for continued growth (Weissbuch et al.,
1991). Most of the research regarding solvent effects on surfaces has
been performed with solutions, but an identical situation should
occur in solvent vapor atmosphere as well.
In our previous works we explored the solvent vapor effects on
phase transition (Petkune et al., 2012) and solvent effects on phase
transition during grinding (Bobrovs and Actin¸sˇ, 2012; Petkune et al.,
2011), but no information about the exact phase transition mecha-
nism was  gained. In this research we  discuss the nature of solvent
and surface interaction using data from solvent desorption studies.
Tegafur (5-ﬂuoro-1-(tetrahydro-2-furyl)-uracil) (see Fig. 1) 
and  modiﬁcations were selected as a model material in this study.
Tegafur is an antitumor agent widely used in the treatment of var-
ious malignancies, particularly gastrointestinal and breast cancers
(Uchida et al., 1993). Over years, the , , ,  and  forms of tega-
fur have been reported (Actin¸sˇ et al., 2006; Needham et al., 2006;
Uchida et al., 1993), but only the  and  modiﬁcations are used for
therapeutic purposes.
2. Materials and methods2.1. Materials
Commercial samples of  and  tegafur were supplied by JSC
Grindeks (Latvia).
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The solvents (methanol, ethanol, ethyl acetate, n-butyl acetate,
cetone, tetrahydrofuran, acetonitrile and toluene) were supplied
y Merck (Germany) and used without further puriﬁcation. All of
he reagents used were certiﬁed >98% pure.
.2. Methods
.2.1. Sample preparation and fractionation
A sample (∼6 g) of  tegafur was ground in a mortar for 3 min
nd then gradually sieved through sieves with mesh sizes of 150, 75
nd 40 m.  Three fractions of  tegafur (∼2 g each) were obtained
ith the following particle sizes: 150–75 m;  75–40 m;  and less
han 40 m.  The same procedure was repeated for  tegafur.
.2.2. Obtaining 95% and 50% relative solvent vapor pressure
To obtain the relative solvent vapor pressure of 95% and 50%,
ethanol and ethanol solutions in glycerol were prepared, and
cetone, acetonitrile, ethyl acetate, n-butyl acetate, tetrahydro-
uran, and toluene solutions in dimethyl sulphoxide were prepared
ccording to the Raoult’s law (Eq. (1))
 = p
p0
= n
n0 + n
(1)
here X is the solvent mole fraction in solution; p0 is the vapor
ressure of pure solvent; p is the partial solvent vapor pressure
ver the solution; n represents the amount of used solvent in the
olution; n0 is the moles of glycerol or dimethyl sulphoxide in the
olution. Desiccators with the prepared solutions were placed in an
ir thermostat (Memmert, Universal Oven UFB-500) at 30.0 ± 0.5 ◦C
8 h prior to the sample insertion.
.2.3. Solvent desorption studies
Samples (∼50 mg)  of each fraction were placed into separate
 mL  vials and positioned in the prethermostated desiccators with
he prepared solvent mixtures for at least 72 h to obtain completely
olvent-saturated samples.
The solvent-saturated samples were quickly placed (in less
han 20 s) in aluminum sample pan, and solvent desorption was
ecorded using a SII TG/DTA6300 EXSTAR6000 (Japan) instrument
ith open aluminum sample pans having internal diameter of
 mm and height of 2.5 mm,  under dry nitrogen atmosphere with
ow rate of 250 mL/min in isothermal conditions at 30 ◦C. It was
bserved that desorption rate was highly dependent on mass of
he sample; therefore samples with equal mass were used. For fast
eighting of the equal amount of sample the sample holder eachime was ﬁlled up to the edge. The following technique allowed
o prepare the samples with mass 30 ± 2 mg  and to reduce the
ime of weighing. If sample weight after this procedure were out
f the range, procedure was repeated with fresh solvent-saturated0 5 10 15 20 25 30
Fig. 2. Acetonitrile desorption curve from  tegafur with particle size 40–75 m.
sample. During the experiment mass of the sample was recorded
every 0.5 s.
2.2.4. Determination of surface area
Surface area was  determined by a modiﬁed chromatograph
“Hrom 3”, detecting the amount of argon involved in a monolayer
adsorption–desorption process.
2.2.5. Calculations of crystal morphology
Predictions of crystal morphology from structure data were
done based on Bravais, Friedel, Donnay and Harker (BFDH) the-
ory using Mercury 3.0 (Macrae et al., 2008). Crystal structures of
both polymorphs were retrieved from the Cambridge Structural
Database (refcodes are BIPDEJ for  tegafur and BIPDEJ02 for 
tegafur).
2.2.6. Sample morphology studies
Particle morphology of  tegafur fraction with particle size
of less than 40 m before and after storage in 95% relative sol-
vent (acetone) vapor pressure for 72 h was  analyzed on a scanning
electron microscope Hitachi S4800 SEM (Japan) at an accelerating
voltage of 2.0 kV.
3. Results and discussion
Desorption process of several solvents from both polymorphic
forms of tegafur was examined to compare solvent–tegafur surface
interaction behavior. The solvent desorption experiment indicated
that in most cases desorption occurred in two steps (see Fig. 2).
There is no clear understanding on this phenomenon, but it could
be a case of classical monolayer and multilayer (with possible cap-
illary condensation) desorption. Solvent molecule desorption from
the top solvent multilayers can be associated with the beginning
of desorption curve (part I in Fig. 2), where rapid sample mass
decrease was detected. The next stage, after the initial rapid loss
of solvent, in most cases appeared exponential and involved sol-
vent monolayer desorption (part II in Fig. 2). Following experiments
were performed to get some understanding about these processes.
3.1. Surface area and relative sample surface coverage
Amount of each solvent necessary to form solvent monolayer
was calculated using determined surface area data (see Table 1),
adsorbed solvent mass and solvent molecule dimensions. Using
mass of solvent, adsorbed during sample storage in 95% relative sol-
vent vapor pressure, and theoretical mass of solvent in monolayer,
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If we take a look at sample surface areas (Table 1), it can be
een that the surface areas of samples with particle size 40–75 m
nd less than 40 m were almost the same for both polymorphs.
EM examinations shows distinct differences in particle size dis-
ribution for both fractions, therefore similar surface areas for both
ractions most likely are due to differences in bulk density – frac-
ion with smaller particles forms more dense sample, but fraction
ith larger particles forms less dense sample. These changes in the
ample density affects the effective/accessible surface area of the
ample and the greater bulk density for fraction with particle size
ess than 40 m causes the apparent reduction of the surface area
n the experimental measurement.
From relative sample surface coverage data we  see that the
mount of acetonitrile, tetrahydrofuran, ethyl acetate and acetone
dsorbed on the tegafur surface is enough to form at least solvent
onolayer and that the decrease of sample surface area increases
he relative sample surface coverage. These calculations shows that
mount of acetonitrile adsorbed on the surface is enough to form
p to 4 solvent molecular layers in the case of 75–150 m  tega-
ur sample, but adsorbed methanol amount is sufﬁcient to cover
p to 10% of the sample surface (for samples with particle size
5–150 m),  while adsorbed toluene, ethanol and n-butyl acetate
overs less than 3% of the sample surface.
The decrease of particle size from 75–150 m to 40–75 m
ncreases the relative sample surface coverage by about 20–40%,
ut particle size decrease from 40–75 m to less than 40 m
ncreases the relative sample surface coverage by about 5–15%. We
elieve that the observation that less solvent multilayers formed
n the smaller particles if compared to the larger particles, is
elated to previously mentioned differences in the bulk densities.
able 1
urface areas of  and  tegafur samples depending on particle size.
Polymorph Particle size (m) Surface area (m2/g)
 <40 12.4
40–75 12.2
75–150 5.9
 <40  14.8
40–75 12.8
75–150 9.2les stored in 95% relative solvent vapor pressure (madsorbed/mtheoretical).
Sample with the smallest particles (less than 40 m)  has
higher bulk density then the rest fractions and therefore effec-
tive/accessible surface area of this sample is lower than it would be
if all the samples had the same density. It is also possible that such
results could be due to the effective surface area decrease during
the solvent adsorption process because of sample recrystallization
and/or solvent sorption on the previous solvent layers; especially
for sample with particle size less than 40 m.
3.2. Solvent desorption rate
From solvent desorption curves desorption rate of used solvents
can be calculated using equation:
 ˛ = dm
dt
(2)
where  ˛ is desorption rate, m is sample mass, and t is time. Sol-
vent desorption rates for all solvents monolayers were calculated
from data points obtained 15 min  after experiment beginning, but
solvent desorption rate of the ﬁrst step (solvent multilayer) for
solvents which formed solvent multilayers – acetone, acetonitrile,
ethyl acetate and tetrahydrofuran – was calculated by using a
middle point from the sample mass before and after the desorp-
tion (shown in Fig. 2), thereby preventing errors stemming from
desorption delay and from imprecise end point determination. Sol-
vent desorption rates depending on tegafur polymorphic form,
particle size and the selected solvent for samples stored at 95% rel-
ative solvent vapor pressure are summarized in Fig. 4 (monolayer
desorption in Fig. 4A and multilayer desorption in Fig. 4B). No ace-
tonitrile and tetrahydrofuran monolayer desorption from  and 
tegafur were observed.
The general trend was  that desorption rates increased with
increasing particle size and there was no distinct difference
between desorption rates from both polymorphs. Faster desorp-
tion from the samples with the larger particles was  due to easier
solvent removal from the sample surface, which is favored by large
volume between particles where solvent can diffuse more eas-
ily if compared to sample with smaller particles. A lack of major
changes between both polymorphs indicated that differences in
crystal structure and surface properties had no great importance
on the solvent desorption rates, therefore the main factor affecting
desorption rate is sample particle size and morphology. Difference
in multilayer solvents desorption rates from samples with particle
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3.3. Solvent–surface interaction
Crystal morphology for both polymorphs was predicted in order
to understand on which of the crystal faces most of the solvent
time
time
A
B
Cig. 4. Desorption rates of (A) acetone, ethyl acetate, n-butyl acetate, ethanol, meth
ultilayers; depending on tegafur polymorphic form and particle size.
ize 40–75 m and less than 40 m in most cases was  considerably
ower than those for multilayer solvent desorption rates from sam-
les with particle size 75 to 150 m and 40 to 75 m just like the
urface areas of the analyzed samples.
Solvent desorption rates from  and  tegafur samples showed
hat desorption rates of acetone, acetonitrile, ethyl acetate and
etrahydrofuran from solvent multilayers were approximately 30
imes higher than those from solvent monolayers. Further experi-
ents with samples stored in 50% relative solvent vapor pressure
onﬁrmed that the higher desorption rates for tetrahydrofuran,
cetonitrile, acetone and ethyl acetate most likely were due to mul-
ilayer sorption. Thus, at 95% relative solvent vapor pressure the
ample surface was covered with tetrahydrofuran, acetonitrile, ace-
one and ethyl acetate as molecular multilayer, and the desorption
ates for molecules situated at the higher layers were much higher
han for molecules in direct contact with the surface. However, if
amples were stored in the same solvents at 50% relative solvent
apor pressure, then monolayer solvent sorption dominated and
nly partial surface saturation above the monolayer occurred. This
nformation was also conﬁrmed by sorption results, as the amount
f adsorbed solvent at 95% and 50% relative solvent vapor pressure
iffered 1.5–3 times for tetrahydrofuran, acetonitrile, acetone and
thyl acetate. This suggests that at 95% relative solvent vapor pres-
ure of acetone, acetonitrile, ethyl acetate and tetrahydrofuran, the
olvent sorption noticeably exceeded monolayer coverage, but for
-butyl acetate, ethanol, methanol and toluene the sorption on the
egafur surface was signiﬁcantly below monolayer coverage.
Schematically solvent desorption process from the surface and
ts effect on the desorption kinetics are illustrated in Fig. 5A shows
he solvent desorption process, the solvent molecules in mono-
ayer having a different interaction energy than the rest of the
olvent molecules (multilayer molecules), and two  separate solvent
esorption phases were observed (solvent molecules with higher
nteraction energy than the rest of the molecules are schemati-
ally represented by ﬁlled circles). From the solvents used, acetone
nd ethyl acetate exhibited such a desorption behavior. Desorp-
ion of acetonitrile and tetrahydrofuran differed from the rest of
he solvents by the absence of the monolayer desorption part (see
ig. 5B). This means that all of the adsorbed solvent molecules
ere energetically equal and the ground layer solvent moleculenteraction with sample surface was not signiﬁcantly stronger
han interaction between the solvent molecules themselves. Our
ssumption was that this phenomenon could be related to solvent
bility to form hydrogen bonds and other effective intermolecularnd toluene monolayers; (B) acetone, acetonitrile, ethyl acetate and tetrahydrofuran
interactions between solvent and surface, as well as between two
solvent molecules. Ethanol, n-butyl acetate, methanol, and toluene
desorption behavior is schematically illustrated in Fig. 5C. These
solvents were desorbed in one step like in the previously described
case; with the difference that in this case it was  a monolayer desorp-
tion.
The effect of the particle size and solvent vapor relative pressure
on desorption curve are summarized in Fig. 6, by illustrating that
solvent relative vapor pressure affects only the amount of solvent
adsorbed on the surface (Fig. 6A), but particle size affects the sol-
vent desorption rate, if the same amount of solvent was  adsorbed
(Fig. 6B).time
Fig. 5. Schematic depiction of solvent desorption behavior and solvent molecule
position on the surface.
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orption will occur. Predicted crystal morphologies can be seen in
ig. 7. Predicted  tegafur crystal has columnar morphology with
arge {0 1 0} faces, whereas the  tegafur crystal has prismatic mor-
hology with large {1 1 0} faces.
Predicted crystal morphologies were ﬁtted to sample crystals
bserved in scanning electron micrographs (see Fig. 8). This com-
arison showed that the same crystal faces dominated in the
alculated morphologies and in experimental samples; although
here were some differences in crystal shape at the crystal tips
especially for  tegafur). This was due to fact that small elongated
ig. 8. Comparison of sample crystal shape and predicted crystal morphology of (A)
 tegafur and (B)  tegafur samples with particle size 40–75 m.  White scale bar is
0 m.f Pharmaceutics 457 (2013) 110– 117
crystalline particles with irregular crystal tips were obtained by
breaking long needled  tegafur crystals during the grinding. Thus
it was possible to ascertain this coincidence of few dominant crys-
tal faces only for the fractions with the largest particles, as the
crystal shape irregularity increases by decreasing the particle size.
There were some more important differences between experimen-
tally observed and calculated crystal shape for  tegafur. Crystal
face family {0 2 0} was  noticeably larger in experimental crystals,
if compared with calculated ones; and smallest calculated crystal
faces, those with relative surface areas below 3%, cannot be dis-
tinguished in experimental samples at all. For the fractions with
smallest particles it was  almost impossible to discern any crystal
faces at all (see Fig. 11 in Section 3.4).
To get some understanding on the possible solvent–surface
interactions, packing diagrams of  and  tegafur at the crystal
faces with largest relative areas were modeled from crystal struc-
ture data using Mercury 3.0 (see Fig. 9). Theoretically largest crystal
faces of the  tegafur is of the families {0 1 0}, {1 0 0}, {0 0 1} and
{1 1 0} with relative areas 49.8%, 19.8%, 14.2% and 9.8% respectively,
but for  tegafur faces of the families {1 1 0}, {0 1 1}, {0 2 0} and
{1 0 1} with relative areas 64.4%, 12.8%, 10.4% and 8.2% respectively.
Inspection of the packing diagrams of  tegafur crystal struc-
ture revealed that {0 1 0} face family comprise regular pockets
on a molecular level and can be regarded as corrugated in two
dimensions (see Fig. 9A), but the rest of the face families were
comparatively smooth (see Fig. 9B–D).
We  may  therefore explain the solvent–surface interaction quali-
tatively as follows. The surface at the {0 1 0} faces exposes primarily
tetrahydrofuran rings, but electrophilic ﬂuorouracil group atoms
are situated at the bottom of these pockets (see Fig. 9A). Fluoroura-
cil group electrophilic atoms are acting as proton acceptors for the
proton donor groups of the solvent molecules and at the same time
electrophilic atoms of solvents are able to form short contacts with
freely accessible tetrahydrofuran group hydrogen atoms.
Common property for solvents, which formed relatively high
sample surface coverage – acetone, acetonitrile, ethyl acetate and
tetrahydrofuran, is that all of these molecules are relatively small
and they are able to ﬁt in these pockets on {0 1 0} faces and
they also have electron donor groups which can form weak inter-
molecular interactions. Acetone carbonyl group, ethyl acetate and
n-butyl acetate carboxylate groups, and tetrahydrofuran ether
group interacts with freely accessible tegafur tetrahydrofuran
group hydrogens and forms weak CH· · ·O interactions, but ace-
tonitrile cyano group forms weak C≡N· · ·H interactions. At the
same time alkyl parts of these solvents forms weak CH· · ·O and
CH· · ·F interactions with ﬂuorouracil ring carbonyl groups and ﬂu-
oro group. Sorption of tetrahydrofuran on the face family {0 1 0} is
also enhanced by the fact that tetrahydrofuran can “continue the
crystal structure” of the tegafur in this direction (see Fig. 10).
If we take a look at systems, where relatively low sample surface
coverage was  observed – n-butyl acetate, ethanol, methanol and
toluene, we  see that the main difference between these two  solvent
groups are that these solvents have weaker electron donor groups
than previously mentioned solvents and most likely this is the main
reason for mayor differences in solvent sorption–desorption behav-
ior. Another reason why toluene and n-butyl acetate falls in to this
solvent group must be the size of the solvent molecule. As pre-
viously mentioned, n-butyl acetate carboxylate group can interact
with proton donors of tegafur molecule, however the size of n-butyl
acetate alkyl part makes it difﬁcult to position the molecule com-
pletely in the pockets on {0 1 0} faces and therefore only part of the
molecules enters the pockets and therefore blocks the surface for
the rest of the solvent molecules.
Similar surface–solvent interactions are observed on other crys-
tal faces as well, with main difference that on crystal face families
{1 0 0}, {0 0 1} and {1 1 0} there are no such deep pockets where
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Fig. 10. Schematic comparison of adsorbed tetrahydrofuran and tegafur molecule
position and location on the (0 1 0) face of  tegafur. Dashed lines represents CH· · ·O
and  CH·  · ·F interactions.of  and  tegafur.
solvent molecules could be stabilized and therefore solvent desorp-
tion from these faces occur more rapidly than form face family
{0 1 0}.
The largest (theoretically)  tegafur face families {1 1 0} and
{0 1 1} are comparatively smooth (see Fig. 9E and F), but face fam-
ily {0 2 0}, which seems to be the largest in experimental crystals,
have somehow similar packing arrangement as {0 1 0} face family
of  tegafur (see Fig. 9G) – with regular pockets on a molecular level,
tetrahydrofuran rings exposed on the surface and electrophilic ﬂuo-
rouracil groups situated deeper in the pockets.
This relatively high degree of similarity of packing at the largest
crystal faces for  and  tegafur might explain why there were
almost no differences in the solvent sorption behavior for both
polymorphs.
3.4. Sample morphology changes during sample storageTegafur sample morphology studies with scanning electron
microscope were performed for the  tegafur fraction with par-
ticle size of 40 m and less. Scanning electron micrographs for
sample before and after the experiment (storage at 95% relative
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cetone vapor pressure for 72 h) are shown in Fig. 11. An accel-
rating voltage of 2.0 kV was chosen because of the high sample
harging.
Scanning electron micrographs show that the sample before
torage in solvent atmosphere consisted of small particle (<2 m)
gglomerates, but after storage there were almost no such particles.
his was due to Ostwald’s ripening – small particles with large sur-
ace, thus high surface energy, tend to reduce their free energy by
educing the ratio of surface to mass, and this occurs by recrys-
allization to larger particles. Another difference between samples
efore and after storage in solvent atmosphere can be seen if we
ake a look at the edges and faces of the large particles. The edges
f  tegafur particles were quite sharp and well deﬁned before
torage, but after storage became rounded and hardly visible. Dif-
erences could be seen also on the surface of large particles – after
he sample storage at 95% relative acetone vapor pressure the sur-
ace of the particles became rough and there are signs that tegafur
rystallized from the solution (see Fig. 11B). This experiment shows
hat minor changes in sample morphology occur during sample
torage, and actually sample with slightly different particle size and
orphology are analyzed during the experiment.
. Conclusions
The results of this study demonstrated that solvent desorption
rom  and  tegafur did not differ signiﬁcantly between these two
hases, and solvent desorption in all cases occurred faster from
amples with the largest particle size. Structure differences and
heir surface properties are not of great importance on the solvent
esorption rates and the main factor affecting desorption rate is
ample particle size and sample morphology.
Two different solvent desorption behaviors can be distinguished
epending on the solvent and surface interaction energy. If the sol-
ent and surface interaction was stronger than interaction between
olvent molecules, than multilayer and monolayer desorption was
bserved, but, if the adsorbed solvent molecules were of equal
nergy, then only one desorption phase was observed.
Solvent desorption rates of acetone, acetonitrile, ethyl
cetate and tetrahydrofuran multilayers from  and  tega-
ur were approximately 30 times higher than those from solvent
onolayers.
The largest crystal face families for  and  tegafur are {0 1 0}
nd {0 2 0}, respectively. Both of them comprise regular pockets on less; (A) before and (B) after sample storage at 95% relative acetone vapor pressure
a molecular level and can be regarded as corrugated in two  dimen-
sions. Solvent desorption rate and amount of adsorbed solvent were
mainly affected by the ability to form short contacts between sol-
vent molecule electron donor groups and freely accessible tegafur
tetrahydrofuran group hydrogens, as well as solvents molecule pro-
ton donor groups and ﬂuorouracil ring carbonyl groups and ﬂuorine
atoms.
Small tegafur particles recrystallized to larger particles during
sample exposure to solvent vapor atmosphere, and there were mor-
phological signs of tegafur recrystallization from solution on the
surface of the particles.
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www.rsc.org/crystengcommSolvent-mediated phase transformation between
two tegafur polymorphs in several solvents†
Raitis Bobrovs,*ab Linda Setonb and Andris Actiņša
This paper describes a study of the solvent-mediated polymorphic transformation (SMPT) of the metastable
α tegafur to the thermodynamically stable β tegafur in several solvents. Phase transformation in acetone,
ethanol, i-propanol, toluene, and water at 22 °C was described using the solid-state kinetic model P2;
the rate constants for this process were in the range from 0.028 min−1 to 0.0056 min−1. In all of the
employed solvents, an induction time was observed. Kinetic, solubility and scanning electron microscopy
data indicated that nucleation kinetics corresponded to a second-order power function and according to
the kinetic model, the nuclei growth rate was constant in the examined SMPT. Surface nucleation
was observed, and the possible nucleation mechanism was given. The phase transition rate depended
linearly on the difference between the equilibrium solubilities of α and β tegafur in the respective solvent,
i.e. supersaturation.Introduction
Different crystalline forms of the same molecular entity
are known as polymorphs. Polymorphism is a very common
phenomenon in chemical manufacturing, for example, in pig-
ments, food, and most of all in the pharmaceutical industry,1
where at least two-thirds of active pharmaceutical compounds
have more than one solid form.2–5 One of the tasks of the
pharmaceutical industry is to find and select the solid forms
with the optimal characteristics for the intended use, because
the solubility, dissolution rate, and bioavailability of drug
substances are influenced by polymorphism. Therefore, it is
a common requirement in the pharmaceutical industry that
a manufactured compound must be in one, strictly defined
crystalline phase.3,5 To ensure product stability, the thermo-
dynamically stable polymorph under ambient conditions
is normally chosen for manufacturing. However, due to
enhanced dissolution or bioavailability profiles, a metastable
form might be chosen for manufacturing. To ensure that
polymorphs do not transform over time, the polymorphic
stability must be evaluated with respect to ambient, storage,
and packaging conditions. The stability of polymorphs under
certain temperature and pressure conditions is defined bytheir free energy, with the most stable polymorph having the
lowest free energy under the given conditions.3–5
Crystallization is the most common method of chemical
compound isolation from solution on the manufacturing
scale, and it is governed by a combination of thermodynamic
and kinetic factors.3–6 Crystallization of polymorphs often
follows Ostwald's rule of stages,7 which postulates that crys-
tallization in a polymorphic system progresses from the
supersaturated state to the equilibrium state in stages. Thus,
according to Ostwald's rule of stages, the metastable form
should crystallize first and then the system should move
through each possible polymorphic structure before the ther-
modynamically stable polymorph crystallizes. In the majority
of cases, the thermodynamically stable polymorph under the
given conditions can be isolated; however, the solvent used
for crystallization can affect the crystallization outcome and
it might promote the crystallization of a specific metastable
polymorph. The metastable polymorph will attempt to trans-
form to the stable form if possible, therefore it is important
to study polymorphic transformation ‘reactions’ to determine
the factors influencing the outcome of polymorphic crystalli-
zation. One type of polymorphic transformation ‘reaction’
that has been drawing attention is solvent-mediated polymor-
phic transformation (SMPT).4,8–10 This is a process where the
metastable polymorph interacts with a bulk solvent phase
and gradually transforms to the more stable polymorph by
dissolution and crystallization. SMPT is interpreted as a
three-step process – dissolution of the metastable phase,
nucleation of the stable phase, and growth of the stable
phase.11,12 The driving force in this process is the difference
between the solubilities and the dissolution rates of both014, 16, 10581–10591 | 10581
Fig. 1 Molecular structure of tegafur Ĳ5-fluoro-1-Ĳtetrahydrofuran-
2-yl)pyrimidine-2,4Ĳ1H,3H)-dione).
CrystEngCommPaperpolymorphs, which consequently determines the supersatura-
tion level during the crystallization of the thermodynamically
stable form. SMPTs have been extensively studied over the
years;8,9,13–30 however, there are no comprehensive studies on
the choice of solvent in the SMPTs. Such studies might be
useful for the pharmaceutical industry in order to use SMPTs
in pharmaceutically active compound manufacturing. SMPTs
can be used to produce the thermodynamically stable poly-
morph if crystallization from a solvent gives a metastable
polymorph. On the other hand, if a metastable polymorph is
desired, knowledge of possible SMPTs of the respective sys-
tem is important, because there might be situations when
the metastable polymorph crystallizes and through unwanted
SMPT subsequently transforms to the thermodynamically
stable polymorph.
Here we study SMPT of the metastable α tegafur to the
thermodynamically stable β tegafur in several popular
solvents from different solvent classes: aprotic polar, ali-
phatic aprotic apolar, hydrogen bond donor and aromatic
apolar. Both polymorphs of tegafur are produced commer-
cially; therefore, knowledge of the SMPT of these polymor-
phic systems might be relevant for the pharmaceutical
industry. The pharmaceutically active compound used in this
research, tegafur Ĳ5-fluoro-1-Ĳtetrahydrofuran-2-yl)pyrimidine-
2,4Ĳ1H,3H)-dione) (Fig. 1), is an antitumor agent, which is
widely used in the treatment of various malignancies, partic-
ularly gastrointestinal and breast cancers.31 Over many years,
the α, β, δ, γ and ε forms of tegafur have been reported in the
pharmaceutical literature,31–33 but only the α and β modifica-
tions are used for therapeutic purposes.
1. Materials and methods
1.1. Materials
Commercial samples of α and β tegafur were supplied by JSC
Grindeks (Latvia). Acetone, cyclohexane, ethanol, i-propanol,
and toluene of analytical grade were purchased from com-
mercial sources, and deionized water (electrical conductivity
<0.1 μS) was prepared using an Adrona Crystal 5 system (Latvia).
Solvents were used without further purification. All of the
reagents used were certified >99% pure.
1.2. Methods
1.2.1. Solvent-mediated polymorphic transformations.
The SMPT was investigated in acetone, cyclohexane, ethanol,10582 | CrystEngComm, 2014, 16, 10581–10591i-propanol, toluene, and water. Slurrying was performed in
Erlenmeyer flasks, where 0.5 g of the α and β tegafur mixture
at a weight ratio of 1 : 1 was added to 5 mL of solvent and
suspended for 5 min, 30 min, 3 h, and 72 h at room
temperature (22 ± 1 °C). The mixture of α and β tegafur
was weighed using an analytical balance (BOECO, Germany,
d = ±0.0001 g) and homogenized by shaking for 5 min using
a Retsch MM300 shaker (Retsch GmbH, Germany) at a
shaking frequency of 10 Hz. Slurrying was performed using a
Biosan OS-10 orbital shaker (Latvia) at a stirring rate of
200 rpm.
The transformation of α tegafur to stable β tegafur was
monitored and quantified via ex situ powder X-ray diffrac-
tion (PXRD) analysis. Quantification of the polymorphic
composition of the dry residue was carried out as described
in section 1.2.3.
In order to assess the impact of sample suspension and
sample drying on the phase transition, comparison experi-
ments were performed, where α and β tegafur mixtures were
placed in glass PXRD sample holders (~0.2 g) and moistened
with appropriate solvents (100 μL) using a micropipette
(±0.3 μL). Sample compositions were quantified using PXRD.
Analogous experiments were performed with pure meta-
stable α tegafur to ensure that such treatment does not pro-
mote phase transition even for samples without β tegafur
impurities.
1.2.2. The kinetics of solvent-mediated polymorphic trans-
formations. Acetone, ethanol, i-propanol, toluene, and water
solutions (~100 mL) saturated with respect to α tegafur were
prepared by stirring excess α tegafur for ~3 h at 22 ± 1 °C.
The excess tegafur was filtered off and the clear solution was
used for SMPT. In order to ensure that the solution was satu-
rated with respect to α tegafur, PXRD patterns of filtrates
were recorded. Solution concentration was determined as
described in section 1.2.5.
SMPT kinetic experiments were performed at 22 °C in a
thermostated (an accuracy ±0.1 °C, Grant TC120, England)
glass flow-through cell (250 mL) with a magnetic stirrer. 1.0 g
of α tegafur (used as received) was added to the saturated
solution and the solid phase was monitored every 10 min for
a period of 2 h throughout the transformation. The stirring
of the slurry was stopped for 20 seconds to allow the
suspended solid particles to settle. Solid phase samples
(~10 mg) for polymorphic composition determination were
collected with a metal spoon from the suspension. The col-
lected solid phase was quickly filtered through 2–3 μm filter
paper using a glass filter funnel with a Büchner flask under
reduced pressure. The quantity of α tegafur in the sample
was monitored and quantified via ex situ powder X-ray dif-
fraction (PXRD) analysis. The PXRD patterns of dry samples
were recorded and analyzed as described in section 1.2.3.
The tegafur concentration in solution was measured every
20 to 40 min throughout SMPT. Samples for solution concen-
tration measurements were gathered at the same time as
solid phase samples for polymorphic composition determina-
tion were collected. Approximately 2 mL of the saturatedThis journal is © The Royal Society of Chemistry 2014
Fig. 2 Experimentally measured (black line) and calculated (grey line)
PXRD patterns of α and β tegafur polymorphs.
Fig. 3 Photomicrographs of α and β tegafur crystals.
CrystEngComm Papersolution was filtered through a 0.20 μm syringe filter and
then 1.00 mL of the clear solution was transferred to a pre-
weighed vial with a micropipette (±10 μL). The solution was
left to evaporate at room temperature, weighed and tegafur
solubility was calculated. Two parallel experiments were
performed.
1.2.3. The PXRD analysis. The samples were analyzed
using Bruker D8 Advance and Bruker D8 Discover powder
X-ray diffractometers (Bruker AXS, Karlsruhe, Germany)
equipped with a LynxEye PSD. Measurements were performed
with Cu Kα radiation (1.54180 Å) at room temperature. The
following conditions were used: step-scan mode with a step
size of 0.02°; scan speed: 0.2° min−1; 2θ range: 8.0°–20.0°;
voltage: 40 kV; current: 40 mA; divergence slit: 0.6 mm; anti-
scattering slit: 8 mm.
PXRD calibration was performed using mixtures of 5.0%,
10.0%, 20.0%, 50.0%, 80.0%, 90.0% and 95.0% β tegafur in α
tegafur (~0.3 g total sample weight). The mixtures were
weighed using an analytical balance and samples were
homogenized by shaking for 5 min using a Retsch MM300
shaker at a shaking frequency of 10 Hz. The powder samples
were packed into glass holders and pressed by a glass slide to
ensure coplanarity of the powder surface with the surface of
the holder.
Quantitative phase analyses were performed using funda-
mental parameter-based Rietveld software BGMN.34 Structure
data necessary for quantitative analysis were acquired from
the Cambridge Structural Database (CSD) with the reference
codes BIPDEJ for α tegafur and BIPDEJ02 for β tegafur.
PXRD patterns of calibration samples and samples
collected from experiments were recorded and analyzed
identically.
1.2.4. Scanning electron microscopy (SEM). SEM imaging
was performed using a Quanta 200 SEM (FEI, Holland)
system. Samples were initially gold-coated using a K550X
sputter coater (EMITECH, UK) and subsequently scanned
using an acceleration voltage of 5.0 kV at a working distance
of approximately 10 mm. SEM analyses were performed for
the same samples that were used for PXRD analysis.
1.2.5. Tegafur solubility measurements. An excess amount
of thermodynamically stable β tegafur was added to 15 mL of
acetone, cyclohexane, ethanol, i-propanol, toluene, and water,
and was left to stir overnight at 22 ± 1 °C. The saturated
solution was filtered through a 0.20 μm syringe filter and
then 10.0 mL of the clear solution was transferred to a pre-
weighed vial. The solution was left to evaporate at room tem-
perature, weighed and tegafur solubility was calculated. The
solubility of metastable α tegafur was determined identically,
except solutions were stirred for ~3 h at 22 ± 1 °C in order to
prevent phase transformation to thermodynamically stable β
tegafur. PXRD patterns of the filtrate were recorded to ensure
that the solubility of the desired polymorph was determined.
Two parallel experiments were performed.
1.2.6. Crystallographic face indexing. Crystallographic face
indexing was done by single-crystal X-ray diffraction using a
Nonius Kappa CCD diffractometer (Bruker AXS, Karlsruhe,This journal is © The Royal Society of Chemistry 2014Germany) with Mo Kα radiation (0.71073 Å) at 60 kV and
30 mA. Data were collected at room temperature. Face
indexing was performed using Collect software.35
2. Results and discussion
2.1. The characterization of starting materials
The α and β forms of tegafur were analyzed using PXRD and
were confirmed to have equivalent peak positions to those
simulated from crystal structure data (CSD, reference codes
BIPDEJ and BIPDEJ02) (Fig. 2). No impurities of other poly-
morphs or any contamination were detected in the starting
materials. A preferred crystal orientation was observed for α
tegafur because of its needle-like crystal morphology. Typical
crystal shapes of both polymorphs are given in Fig. 3.
Crystallographic information of α and β tegafur is given in
Table 1. The base motif of α and β tegafur crystal structures
is a tegafur molecule dimer with a R22(8) motif, where tegafur
molecules are connected via two N2–H⋯O7 hydrogen bonds
(Fig. 4). The dimers are not identical in both polymorphs,
because the crystal structure of α tegafur consists of twoCrystEngComm, 2014, 16, 10581–10591 | 10583
Table 1 Crystallographic information of α and β tegafur36
α tegafur β tegafur
System Triclinic Monoclinic
Space group P1¯ P21/n
a, Å 8.994(8) 11.891(5)
b, Å 16.612(9) 14.556(2)
c, Å 5.981(5) 5.062(1)
α, ° 86.40(6) 90
β, ° 94.06(15) 99.05(2)
γ, ° 80.29(8) 90
Z 4 4
Fig. 4 Crystal packing of (A) α tegafur and (B) β tegafur. Hydrogen
atoms are omitted for clarity.
Fig. 5 Dependence of the calculated β tegafur weight fraction (ωβ calc.)
upon the actual β tegafur content in the sample (ωβ actual). Statistical
probability p < 0.05.
CrystEngCommPaperconformationally different molecules (A and B), whereas β
tegafur has one molecule in its asymmetric unit and the
conformation of this molecule matches the conformation of
molecule B in α tegafur.37 Dimers in α tegafur are formed
between conformationally identical molecules; that is, one α
tegafur dimer is formed by two A molecules and the second
by two B molecules. Tegafur dimers in the α polymorph are
cross-linked by weak C5–H⋯O9 and C11–H⋯O8 hydrogen
bonds, whereas in β tegafur dimers are stabilized by weak
C5–H⋯O7 and C12–H⋯F14 hydrogen bonds. It is worth not-
ing that α tegafur dimers form between the same enantio-
mers (there are two enantiomerically and conformationally
different dimers), whereas β tegafur dimers form between
two enantiomerically different molecules.37 Crystallographic
face indexing of α tegafur crystals (see section 2.4) indicated10584 | CrystEngComm, 2014, 16, 10581–10591that crystal growth along the a axis is promoted. This is
because of the relatively easy tegafur dimer access to the
growing surface and the possibility of forming multiple weak
hydrogen bonds between F14, O8, O9 and C5–H, C11–H.
Hydrogen bonds in β tegafur are distributed more evenly and
they are stronger than those in α tegafur. The same groups
are involved in hydrogen bonding for β tegafur, with the dif-
ference that instead of C11–H hydrogen, C12–H forms a
hydrogen bond with the fluorine atom. Hydrogen bonding in
β tegafur enables cross-linked zigzag chains in the b direction;
however, no preferred crystal growth orientation is observed
for β tegafur.2.2. Quantitative phase analysis
The calibration curve of the α and β tegafur mixture is given
in Fig. 5. The homogenous composition of the analysed mix-
tures and the equivalent extinction effects for both poly-
morphs could ensure that the diffraction peak intensity of
each phase depends linearly on the phase weight fractions
in the sample.38 It is evident that the correlation was not
completely linear and the calculated content of β tegafur in
the samples was up to 2% higher than was actually weighed.
We believe that this was because of the preferred orientation
of α tegafur, different degrees of crystallinity for both poly-
morphs and possible microabsorption. Nevertheless, experi-
mental data can be described by the linear equation y = (1.02 ±
0.01)x with an R2 value of 0.9990. The method used was
found to be linear in the range of 0–100% with the limit of
detection (LOD) and limit of quantification (LOQ) calcu-
lated39 to be 3.0 and 9.2%, respectively. The method was
found to be precise with a relative standard deviation (RSD)This journal is © The Royal Society of Chemistry 2014
CrystEngComm Paperof 2.0%. Statistical probability ( p) used was p < 0.05. The
relatively high LOD, LOQ and RSD values obtained are
because of the fast scan speed (0.2° min−1) used in the experi-
ments. In order to maintain consistency, the scan speed used
for calibration was the same as that used for SMPT quantita-
tive analysis. The scan speed of 0.2° min−1 was chosen
because of the ability to provide fast PXRD measurements
necessary for kinetic SMPT studies.2.3. Solvent-mediated polymorphic transformations
Initially, SMPT experiments for the α and β tegafur mixture
with a weight ratio of 1 : 1 were performed to estimate the
approximate phase transition rate. The results of the slurry
bridging experiments showed that in all of the employed
solvents the metastable form converted into the thermody-
namically stable form. The weight fraction of β tegafur in the
starting material was 50 ± 2%. The weight fractions of β
tegafur in the samples after slurry bridging experiments with
various solvents are given in Fig. 6.
It is known3,5,40–42 that substantial phase transition from
one phase to another in a polymorph mixture can be
promoted even by solvent addition (without any external
influence). This is because both polymorphs of the substance
dissolve in the solvent added and then the stable polymorph
under the given conditions will crystallize. In order to evalu-
ate the impact of residual solvent on SMPT during drying,
experiments where samples were only moistened and dried
were performed. The weight fractions of β tegafur after
these experiments are given in Fig. 6 and are indicated as
“moistened/dried starting material”.
Experiments showed that phase transformation took
place over a period of time, which varied across the solvents
studied. Almost complete phase transition to the thermody-
namically stable β polymorph was observed in acetone,
ethanol, and water after only 5 min of slurrying. The phase
transition was slower in i-propanol and toluene, andThis journal is © The Royal Society of Chemistry 2014
Fig. 6 Weight fraction of β tegafur in the samples after slurrying a 1 : 1 m
ethanol, i-propanol, water, toluene, and cyclohexane. The dashed line (⋯
experiment, where no slurrying was performed and the sample was only m
dried starting material”).complete phase transition to the β polymorph was observed
only after more than 3 h of slurrying. Minor changes (<10%)
in the weight fraction of β tegafur were observed for samples
slurried in cyclohexane for 3 days. We believe that no or only
minor phase transition occurred in cyclohexane because of
its aprotic apolar nature and the negligible solubility of
tegafur in this solvent. It is also possible that the observed
negligible weight fraction changes in cyclohexane could be
related to sample homogeneity and accuracy of the PXRD
method (RSD = 2.0%).
As previously mentioned, the experiments where no slurry-
ing was performed, but instead the sample was only moist-
ened and dried were performed for comparison purposes.
This procedure gave a major increase in the weight fraction
of β tegafur for samples that were moistened with water and
toluene, but for samples that were moistened with acetone,
cyclohexane, ethanol, and i-propanol a minor increase in the
weight fraction of β tegafur was found. One of the explana-
tions for such results could be as follows. As previously
mentioned, SMPTs are considered as three-step processes
consisting of dissolution of the metastable phase, nucleation
of the stable phase, and growth of the stable phase. All of
these stages and hence the phase transition extent are
affected by the solvent and solid phase interaction time;
therefore, it is possible that phase transition extent was
affected by the solvent evaporation time. Acetone, ethanol,
and i-propanol are relatively volatile compared to water and
toluene, thus phase transitions in acetone, ethanol, and
i-propanol have less time to occur. In order to understand
solvent effect on studied SMPT and to find out factors affect-
ing this phase transformation, more detailed phase transfor-
mation kinetic experiments were performed.
2.4. The kinetics of solvent-mediated polymorphic
transformations
During our first SMPT kinetic experiments, we noticed that
the sample drying time has an impact on the extent of phaseCrystEngComm, 2014, 16, 10581–10591 | 10585
ixture of α and β tegafur for 5 min, 30 min, 3 h and 72 h in acetone,
) represents the weight fraction of β tegafur in the sample after the
oistened and dried at ambient temperature (indicated as “moistened/
Fig. 8 Weight fraction of β tegafur during the SMPT in acetone,
ethanol, i-propanol, toluene, and water at 22 °C, normalized to a state
where the transition to β tegafur is complete.
CrystEngCommPapertransition – samples dried at ambient temperature have
increased β tegafur content. This was because the thermody-
namically stable β tegafur crystallized from the saturated
tegafur solution that was sampled together with the solid
phase, i.e., phase transition to β tegafur not only occurred
during slurrying but also partially occurred during sample
drying. In order to avoid this effect, samples for SMPT kinetic
experiments were quickly filtered using a glass filter funnel
with a Bunsen flask under reduced pressure.
Kinetic experiments with cyclohexane were not performed,
since only negligible changes in the β tegafur weight fraction
during slurrying in cyclohexane were observed in the previous
experiments.
For further data analysis, it is worth mentioning that in
the previously discussed experiments, samples were treated
with pure solvents, but in kinetic experiments tegafur-
saturated solvents were used to analyze tegafur dissolution
effects.
The results of the kinetic experiments performed at
room temperature (22 ± 1 °C) represent a series of plots
documenting the composition of the solid phase during
SMPT, as detected by the PXRD method. Fig. 7 shows the
composition of the solid phase during the SMPT in acetone,
ethanol, i-propanol, toluene, and water. These data were
used to generate an additional data plot where phase transi-
tion kinetic curves were normalized to a state where a
complete transition to β tegafur was observed (Fig. 8). This
means that the phase transformation time throughout SMPT
was expressed in percents, where the beginning of SMPT in
each solvent was regarded as 0% and time necessary for
complete phase transformation was regarded as 100%. Using
this approach, we could compare the reaction rate and reac-
tion path in all of the solvents used. This figure clearly10586 | CrystEngComm, 2014, 16, 10581–10591
Fig. 7 Weight fraction of β tegafur during the SMPT from α tegafur to β te
added as a guide.demonstrates that the phase transition models were the
same in all of the solvents, and the only factor that changed
was the phase transition rate. An induction time was
observed at the beginning of phase transitions in all solvents.
We cannot clearly assure whether the observed delay of phase
transition is an induction time or it is the time necessary
for β tegafur crystals to grow; however, we believe that this
was the limiting step in investigated SMPTs. We see that
the induction times in all of the solvents were proportionallyThis journal is © The Royal Society of Chemistry 2014
gafur in acetone, ethanol, i-propanol, toluene, and water at 22 °C. Line
CrystEngComm Paperthe same – about 10% of the phase transition time. It is
worth noting that the LOD of our quantitative analysis
method was 3.0%, therefore the observed induction time
might be the time necessary to overcome this 3.0% range.
Solution concentration throughout SPMT remained at the
level of α tegafur solubility and started to decay only when all
α tegafur transformed to stable β tegafur (Fig. 9). This means
that the overall rate of consumption of supersaturation by β
tegafur crystal growth was lower than the overall rate of α
tegafur dissolution. This case is denoted as “nucleation–
growth controlled polymorphic transformation”.16
The induction time was followed by a gradual increase of
the thermodynamically stable β tegafur fraction. SEM analy-
sis of the sample, where β tegafur was first detected by the
PXRD method, revealed that the blocky β tegafur crystal was
in contact with the surface of α tegafur needle-like crystal
side faces (Fig. 10). Although it is possible that α and β
tegafur crystals simply agglomerated together during sample
filtration and drying, the fact that it was not possible to sepa-
rate these crystals without damaging them indicated that
β tegafur most likely nucleated epitaxially on the surface of αThis journal is © The Royal Society of Chemistry 2014
Fig. 9 Solution concentration (●) and weight fraction (○) of β tegafur
in the solid phase during the SMPT from α tegafur to β tegafur in
acetone at 22 °C. The dashed line (- - -) represents the solubility of
α tegafur; continuous line (—) represents the solubility of β tegafur.
Grey line added as a guide.
Fig. 10 SEM images of the solid phase of SMPT in acetone taken at
60 min. Scale bar: 40 μm.tegafur. These observed epitaxially driven polymorphic
transformations are common in SMPTs.8,9,14,21,23,25,43 The
surface of α tegafur here acted as a nucleation substrate for β
tegafur by either decreasing the solution–nucleus interfacial
energy by topographical contribution or by a crystal lattice
match.9 Surface nucleation might have also been a conse-
quence of a local lattice disorder or an amorphous region
that has a similarity to crystallizing β tegafur.8
In order to estimate the nucleation mechanism and
understand which α and β tegafur crystal faces were in
contact, crystal face indexing was performed for both poly-
morphs. Crystals, where β tegafur was in contact with α
tegafur (like those in Fig. 10), were not suitable for β tegafur
crystal face indexing, therefore individual β tegafur crystals
were indexed. Crystals for β tegafur face indexing were
collected at a period of 300 min, when individual β tegafur
crystals suitable for crystal face indexing were in the sample.
Appropriate β tegafur crystals were picked out from the phase
mixture. Face indexing of α tegafur crystals was performed
for samples collected at a period of 60 min.
SEM images showed that β tegafur nucleated on one of
the needle-like crystal side faces, while crystallographic face
indexing of the α tegafur crystal (Fig. 11A) indicated that
these faces were {001}, {011} and {010}. A visual comparison
of epitaxially nucleated β tegafur crystal morphology and
indexed crystal morphology (Fig. 11B) indicated that the crys-
tal face family {100}, {110} or {010} must be in contact with
the α tegafur surface. Intermolecular distance and molecule
alignment analysis along these faces revealed that there was
a good agreement at a molecular level between the {110} face
of β tegafur and the {010} face of α tegafur (Fig. 12), while no
match was observed along other crystal faces. A possible
lattice match between {100}, {110} and {010} faces of β
tegafur and {001}, {011} and {010} faces of α tegafur was
examined using EpiCalc Version 5.0 software.44 Lattice
matching calculations indicated that there was no lattice
matching between any of the studied faces (EpiCalc data
can be found in the ESI†).
However, it should be taken into account that crystal
surface molecules are not static – they change their position,CrystEngComm, 2014, 16, 10581–10591 | 10587
Fig. 11 Single crystal face indexing of (A) α tegafur and (B) β tegafur.
Fig. 12 Schematic model of β tegafur growing on the α tegafur (010)
surface. Hydrogen atoms are omitted for clarity.
CrystEngCommPaperarrangement and conformation,45,46 and therefore they could
arrange into a state which promotes the growth of β tegafur.
This means that the nucleation of β tegafur might be
favoured by surface molecule rearrangement. The {110}
surface of β tegafur and the {010} surface of α tegafur have
similar tegafur molecular arrangement at the surface and dis-
tances between tegafur dimers are the same for both poly-
morphs in relevant directions. Because of this, nucleation of
β tegafur on the {010} face of α tegafur might be initiated by
minor surface tegafur dimer displacement, conformation
change, and rotation. The strongest hydrogen bond donor
and acceptor groups are involved in dimer formation and
interactions between dimers are relatively weak. These weak
interactions at the growing surface are less efficient at
directing the orientation of an incoming dimer synthon and
therefore tegafur dimers at the surface are relatively mobile.
Fig. 13 shows that the tegafur dimer arrangement similar to
that in β tegafur could be achieved by minor α tegafur sur-
face molecule rotation. Such local lattice disorder would
spread and eventually thermodynamically stable β tegafur
would nucleate and continue to grow.
In order to quantitatively compare SMPT rates in different
solvents, experimental data were described with an appropri-
ate kinetic model. Solid-state kinetic models are theoretical,
mathematical descriptions of experimental data and are usu-
ally expressed as rate equations.47 Many solid-state kinetic
models have been developed based on certain mechanistic
assumptions, while other models are more empirical and
may have little mechanistic meaning. Models currently used
in solid-state kinetic studies are classified according to10588 | CrystEngComm, 2014, 16, 10581–10591
Fig. 13 Schematic representation of the tegafur dimer rearrangement o
atoms are omitted for clarity.their mechanistic features, such as nucleation, geometrical
contraction, diffusion, and reaction order.47 SEM imaging of
the studied SMPT revealed that the phase transition took
place on the solid phase surface (the phase transition was
heterogeneous); therefore attempts were made to describe
experimental data points with the most common solid-state
kinetic models.47 Evaluation of the observed phase transfor-
mation nature and crystal growth morphology indicated that
experimental data were in agreement with those for power
solid-sate kinetic models. The best correlation was observed
when the experimental data points were fitted to the power
model P2:
α = (kt)2 (1)
where k is the phase transition rate constant, α is the weight
fraction of β tegafur in the sample, and t is time. The correla-
tion of the experimental data with the theoretical model and
the phase transition rate constants in each solvent are given in
Table 2. Rate constants were calculated using MS Excel Solver
optimization software based on the least squares method.48,49
The power law model P2 used here assumes that the
nucleation rate follows the power law, while nuclei growth is
assumed to be constant.47,50,51 Nuclei and crystal growth was
constant, because it took place through crystallization from a
saturated α tegafur solution. The limiting step in nuclei
growth was the transport of the tegafur molecule to the crys-
tallization zone. Diffusion of tegafur molecules was expected
to occur at a constant rate throughout the phase transition,
because the studied phase transition occurred in solution,
which was saturated with respect to α tegafur (supersatura-
tion was constant during phase transformation). Taking this
into account, the nuclei growth rate can be assumed to be
constant. This means that the rate-controlling step in the
examined SMPT was nucleation. There are two scenarios for
nucleation.51 The first option is the simultaneous formation
of all nuclei; the second option is that nucleation occurs step-
wise, with nuclei forming over a period of time. SEM imaging
(Fig. 10) shows that β tegafur crystals, observed in the sample
where β tegafur was first detected, had deviations in the crys-
tal size. This indicates that nucleation in the examined SMPTThis journal is © The Royal Society of Chemistry 2014
n the α tegafur surface to initiate the growth of β tegafur. Hydrogen
Table 2 The P2 model rate constants for SMPT and correlation coeffi-
cients depending on the solvent used; the experiment was performed at
22 °C
Solvent Rate constant, min−1
Correlation with
the P2 model, R2
Acetone 0.028 0.92
Ethanol 0.023 0.96
i-Propanol 0.0090 0.92
Water 0.0065 0.98
Toluene 0.0056 0.98
Fig. 14 Correlation between the SMPT rate constant in acetone,
ethanol, i-propanol, toluene, and water and the difference between
α and β tegafur solubilities (Δsol.) in the respective solvent. Correlation
equation y = (0.72 ± 0.07)x + (0.005 ± 0.001); R2 = 0.97.
CrystEngComm Paperoccurred over a period of time. Besides, it is very unlikely that
all of the nucleation sites would have approximately the same
minimum reaction (phase transition) activation energy,
which would be necessary for simultaneous nucleation.
Clearly, nuclei formed first at the nucleation sites with the
lowest activation energy, and then nucleation gradually
spread to the other nucleation sites in an increasing activa-
tion energy order. Since nuclei and crystal growth was con-
stant, this nucleation behavior can be described with a
second-order power function.
The fact that the best experimental and theoretical data
correlation was observed for the 2-dimensional model indi-
cates that the phase transition rate most likely was propor-
tional to the surface area of the β tegafur crystals formed.51
With that said, we can conclude that in the examined SMPT,
nucleation of β tegafur crystals corresponds to a second-
order power function, their growth rate was constant, and the
phase transition rate was proportional to the β tegafur crystal
surface area.
Despite the fact that solubility and phase transformation
kinetic data suggested that this phase transformation was
limited by nucleation, the correlation between the SMPT rate
constant and the difference between α and β tegafur solubil-
ities in the respective solvent was observed: a faster phase
transition was observed for the samples slurried in solvents
where the difference in polymorph solubilities was high
(Fig. 14). This trend in the SMPT from α tegafur to β tegafur
was described by the equation:
k = (0.72 ± 0.07)Δsol. + (0.005 ± 0.001) (2)
where Δsol. is the difference between α and β tegafur equilib-
rium solubilities in the respective solvent, and k is the rate
constant for the SMPT in the same solvent. The correlation
coefficient was R2 = 0.97. This correlation means that the
driving force in the studied SMPT was excess concentration
above the equilibrium concentration of β tegafur, i.e. super-
saturation with respect to β tegafur. Supersaturation provided
the necessary driving force to overcome the energy barrier to
promote β tegafur nuclei and crystal growth.3 In this case,
supersaturation coincided with the difference between α and
β tegafur equilibrium solubilities in the respective solvent,
because the solution concentration throughout the phase
transformation was fixed at the equilibrium concentration of
α tegafur. Such a solution concentration profile also meansThis journal is © The Royal Society of Chemistry 2014that the driving force was constant throughout the SMPT.
Higher tegafur supersaturation in the solution promoted
faster phase transformation to the thermodynamically stable
β tegafur because of the increased degree of local organiza-
tion in the solution necessary for crystallization46 and the
faster tegafur molecule transfer to the crystallization zone
(molecules were relatively close). Absolute tegafur solubility
and the difference between polymorph solubilities depend on
the chosen solvent, however, the free energy (ΔG) difference
between polymorphs does not depend on the solvent.28 This
means that the overall driving force of phase transformation
was not dependent on the chosen solvent, and the SMPT rate
depended only on the difference between polymorph solubil-
ities (supersaturation). The only SMPT step that might be
affected by solvent choice was β tegafur nucleation.52–55
Tegafur molecules were solvated in the solution, similar to
the surface of molecular aggregates and crystals. In order to
nucleate and continue crystallization, tegafur molecules have
to be desolvated, and solvent molecules on the nuclei or crys-
tal surface have to be replaced by incoming tegafur mole-
cules. This process, most likely, was affected by the nature
of the solvent and its electron donor/acceptor properties,
because strong solute–solvent interaction would inhibit
desolvation and therefore nuclei growth, while weak solute–
solvent interaction would not have a significant impact on
nuclei growth.
3. Conclusions
The SMPT from α tegafur to β tegafur in acetone, cyclohex-
ane, ethanol, i-propanol, toluene, and water at 22 °C is nucle-
ation–growth controlled and can be described by the P2
power model. The rate constants for this process were in the
range from 0.028 min−1 to 0.0056 min−1. In all of the
employed solvents, an induction time (about 10% of the time
required for complete phase transition) was observed, indi-
cating that nucleation and/or initial crystal growth was theCrystEngComm, 2014, 16, 10581–10591 | 10589
CrystEngCommPaperlimiting factor for SMPTs performed in saturated solutions.
In the examined SMPT, the nucleation of β tegafur crystals
corresponded to a second-order power function, the nuclei
and crystal growth rate was constant, and the phase transi-
tion rate was proportional to the β tegafur crystal surface
area. Surface nucleation was observed in the studied SMPT.
Crystal habit investigation indicated that β tegafur nucleated
on the {010} face of α tegafur, and the {110} face of β tegafur
was in contact with the α tegafur crystal. The SMPT rate
depended linearly on the supersaturation level, i.e. the differ-
ence between α and β tegafur equilibrium solubilities in the
respective solvent.
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www.rsc.org/crystengcommThe reluctant polymorph: investigation into the
effect of self-association on the solvent mediated
phase transformation and nucleation of
theophylline†
Raitis Bobrovs,*ab Linda Seton*a and Nicola Dempstera
Little is known concerning the pathway of the crystallization of the thermodynamically stable polymorph of
theophylline, form IV. Here we study the reasons why the thermodynamically stable theophylline form IV
can be obtained only by slow, solvent mediated phase transformation (SMPT) in specific solvents, and
whether the presence of prenucleation aggregates affect the polymorphic outcome. Solution
concentration, polymorphic composition and morphology were monitored over time during the
transformation from form II to form IV in several solvents. NMR and FTIR spectroscopy were used to
detect prenucleation molecular aggregates present in the solutions. It was determined that theophylline
self-associates in solvents which are good H-bond donors and the presence of these aggregates hinder
the nucleation and phase transformation. SMPT from form II to form IV is a nucleation-growth controlled
polymorphic transformation, nucleation is most likely homogenous, and form IV crystals grow along the
(001) plane, forming plate-like crystals.1. Introduction
Polymorphism is a well-known phenomenon whereby a chemi-
cal compound may exist in more than one crystalline form, and
each of these forms displays different physical characteristics
such as density, melting point and solubility. Polymorphism is
of great importance in the pharmaceutical industry, because
these differences in physical properties among the polymorphs
can sometimes lead to apparent differences in drug processing,
formulation, and bioavailability. Therefore, it is a common
requirement in Pharmacopeia for active pharmaceutical ingredi-
ents to be produced in one fixed crystalline form, and for this
reason the thermodynamically stable form is generally preferred
for pharmaceutical production. However, a metastable poly-
morph may be preferred if the solubility and/or bioavailability
of the thermodynamically stable polymorph does not meet
required criteria.1–3 In such cases knowledge of the possible
phase transformation in a given polymorphic system is essential.
Theophylline – a methyl xanthine derivative (3,7 dihydro-1,3-
dimethyl-1H-purine-2,6-dione) is an example of a pharmaceutically
active compound that has been manufactured and used in ametastable crystalline phase (clearly, because of the lack of
comprehensive knowledge of the polymorphic landscape of
this compound) (Scheme 1). Theophylline is known to exist
in four polymorphic forms (I, II, III and IV), as a mono-
hydrate and a dimethyl sulfoxide solvate.4 Theophylline form
II is a metastable polymorph crystallized from most non-
aqueous solution at room temperature. It is kinetically stable
and was historically considered as the thermodynamically
stable polymorph, until form IV was presented5 and proved
to be more stable. The fact that the thermodynamically stable
theophylline polymorph was discovered only recently, is
because it does not crystallize directly from solution, and is
obtained only by slow, solvent mediated transformation
(SMPT) from form II in contact with solvent e.g. methanol,
2-propanol or chloroform.5 Theophylline form I has been
reported as the stable polymorph at higher temperatures,
whereas form III is highly metastable and has been obtained
only during the dehydration of monohydrate.6,7 Theophylline
monohydrate (referred to as form M) is a monoclinic channelCrystEngComm
ophylline (3,7 dihydro-1,3-
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View Article Onlinetype hydrate which has been shown to lose water, either in
low humidity or at temperatures above 353 K, to produce
form II.8,9 Theophylline has been screened for cocrystallization
and shown to produce co-crystals with a range of coformers;
many complexes formed between theophylline and acids (e.g.
oxalic acid, malonic acid, salicylic acid, sulfathiazole, acet-
aminophen, etc.) as well as bases (e.g. urea, benzylamine, phe-
nobarbital, etc.) have been summarized by Childs et al.10
The aim of this work is to understand why the thermody-
namically stable theophylline form IV can be obtained only
by solvent mediated transformation in specific solvents, and
to investigate the presence of prenucleation aggregates which
direct the polymorphic outcome of crystallization.
Hunter et al.11–13 and Davey et al.14,15 have shown that there
is a correlation between supramolecular aggregates in solution
and the solid state structure which subsequently crystallizes.
Early experiments16–19 on theophylline self-association provide
evidence that theophylline does self-associate in aqueous solu-
tion and the proposed aggregate is the theophylline dimer. The
theophylline dimer discussed in these studies is present in the
thermodynamically stable form IV, and theophylline mono-
hydrate, form M, which crystallizes from aqueous solutions.
Theophylline form II, the polymorph commonly crystallized
frommost non-aqueous solutions, does not contain this dimer
motif (crystal structures of theophylline polymorphs are
discussed in detail in section 2.1). Such behaviour raises two
questions: why does metastable form II crystallize from non-
aqueous solvents; what prenucleation aggregates are present in
non-aqueous solvents? In order to answer these questions, we
need to determine (a) does theophylline self-associate in other
solvents besides water, and, if it does, what is the nature of the
association, and (b) since the nucleation of form IV is kineti-
cally slow, does solution aggregation change over time?
2. Background
2.1. Polymorphism of theophylline
Crystal structures of theophylline crystalline forms relevant
for this research are shown in Fig. 1. In the form II structureCrystEngComm
Fig. 1 Crystal packing motifs in theophylline form II, form IV, theophyllinethe best hydrogen bond donor (N7–H) bonds to the best
hydrogen bond acceptor (N9),20,21 consistent with Etter's
rules,22 forming an R22(8) motif. The structure has two weak,
bifurcated C8–H⋯O13 hydrogen bonds. Theophylline mole-
cules are linked in chains and stacked along (010). This
catemer arrangement promotes crystal growth along the
molecular chains leading to an elongated crystal morphology.
Form IV has two molecules in its asymmetric unit,23 forming
a dimer with the R22(10) motif and connected via
(N7–H⋯O13) hydrogen bonds. The dimer is discrete and
only links to other dimers by weak interactions: C8–H⋯N9,
C8–H⋯O11, and by π–π stacking, forming a two-dimensional
network parallel to the (001). The dimer is similar to the
motif observed in the monohydrate and in a number of the-
ophylline cocrystals.10,21 The presence of this dimer motif in
the thermodynamically stable form IV and theophylline
monohydrate, considered to be the most stable structure in
an aqueous environment, may account for the thermody-
namic stability of this structural motif compared to the chain
motif of form II. In form M, two centrosymmetrically related
theophylline molecules form a dimer through two hydrogen
bonds (N7–H⋯O13).24 Theophylline dimers are connected by
water molecules through hydrogen bonds, forming parallel,
crosslinked chains, leading to two-dimensional hydrogen
bonded layers, parallel to (10−1) plane. Water molecules are
situated in channels along the a axis, where they form hydro-
gen bonds to the theophylline N9 atom. In theophylline
dimethyl sulfoxide solvate theophylline is hydrogen bonded
to the dimethyl sulfoxide molecule through an N7–H⋯OS
hydrogen bond.4 The packing consists of molecular chains
lying parallel to the (010), stacked by π–π interaction between
pyrimidine and imidazole rings, and weak hydrogen bonds
between dimethyl sulfoxide methyl groups and theophylline
carbonyl group (CDMSO–H⋯O13).
2.2. Solvent mediated phase transformations
Solvent mediated phase transformations (SMPTs) are com-
mon in polymorphic materials which often follow Ostwald's
rule of stages.25 The transformation proceeds by three stages:This journal is © The Royal Society of Chemistry 2015
monohydrate and DMSO solvate.
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View Article Onlinefirstly, the metastable polymorph in contact with solution
dissolves into the bulk. Secondly, the stable form nucleates,
and thirdly undergoes crystal growth. When complete, only
the stable form remains in solution. The thermodynamic
driving force is the Gibbs free energy difference between the
two solid structures, whereas the kinetic driving force is the
difference in the solubilities of the two polymorphs and thus
the level of supersaturation with respect to the stable
form.26–30
SMPTs are characterized by the phase transformation
time, induction time, and active phase transformation time.
The term “phase transformation” refers to the whole process
from the beginning of the experiment until the phase trans-
formation is complete; the initial period during which no
phase transformation product is observed is called “induc-
tion”; and the time from the point when thermodynamically
stable phase appears until the sample has been fully
converted is called the “active transformation phase”.31 All of
these parameters can be influenced by choice of solvent and
solution composition.2.3. Spectroscopic self-association studies
NMR spectroscopy is mainly used as a method for organic
compound identification and characterization; however NMR
methods have been demonstrated to be useful for the study
of molecular aggregation and self-association in solution. It
is possible to use solution NMR measurements to study
molecular association because 1H chemical shifts are sensi-
tive to changes in the local environment. Hydrogen bonding
between solute molecules and associate formation affects the
1H local environment and a result of this interaction is a
chemical shift displacement in the NMR spectrum.32–34
It is generally recognized that dimer and other associate
formation and their concentration are affected by solution
concentration – the more concentrated the solution, the more
dimers and other associates are present, therefore depen-
dence of 1H chemical shifts on concentration is analysed.
This approach has been used in numerous studies.35–44 Most
of the previous studies show a decrease in the 1H chemical
shifts with concentration increase, suggesting that the
analysed compounds are involved in self-association pro-
cesses. Upon self-association, 1H chemical shifts are
displaced to lower field due to proton deshielding – the bond
of the proton involved in self-association weakens, bond
length increases, stretching frequency decreases.45–49 The
limitations for 1H NMR self-association studies are that 1H
NMR shifts for nonexchangeable hydrogens only can be mea-
sured, and the NMR method has a limited sensitivity at the
low concentrations often necessary for initial self-association
studies.
In recent years, 1H NMR chemical shift displacement mea-
surements have been used to provide information on the
structure of prenucleation aggregates in the solution.50
Hunter et al.13,51 showed that the predictions from
concentration-dependent changes in 1H NMR chemical shiftsThis journal is © The Royal Society of Chemistry 2015agreed with the structures of dimers found in the corre-
sponding X-ray crystal structures.
Other magnetically active nuclei (13C, 15N and others)
involved in hydrogen bonding or aromatic stacking also show
displacement in chemical shifts upon concentration
changes.35,52–55
Theophylline self-association in aqueous solution has
been previously studied using NMR spectroscopy,17,18
partitioning between water and chloroform–isooctane mix-
ture,19 analytical ultracentrifuge;16 and in chloroform-D solu-
tion using IR spectroscopy.56 These studies suggest that the-
ophylline does self-associate in aqueous solutions and
chloroform-D solution; however there is no consensus
between these studies on the degree of self-association and
nature of aggregates present in the solution.
3. Results and discussion
3.1. Characterisation of solvent mediated phase
transformation
The SMPT of unprocessed commercial anhydrous theophyl-
line form II in methanol was investigated. Three parallel
experiments were performed, but for the sake of clarity only
one case is taken as an example of the whole set of experi-
ments to describe and discuss in detail the results obtained.
During the solvent mediated phase transformation quali-
tative and quantitative analysis of the solid phase were
performed using powder X-ray diffractometry (PXRD), Fourier
transform infrared spectroscopy (FTIR) and scanning electron
microscopy (SEM) methods; while the solution concentration
throughout the transformation was monitored using
ultraviolet-visible (UV/Vis) spectroscopy. The composition of
solid phase determined by PXRD method and solution con-
centration throughout SMPT is presented in Fig. 2. Results of
all three parallel experiments showed that the phase transfor-
mation from theophylline form II to form IV took ~6 to
8 days. Phase transformation had a considerable induction
time with a relatively high dispersion (4 to 6 days), while
the active phase transition (actual form IV increase in the
sample) consistently took ~2 days. Such behaviour, that
induction time for parallel experiments had a great variation,
while the active phase transition time in all cases was approx-
imately the same, suggests that the limiting step for this
SMPT is the nucleation of form IV. The main factors that
might affect the nucleation and hence the induction time are
discussed further.
The equilibrium saturation of the metastable form II was
reached ~3 h after the theophylline addition to methanol.
The concentration of the solution remained the same until
phase transformation was completed. Solution concentration
dropped to the equilibrium saturation of the thermodynami-
cally stable form IV within a few hours of the phase transfor-
mation being completed, indicating that, once all of the form
II in the sample had dissolved, form IV continued to grow
until the solution reached the form IV equilibrium concentra-
tion. This shows that the dissolution rate of theophyllineCrystEngComm
Fig. 2 Solution concentration (●), and weight fraction of the
theophylline form IV in the solid phase (○) during the solution
mediated transformation from theophylline form II to form IV in
methanol at 23 °C. The dashed line (—) represents the solubility of
theophylline form II, continuous line (—) – solubility of theophylline
form IV.
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View Article Onlineform II was faster than the growth of form IV and dissolution
was not the limiting step in the phase transformation. Such a
solution concentration profile and pronounced induction
period indicates that the SMPT was a ‘nucleation-growth con-
trolled polymorphic transformation’.57 The fact that phase
transformation is also growth limited was confirmed by the
time scale of the studied SMPT – most of the SMPTs
described in the literature take place within a few
hours,29,57–65 but here phase transformation took ~2 days
from the moment when form IV nucleated. This might be
due to low supersaturation, which provided the necessaryCrystEngComm
Fig. 3 SEM images throughout SMPT from theophylline form II to form I
scale bar, crystals of theophylline form IV indicated with blue colour.driving force to overcome the energy barrier and promoted
form IV crystallization.3 In this case, supersaturation is the
difference between the solubilities of form II and form IV.
The increase of the form IV content in the sample
exhibited an exponential nature – the amount of form IV
increased slowly in the initial stage and then accelerated.
Such behaviour suggests that the growth of form IV might be
limited by the surface area of form IV in the sample; hence,
the rate of SMPT increased as the crystal size (surface area)
in the sample increased. This assumption was consistent
with SEM imaging data, shown in Fig. 3.
It is known5 that theophylline form II exhibits a needle-
like morphology, while form IV crystallizes in hexagonal
plate-like crystals. These distinct differences in the crystal
shape allowed phase transition monitoring using microscopy
methods. SEM imaging of the solid phase throughout SMPT
(Fig. 3) revealed that during the first days, while no phase
transformation was observed, the only apparent change in
the solid phase was the agitation and Ostwald's ripening of
the theophylline form II crystals – small theophylline form II
crystals dissolved as growth occurred on the larger form II
crystal side planes (see Fig. 3, day 1 and day 3). Thus, larger
theophylline form II crystals grew at the expense of the small
particles. The reason for this process was the difference in
dissolution rate between small and large particles.66 Theoph-
ylline form IV crystals were first observed after 5 days, and all
observed hexagonal form IV crystals were approximately the
same size: ~40 μm in diameter and 1–2 μm thick. A similar
size for all observed form IV crystals suggests that they nucle-
ated simultaneously or in a very short time interval. Recent
studies60,65,67,68 show that surface nucleation dominates in
most of SMPTs, however in our case there was no clear evi-
dence of such behaviour. We believe that theophylline form
IV nucleated by homogeneous primary nucleation from satu-
rated solution because none of the observed form IV crystals
were clearly merged together with metastable form II.This journal is © The Royal Society of Chemistry 2015
V in methanol at 23 °C. Inset: time of sample gathering (days); 40 μm
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View Article OnlineMoreover, taking in to account that theophylline form IV
nucleated only after several days, homogeneous nucleation is
more likely as heterogeneous nucleation usually takes place
in shorter time scale due to lower energy barrier. Over time
form IV crystals grew significantly in 2 dimensions, forming
large, plate-like crystals. This growth pattern indicates that
the growth of the form IV was governed by the surface of the
crystal edges. Eventually, breakage of form IV crystals was
observed (day 6), which would lead to increased surface area
of the edge faces, where crystal growth was fastest, thereby
accelerating the crystallization rate of form IV.
Preferred form IV crystal growth directions were deter-
mined by the PXRD method. It is observed that the PXRD
pattern of form IV crystals after the SMPT have two very
intensive peaks at 12 and 23° 2θ (Fig. 4), suggesting that the
sample exhibits preferred orientation. Comparison of the pat-
tern with that simulated from the crystal structure revealed
that these intensive diffraction peaks arise from crystal
planes (002) and (004) – the multiple planes of the {001} face
family. Since plate-like crystals tend to lay down with the
dominant faces parallel to the PXRD sample holder, the most
intense diffraction should occur from this plane. It can there-
fore be concluded that the dominant face in the form IV crys-
tals obtained during SMPT is (001) and crystal growth
occurred almost exclusively along this plane. The reason for
such crystal growth behaviour is that there are no significant
intermolecular interactions in the c-direction of theophylline
form IV, whereas crystal growth along (001) plane is favoured
by hydrogen bonding and π–π stacking (Fig. 5).
Based on morphological observation, form IV crystal
growth perpendicular to (001) was observed only when phase
transformation was finished – during the SMPT the surfaces
of form IV crystal plane (001) were flat (Fig. 3, day 8.3),
whereas 2 days after the SMPT elevations on the surface ofThis journal is © The Royal Society of Chemistry 2015
Fig. 4 PXRD patterns of form IV obtained by SMPT inmethanol (solid line);
and simulated from crystal structure (dashed line).the form IV were observed because of crystal agitation (Fig. 3,
day 10). The crystal growth rate along (001) was considerably
higher than growth rate perpendicular to (001) during phase
transformation, likely to be because energy released on solu-
tion molecule attachment to growing crystal edge surface was
higher.69 When phase transformation was complete,
Ostwald's ripening66 took place and crystals tended to
achieve minimum total surface energy by reducing the crystal
surface area. Here, this means that crystals grew perpendicu-
lar to the large (001) plane at the expense of the crystal edges,
which dissolved more easily.66
Surface nucleation dominates in the majority of SMPTs,
therefore experiments with ground and lyophilized theophyl-
line as a starting material were performed to evaluate the
effect of the form II surface on the nucleation and crystalliza-
tion of form IV. There were no significant differences in the
phase transformation behaviour when ground and unground
theophylline was used. PXRD and SEM data showed that
when the ground form II was agitated, Ostwald's ripening
took place, and crystallization of form IV followed only after
6 days. If theophylline form IV nucleated on the surface of
the form II, the increase of the form II surface area in the
ground sample should reduce the induction time. However,
this was not observed, suggesting that form IV did not nucle-
ate on the surface of form II. When lyophilized theophylline,
confirmed as a mixture of amorphous theophylline and
microcrystalline form II, was used, no phase transition to
form IV was observed within the studied time (90 days). The
crystallinity of lyophilized material increased due to transfor-
mation of amorphous material to form II (Fig. 6), but no
phase transformation to form IV was detected. It is not clear
why crystallinity of the form II starting material should influ-
ence the nucleation of form IV since this is not a surface
nucleation process. Later experiments on water content (see
below) indicate that the ability of amorphous material to
absorb water might be more important than crystallinity.
In order to ascertain whether theophylline aggregates
present in the methanol solution affect the phase transforma-
tion, an experiment using methanol solution saturated with
respect to form IV as a solution medium was performed. The
SMPT held approximately the same induction and active
phase transformation time (5 and 2 days, respectively) as
experiments in methanol.
Similar experiments with theophylline form II and form IV
mixture ĲwII/wIV; 90/10) as a starting material were performed
to exclude induction time and observe only phaseCrystEngComm
Fig. 5 Crystal packing in theophylline form IV along (001) plane.
Hydrogens are omitted for clarity.
Fig. 6 SEM images throughout lyophilized theophylline slurrying in
methanol at 23 °C. Inset: time of sample gathering (days) and 20 μm
scale bar.
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View Article Onlinetransformation. No induction times were observed in either
case, and phase transformation rates were the same regard-
less of solution composition (Fig. 7). This means the molecu-
lar aggregates, if there were any at all, in both saturated solu-
tions were the same and/or they did not play a significant
role in the phase transformation. If we compare theophylline
form IV weight fraction change over the time in these experi-
ments and those performed with commercial form II as a
starting material, we see that active phase transformation
with theophylline form II and IV mixture as a starting mate-
rial occurs three times faster. It is possible that this phase
transformation rate mismatch is due to differences in the
form IV crystal active edge surface areas for the samples.
SEM imaging confirmed that form IV edge surface area in
prepared polymorphic mixtures were larger, than in the sam-
ple where the same amount of form IV was generated by
SMPT. Since this is the region in which growth of form IV
dominates, larger surface area leads to faster rate of growth,CrystEngComm
Fig. 7 Weight fraction of the theophylline form IV in the SMPT from
theophylline form II/form IV mixture ĲwII/wIV; 90/10) to form IV, in
saturated (○) form IV and (●) form II methanol solutions at 23 °C. Δ
represents the weight fraction of the theophylline form IV in the solid
phase during the SMPT from theophylline form II in methanol at 23 °C.
All kinetic curves are aligned to the point when solid phase of
respective SMPT contained 10% of form IV.therefore a faster transformation. It is also possible that in
the studied SMPT the initial nucleation is homogeneous, but,
once form IV is present, then secondary nucleation may sub-
sequently occur, leading to increasing transformation rate as
observed. By seeding with form IV in this experiment, the ini-
tial phase was skipped and form IV nucleated by secondary
nucleation. Secondary nucleation promoted faster phase
transformation by detachment of weak outgrowths of form IV
seed crystals or fragmentation of a weak polycrystalline form
IV mass.66
Seton et al.5 reported that theophylline equilibrium solid
phase depends on the water activity in the solution, and that
form IV is preferred when water activity in the solution is
below 0.69 ĲVMeOH/VH2O, 55/45). To investigate the possibility
that water activity also influences the phase transformation
rate to form IV, SMPT was observed in methanol samples
with different water contents. SMPT from theophylline form
II to form IV, performed in dried methanol and methanol/
water mixtures with volume ratios ĲVMeOH/VH2O) 99 : 1, 95 : 5
and 80 : 20, clearly showed that increased water in the solu-
tion increased the induction time (Fig. 8A). Given the sto-
chastic nature of nucleation, it can be difficult to draw con-
clusions from a few experiments, however, the three parallel
SMPT showed relatively good reproducibility and a clear
trend. Active phase transformation time also increased but
with a lesser effect – from 1.5 days in dried methanol to 5
days in methanol/water mixture ĲVMeOH/VH2O; 95/5).
These results might explain why fluctuation of induction
time were observed in the earlier SMPTs. Methanol used in
initial experiments was used as received and was taken from
different batches, therefore the water content (adsorbed from
the air) was not the same in all samples. Karl Fisher titration
showed that batch methanol contained ~0.2% of water,
whereas methanol dried with anhydrous NaSO4 contained
less than 0.1% water. These minor water impurities affected
the induction time of the SMPT. This might be the reason
why phase transformation with lyophilized theophylline as
starting material was hindered. Theophylline lyophilisation
resulted in partially amorphous theophylline, which tends to
absorb more water from the air than crystalline phases,70
and it is possible that the phase transition in this case was
slowed down by adsorbed water.
The induction times and transformation times in a range
of solvents were measured and compared (Fig. 8B). We see
that phase transition times correlated to induction times –
the longer the induction time, the slower the phase transfor-
mation. This might indicate that nucleation and form IV
growth were limited by the same factors. The solvents were
used as received and were from newly opened bottles. Water
doping experiments were not performed in the other sol-
vents, so further investigation would show whether induction
and transformation times were similarly affected in all
solvents.
It has been shown previously30 that in the nucleation-
growth controlled SMPT between α and β tegafur, the phase
transformation rate and induction time linearly depends onThis journal is © The Royal Society of Chemistry 2015
Fig. 8 Induction and phase transformation times of SMPT from theophylline form II to form IV at 23 °C depending on used solvent environment.
No phase transformation to form IV was observed in formic acid and methanol/water mixtures with 5% and 20% of water within the studied period
(40 days).
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View Article Onlinesupersaturation level, i.e. difference between solubilities of
the polymorphs. The difference in solubility of the two forms
in methanol is low, so supersaturation with respect to form
IV is always low. In formic acid, the solubility of form II is
high, (30 times that in methanol, see ESI†) which might
favour the metastable form according to Ostwald's rule.
Crystallization always gave form II, including crystalliza-
tion from solutions with form IV equilibrium concentration.
Even seeding with form IV, gave form II and form IV mixture.
Induction and phase transition times were longer in sol-
vents (solvent mixtures) which had good proton donor
groups. Fastest phase transformation and shortest induction
time were observed in dried methanol, followed by stock
methanol, acetonitrile and acetone. Longest induction times
were observed in proton donor solvents – chloroform and
formic acid, and previously discussed methanol/water mix-
tures. In fact, no form IV has been detected in formic acid
and methanol/water mixtures 95/5 and 80/20 within the stud-
ied period of 90 days. An influencing factor might be behav-
iour of solvated/aggregated theophylline molecules in solu-
tion. Theophylline molecules are solvated in the solution, but
in order to nucleate form IV and continue its growth, theoph-
ylline molecules have to be desolvated, and solvent molecules
on the nuclei or crystal surface be replaced by incoming
theophylline molecules. Taking in to account that induction
time was several days and phase transformation was very
slow, we can assume that solute–solvent interaction in stud-
ied SMPT was strong compared to solute–solute interaction
and thus the desolvation process inhibited form IV nucle-
ation and growth.
In order to further understand how the solvent environ-
ment affects SMPT rate and induction time, NMR spectro-
scopy was used to investigate for prenucleation aggregates in
the solution.3.2. Theophylline self-association studies
To understand solution chemistry and ascertain possible
aggregation of theophylline molecules in solution, theThis journal is © The Royal Society of Chemistry 2015influence of theophylline solution concentration on 1H NMR
chemical shift displacement was analysed. 1H NMR experi-
ments were carried out in seven solvents (methanol-D4,
chloroform-D, acetone-D6, dimethyl sulfoxide-D6, deuterium
oxide, acetonitrile-D3 and formic acid-D2). These solvents
were chosen because: (a) it is known that in dimethyl sulfox-
ide and water theophylline crystallizes as solvates and the
crystal structures of these solvates are not similar; (b) they
have different H-bond donor/acceptor properties: acetone,
acetonitrile and dimethyl sulfoxide are H-bond acceptor;
chloroform is H-bond donor; water, methanol and formic
acid are both – H-bond donor and acceptor; and (c) from
formic acid theophylline crystallizes into form II with no sub-
sequent transformation observed.
The concentration range covered in this experiment was
the same for all solvents – from saturated to 1 μM theophyl-
line form II solution. The number of scans for NMR spectra
acquisition was adjusted depending on solution concentra-
tion. Theophylline solutions with lower concentrations were
not studied because the NMR spectra acquisition time, neces-
sary to obtain spectra with acceptable signal/noise ratio,
would be unreasonably long.
The theophylline used in the experiment had natural 1H/2H
abundances and therefore the most acidic imidazolium group
proton (N7–H) took part in proton exchange with the deuter-
ated solvent deuterium atoms. As a result, the imidazolium
group proton was visible in the NMR spectra in solvents where
only partial proton exchange took place – chloroform-D,
dimethyl sulfoxide-D6 and acetonitrile-D3. Methyl group pro-
tons and alkene group proton (C8–H) did not showed any effect
on proton exchange.
If there are multiple structures that have different thermo-
dynamic stabilities and perturb the 1H NMR chemical shifts
in different ways, the shapes of the dilution curves differ for
different signals. While this does not rule out the possibility
of multiple structures, the data can be treated as a simple
two state equilibrium, and the complexation-induced changes
in chemical shift are assumed to relate to a single specific
aggregate structure.51 Since the solubility of the theophyllineCrystEngComm
Fig. 10 Theophylline dimer present in crystal structures of
monohydrate, form IV and most cocrystals (A); and the preferred
theophylline dimer according to Etter’s rules (B).
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View Article Onlinein all selected solvents except formic acid is low (>0.06 M)
multiple aggregate structures are not expected.
No chemical shift displacement upon concentration
changes were observed in methanol-D4, acetone-D6, dimethyl
sulfoxide-D6 and acetonitrile-D3. This means that no self-
association takes place in these solvents, or theophylline
undergoes dimerization or other self-association at concen-
trations lower than those covered in the experiment, i.e.
below 1 μM, and other agglomerates do not form in the con-
centration region studied. It is unlikely that self-association
occurs at such low concentrations, and it is probable that sol-
vated theophylline monomers were the main species in the
solution.
1H NMR dilution studies in chloroform-D, deuterium
oxide and formic acid-D2 showed large concentration-
dependent changes in chemical shifts. In the chloroform-D
all chemical shifts were displaced to lower fields as concen-
tration increased (Fig. 9A). In deuterium oxide methyl groups
1H chemical shifts were displaced to higher field while the
alkene group proton (C8–H) chemical shift was displaced to
the lower field (Fig. 9B). Imidazolium group proton (N7–H)
chemical shift was not observed in the deuterium oxide due
to proton exchange. In formic acid-D2 alkene group proton
(C8–H) chemical shift was displaced to higher field, whereas
imidazolium group proton (N7–H) chemical shift was
displaced to lower field (Fig. 9C). Minor methyl groups 1H
chemical shift displacement to higher and field were
observed as concentration increased. The pattern and magni-
tude of chemical shift changes are completely different in all
solvents, indicating that aggregates present in these solutions
are different. It is likely the associate existing in the deute-
rium oxide is the theophylline dimer which is also present in
the crystal structure of theophylline monohydrate (Fig. 10A).
The associates in chloroform-D solution might be the asym-
metric dimer corresponding to Etter’s rule (Fig. 10B), π–π
stacked dimer or some associate involving solvent molecules.
It is also possible, that chemical shift displacement is
reflecting the average structure of multiple aggregates. Since
theophylline solubility in formic acid is noticeably higher
than in other solvents (more than 30 times), it is possibleCrystEngComm
Fig. 9 Theophylline chemical shift displacement depending on chlorofor
Chemical shifts are indicated as: methyl group C10 protons (●); methyl gr
group proton (N7–H) (▲).that associates present in formic acid-D2 were oligomers and
not dimers. Data shows that theophylline concentration at
which associates were formed were different in each solvent.
In deuterium oxide theophylline formed self-associates at
10−4 M solution, in chloroform at 10−3 M solution, and in
formic acid-D2 at 10−2 M solution.
No change in chemical shift displacement was observed
with time (>20 days) in any studied solvents. Small scale
SMPT performed in methanol-D4 showed the same – solution
composition did not change over time; hence, no aggregates
are formed or disarranged during slurrying indicating that
this is not the reason for long induction times.
Theophylline aggregates formed in solvents which are
good proton donors.71 These were the solvents where SMPT
exhibited longest induction times and phase transition rates
(we should mention that SMPT in water does not occur,
because theophylline monohydrate is the most stable crystal-
line form in aqueous environments). Such correlation implies
that the presence of theophylline dimers or aggregates in the
solution hinders the nucleation and growth of form IV. It is
likely that the reason why good proton donors inhibit phase
transformation and extend induction time is the formation
of solvent molecule stabilized theophylline aggregates. Trask
et al.21 have suggested that the theophylline dimer motif is
favoured by the presence of a competing strong hydrogen
bond donor in the system (in this case formic acid, chloro-
form or water in methanol/water mixture). The strongest
hydrogen bond donor in theophylline solution forms aThis journal is © The Royal Society of Chemistry 2015
m-D (A); deuterium oxide (B); and formic acid-D2 (C) concentration.
oup C12 protons (○); alkene group proton (C8–H) (Δ); and imidazolium
Fig. 11 FTIR spectra of theophylline form II (solid line) and form IV
(dashed line), showing carbonyl group, alkene group hydrogen bond
and imidazolium group hydrogen bond stretching band assignment.
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View Article Onlinehydrogen bond with the system's most basic group – theoph-
ylline imidazole group nitrogen (N9). This bond fulfils the
‘best-donor–best-acceptor’ rule and consequently permits
theophylline dimer formation by secondary hydrogen bond-
ing (N7–H⋯O13). Such solvated theophylline dimer should
be the most stable aggregate in the solution, since it uses the
system's best donors and acceptors. This explains why
increasing water in the methanol sample increased induction
time and extended phase transformation time. The increase
of water in methanol/water mixture increased the level of
hydrated aggregates in the solution, and the more solution
theophylline molecules were bound in these dimers, the
more formation of form IV was hindered.
Solvated theophylline aggregates inhibit nucleation and
growth of form IV, either because they are not the correct
structure to nucleate form IV or because these associates
need to be desolvated or disarranged in order to crystallize. If
the solute solvent bonds are stronger than the weak inter
dimer interactions in the solid structure, then the desolvation
process is unfavourable and therefore phase transition is
slow. Recent work by Sullivan et al.72 shows that desolvation
is a significant factor in the nucleation process and can dom-
inate nucleation kinetics.3.3. FTIR studies of theophylline crystallization from
saturated solutions
It is known2,3,73–75 that FTIR spectra of polymorphs and their
solutions are different. Parveen et al.76 have shown that FTIR
spectroscopy can be used to show a direct relationship
between molecular self-associates in solution and motifs in
the subsequently crystallized solid phases. Here we use FTIR
spectroscopy to monitor theophylline crystallization from ace-
tone, acetonitrile, chloroform, methanol and water. FTIR
spectra of saturated theophylline solution were continuously
recorded during solvent evaporation and subsequent theoph-
ylline crystallization. FTIR spectra of both theophylline
polymorphs studied in this work are clearly different and
therefore suitable for such an experiment (Fig. 11). However,
due to low theophylline solubility in the selected solvents,
only the strongest carbonyl group stretching bands were visi-
ble in the initial spectra.
It is known77 that hydrogen bonding lengthens and
weakens the CO bond, therefore the carbonyl group
stretching band is observed at a lower frequency; thus the
stronger the hydrogen bonding, the lower the stretching fre-
quency. FTIR can be used to show hydrogen bonding of the
carbonyl group.78 This rule can be clearly seen in the case of
theophylline. Carbonyl group C2O11, which is not involved
in the hydrogen bonding in either polymorph (there are only
weak interactions with theophylline methyl group hydro-
gens), has an identical band position in the FTIR spectra
(1706 cm−1) and the stretching frequency is higher than that
of C6O13 carbonyl group. In form IV, the carbonyl group
C6O13 is involved in strong hydrogen bonding with the best
hydrogen bond donor (N7–H) and this results in a stretchingThis journal is © The Royal Society of Chemistry 2015frequency of 1640 cm−1; while in form II, the C6O13 group is
involved in two weak bifurcated C8–H⋯O13 hydrogen bonds,
stretching band is observed at 1664 cm−1.
Fig. 12 illustrates the carbonyl group stretching band posi-
tion and intensity changes during theophylline crystallization
from saturated form II solutions during solvent evaporation.
The stretching bands of other groups/bonds expected to
take part in self-association – alkene group hydrogen bond
and imidazolium group hydrogen bond – were not visible in
solution FTIR spectra due to low theophylline solubility in
the chosen solvents, and they were observed only when all
the solvent had evaporated. During the solvent evaporation
the intensities of all theophylline bands increased because of
increasing theophylline concentration in the solution. An
exception to this was the final part of crystallization from sat-
urated methanol solution, where theophylline carbonyl group
intensities decreased. For clarity these spectra are shifted by
y axis. Crystallization from acetone, acetonitrile, chloroform,
methanol and formic acid gave theophylline form II, and
water produced theophylline monohydrate. Intensive water
OH bending band was overlapping with both theophylline
carbonyl group stretching bands, therefore the crystallization
experiment from saturated water solution was not suitable
for studies.
The strongest carbonyl group stretching bands in theoph-
ylline solution spectra were observed in concentrated solu-
tion, whereas weaker spectral bands appeared only when the-
ophylline crystals emerged. In all solvents the most distinct
changes in theophylline band positions and intensities were
observed at the moment when solid theophylline emerged.
This was due to fact that, before the crystallization FTIR spec-
tra represented mostly solvated theophylline and theophyl-
line associates, whereas during the crystallization, spectra
were reflecting the average spectra of solvated theophylline,
multiple theophylline associates and crystalline theophylline.
The ratio of these species changed during the evaporation/CrystEngComm
Fig. 12 FTIR spectra of carbonyl group stretching band region during theophylline crystallization from saturated solutions upon solvent
evaporation at room temperature. Colour gradient shows FTIR spectra changes throughout crystallization (red – saturated solution, blue –
crystallization product). FTIR spectra of solid theophylline form II (dashed line) and IV (continuous line) are added for comparison purpose.
Acetone carbonyl group stretching band is marked with ▲.
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View Article Onlinecrystallization and therefore, the band position of functional
groups involved in these processes also changed. Finally,
when all solvent have evaporated, FTIR spectra of crystalline
theophylline was observed.
The position of C2O11 carbonyl group stretching band
in methanol, acetonitrile and chloroform solutions were the
same (1706 cm−1) and it coincided with the position of this
group in both polymorphs, therefore we can conclude that
this group was not involved in strong hydrogen bonding in
the solution (similar to crystalline theophylline) and the
nearby environment of this group was similar to that in both
polymorphs. The position of this stretching band in acetone
solution cannot be determined, as acetone carbonyl group
stretching bands overlaps with this carbonyl group stretching
band. The position of C2O11 carbonyl group stretching
band does not change during the crystallization from metha-
nol solution, whereas during the crystallization from acetoni-
trile and chloroform solutions the band shifted to 1720 cm−1
indicating a change in bonding. The final position of this
group stretching band does not match that in the solid form
II. FTIR spectra did not change within 5 h. Such band shift
to higher frequency indicates that hydrogen bonding was
weaker in the crystallized material than in solution. Crystalli-
zations from both solvents were repeated in larger scale.
PXRD showed that crystallization products were form II, and
FTIR spectra of obtained material coincided with form II
spectra. The reason why C2O11 carbonyl group stretching
band position in FTIR in situ experiment does not match the
position of this band in form II spectra might be related to
theophylline crystallization manner from acetonitrile andCrystEngCommchloroform. No distinct theophylline crystals were observed
on the FTIR spectrometer liquids plate after solvent evapora-
tion, meaning that theophylline crystallized as a thin film.
Such crystallization behaviour might promote monolayer
product along (100) plane, where this carbonyl group is on
the surface and it is not involved in any hydrogen bonding.
Consequently, C2O11 carbonyl group stretching band
would be shifted to higher frequency for such crystallization
product.
In saturated formic acid solution position of C2O11 car-
bonyl group stretching band was 1696 cm−1 and during the
crystallization it gradually shifted to the position of this car-
bonyl group in crystalline theophylline. This happened
because in the solution this carbonyl group was involved in
hydrogen bonding with formic acid proton, whereas during
the crystallization this hydrogen bond was disarranged.
Unlike C2O11 carbonyl group, the position of the
C6O13 carbonyl group stretching bands were not the same
in the methanol solution and crystallized material (Fig. 12A).
In the methanol solution the carbonyl group C6O13
stretching band was observed at 1656 cm−1, i.e. in between
the stretching bands of this carbonyl group in solid form II
and form IV. This suggest that the associates (dimers, aggre-
gates, solvated entities) in the solution were not the same as
in the solid phases and that the hydrogen bonding in the
solution was stronger than that in the form II and weaker
than that in form IV. From 1H NMR experiment we know that
there was no theophylline self-association in methanol, there-
fore we can conclude that the association causing band shift
must be hydrogen bonding between the carbonyl group andThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinemethanol –OH group proton. The changes of the C6O13
stretching band position were observed at the final part of
the crystallization and the band position shifted from 1656 to
1664 cm−1, which is the position of this band in theophylline
form II.
In chloroform, analogous C6O13 carbonyl group
stretching band shift were observed (Fig. 12D), with the only
difference that initially this band had two maxima – at 1656
cm−1 and 1648 cm−1. The band at 1656 cm−1 corresponds to
solvated theophylline species, analogous to those in metha-
nol, whereas the band at 1648 cm−1 most likely corresponds
to the dimer detected by NMR measurements. A similar situa-
tion was observed when theophylline crystallized from formic
acid; with the difference that in saturated formic acid solu-
tion a wide band in this region was observed. The wider car-
bonyl group stretching band must be a result of multiple
associates. The concentration of saturated formic acid solu-
tion was ~100 times higher than the concentration of satu-
rated chloroform solution, therefore it was expected that
associates formed were more complex than dimers and with
some diversity. Upon crystallization these agglomerates were
disarranged and desolvated, and the final position of
C6O13 carbonyl group stretching band matched the posi-
tion of form II.
Minor changes in the position of the C6O13 carbonyl
group stretching band were observed when theophylline crys-
tallized from acetone solution. This suggests that theophyl-
line hydrogen bonding did not change significantly upon
crystallization from acetone, at least as regards to this car-
bonyl group. The position of C6O13 carbonyl group
stretching band remained the same during the crystallization
from acetonitrile. Such behaviour points out, that this the-
ophylline carbonyl group does not form hydrogen bonds in
acetone and acetonitrile solutions, neither to solvent mole-
cules, nor to other theophylline molecules. It is understand-
able – acetone and acetonitrile are not proton donor solvents.
However it was expected that these solvents would compete
with the basic theophylline imidazole group nitrogen (N9) to
form a hydrogen bond with the most acidic theophylline pro-
ton (N7–H). NMR experiments showed that theophylline mol-
ecules in the acetone and acetonitrile solution are mono-
meric and self-association does not occur in these solvents,
meaning that species with solvated (N7–H) group dominated
in acetone and acetonitrile.
The same FTIR in situ crystallization experiment was
repeated with saturated form IV solution in methanol and
identical results were obtained, suggesting that there are the
same associates in the solution regardless of to which poly-
morph the solution is saturated.
4. Conclusions
The SMPT from theophylline form II to form IV is a very slow
nucleation-growth controlled polymorphic transformation.
Form IV nucleation is most likely homogenous and is slow.
Nucleation of and therefore induction of the phaseThis journal is © The Royal Society of Chemistry 2015transformation is hindered by solution aggregates. Form IV
crystals grow along the (001) direction, forming plate-like
crystals. SMPT induction times correlate to phase transition
times in studied solvents, indicating that nucleation and
form IV growth is limited by the same factors. Theophylline
forms associates in solvents which are good H-bond donors
i.e. chloroform, water and formic acid. There are the same
molecular aggregates in the solutions saturated with respect
to form II and form IV. The theophylline aggregates present
in solution do not change over time and therefore the long
induction time of form IV is not dependent on aggregation
kinetics. NMR and FTIR data suggest that the nature of
solution aggregates is solvent dependent, most likely linked
to hydrogen bonding character of the solvent.
5. Experimental section
5.1. Materials
Anhydrous theophylline was obtained from Sigma-Aldrich
and was certified >99% pure. Anhydrous theophylline was
confirmed to be form II and was used as received. Methanol
(HPLC grade), acetonitrile (HPLC grade), acetone (ARC grade)
and chloroform (HPLC grade) were obtained from Fischer
Scientific, formic acid (>98%) from Sigma-Aldrich. Solvents
were used without further purification. Distilled water was
used. Methanol-D4 (CD3OD, 99.8%), acetone-D6 Ĳ(CD3)2O,
99.9%), dimethyl sulfoxide-D6 Ĳ(CD3)2SO, 99.9%) and formic
acid-D2 (98%; <5% D2O) were obtained from Cambridge Iso-
tope Laboratories, deuterium oxide (D2O, 99.96%) from BDH
Chemicals, chloroform-D (CCl3D, 99.8%) from Euriso-top,
and acetonitrile-D3 (CD3CN, 99.8%) from Apollo Scientific.5.2. Preparation of theophylline crystalline forms
Theophylline form IV. Theophylline form IV was prepared
as described previously.5 An excess amount of anhydrous the-
ophylline (1.0 g) was added to 25 mL of methanol and stirred
at 600 rpm for 14 days at 23 ± 1 °C (temperature was con-
trolled because temperature deviations was found to hinder
form IV nucleation). The resulting solid phase was filtered
through a Buchner funnel under reduced pressure. The poly-
morphic form of the dry residue was confirmed using PXRD.
Theophylline form I. Anhydrous theophylline form II
(~1.0 g), was ground in a mortar with pestle for 3 min,
transferred to a petri dish, covered by a glass slide and
heated at 268 ± 1 °C for 2 h. The sample was cooled to
room temperature and the polymorphic form was confirmed
using PXRD.
Lyophilized (microcrystalline) theophylline. The excess
amount of anhydrous theophylline (~5.0 g) was added to
250 mL of water and was left to stir overnight. The solid phase
was removed by filtration and the remaining clear solution was
spray dried using a Buchi mini spray dryer B-290. A top spray
method was used with the inlet temperature set at 120 °C, the
outlet at 70 °C and the pressure at 6 bar. The crystallinity of the
material obtained was examined using PXRD.CrystEngComm
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View Article OnlineTheophylline monohydrate. The excess amount (~3.0 g) of
anhydrous theophylline was dissolved in ~100 mL of warm
water (~70 °C) and was left to stir overnight. The precipitated
solid phase was filtered, air dried and the crystalline phase
obtained was confirmed using PXRD.
5.3. Examination of solution mediated phase transformation
An excess amount (2.5 g) of anhydrous theophylline form II
(used as received) was added to 100 mL of methanol. The
suspension was stirred at 600 rpm for 14 days at room tem-
perature (23 ± 1 °C) and the following measurements were
performed every 7 to 24 h.
(a) Solution concentration monitoring. Theophylline con-
centration in the solution was measured every 1 h to 1 day.
The solution (~1 mL) was filtered through a syringe filter of
0.20 μm size, and solution concentration was determined as
described in section 5.7. Three parallel solution concentra-
tion determination experiments were performed.
(b) Crystallization product from solution. 2 mL of the solu-
tion was filtered through 0.20 μm syringe filter, transferred
to a Petri dish and was left to evaporate at room temperature.
Crystallized dry residue of three parallel experiments was
combined and phase composition was examined using
PXRD.
(c) FTIR spectra of the solution. ~0.3 mL of the filtered
solution was gathered as described above, and the FTIR spec-
tra of solution were recorded immediately after sample
gathering.
(d) Phase composition of the solid phase. The stirring of
the slurry was stopped 30 seconds prior to sample gathering,
to allow the suspended solid particles to settle. Solid phase
sample (10–20 mg) was collected with a metal spoon from
the suspension and was quickly filtered through Buhner fun-
nel filter under reduced pressure. The solid phase was exam-
ined using PXRD, FTIR and SEM.
SMPT was repeated in triplicate.
SMPT was additionally performed with different starting
materials and solvents (given in Table 1). Single runs wereCrystEngComm
Table 1 Starting materials and solvents used in SMPT
Starting material
Commercial form II
Form II, ground in mortar with pestle for 3 min
Lyophilized form IIa
Commercial form II
Commercial form II/form IVa mixture ĲwII/wIV; 90/10)
Commercial form II/form IVa mixture ĲwII/wIV; 90/10)
Commercial form II
Commercial form II
Commercial form II
Commercial form II
Commercial form II
Commercial form II
Commercial form II
Commercial form II
a Prepared as described in section 5.2. b Small scale experiment, Vtotal = 4performed for these experiments. The phase composition of
the solid phase was monitored every 1 to 7 days, except exper-
iments where form II and form IV mixture was used; the
phase composition in these experiments was monitored every
10 min to 1 h. The solvent and theophylline ratio in all SMPT
experiments were the same (2.5 g of theophylline and 100 mL
of solvent), except SMPT in formic acid, where 15.0 g of the-
ophylline were added to 25 ml of formic acid due to high the-
ophylline solubility in formic acid.
SMPT in methanol-D4 was performed for H1 NMR studies.
An excess amount (0.5 g) of commercial theophylline form II
was added to 4.0 mL of methanol-D. The suspension was
stirred at 600 rpm for 10 days at room temperature (23 ± 1 °C).
PXRD patterns of solid phase and solution H1 NMR spectra
(see section 5.9) were recorded each day. Stirring was
stopped 1 min prior to sample collection, and: (a) clear solu-
tion (~1 mL) was transferred to NMR tube; (b) solid phase
(10–20 mg) was collected with a metal spoon and quickly
filtered through a Buchner funnel filter under reduced
pressure. PXRD and H1 NMR measurements were performed
immediately after sample collection. Solution from NMR
experiment was returned back to the reaction vial immedi-
ately after recording the NMR spectrum.5.4. Determination of theophylline solubility
Theophylline form II solubility in acetone, acetonitrile, meth-
anol, chloroform and formic acid and form IV solubility in
methanol were determined as follows. An excess amount of
theophylline was added to 15 mL of solvent and was left to
stir overnight at 23 ± 1 °C. The saturated solution was filtered
through a 0.20 μm syringe filter and then 10.0 mL of clear
solution was transferred to a preweighed vial. Solution was
left to evaporate at room temperature, weighed and theophyl-
line solubility was calculated. The PXRD pattern of the filtrate
was recorded to ensure that the solubility of the desired poly-
morph was determined. Two parallel experiments were
performed.This journal is © The Royal Society of Chemistry 2015
Solvent
Methanol
Methanol
Methanol
Methanol saturated to theophylline form IV
Methanol saturated to theophylline form II
Methanol saturated to theophylline form IV
Methanol/water mixture ĲVMeOH/VH2O; 99/1)
Methanol/water mixture ĲVMeOH/VH2O; 95/5)
Methanol/water mixture ĲVMeOH/VH2O; 80/20)
Acetone
Acetonitrile
Chloroform
Formic acid
Methanol-D4b
.0 Ml.
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View Article Online5.5. Powder X-ray diffraction (PXRD)
Samples were analysed with a Rigaku Miniflex powder X-ray
diffractometer. Diffraction patterns within the 2θ range of 5°
to 40° were recorded at room temperature using Cu Kα radia-
tion at 1.54180 Å, with the following measurement condi-
tions: tube voltage 30 kV, tube current 15 mA, step-scan
mode with the step size 2θ = 0.02°, and the counting time
2 s per step. Diffractometer slits were set as follows: divergence
slit – variable; scattering slit – 4.2°, receiving slit – 0.3 mm.
Powder samples were packed into aluminium sample holders
and pressed by a glass slide to ensure co-planarity of the
powder surface with the surface of the holder.
Qualitative phase analysis. Reference powder patterns
were calculated with Mercury 3.3 (ref. 79) software from Cam-
bridge Structural Database (CSD) crystal structure data with
the reference codes BAPLOT for theophylline form II and
BAPLOT03 for theophylline form IV.
Quantitative phase analysis. The quantitative Rietveld
phase analysis were performed using BGMN software (version
1.8.6b)80 with Profex (version 3.1.1) interface. Crystal struc-
ture data previously mentioned were used for Rietveld
analysis.
5.6. FTIR spectroscopy
FTIR spectra were recorded using a Perkin-Elmer Spectrum
BX spectrometer fitted with a PIKE Technologies MIRacle
sampling accessory. MIRacle liquids plate was used when
spectra of solutions were recorded. The samples were
scanned at a resolution of 4 cm−1 between 4000 cm−1 and
600 cm−1. Each spectrum consisted of 16 co-added scans if
not otherwise stated.
5.7. UV/Vis spectroscopic solution concentration monitoring
Solution concentration throughout SPMTs in methanol was
monitored by measurements of the UV/Vis absorption at
272 nm using a Perkin-Elmer Lambda 25 UV/Vis spectropho-
tometer. Calibration was performed in the concentration
region between 0.2 mM and 0.01 mM (R2 = 0.99990). For
solution concentration determination 20 μL aliquot of fil-
tered reaction medium was diluted with 40 mL of methanol.
5.8. Scanning electron microscopy (SEM)
SEM imaging was performed using Inspect S SEM (FEI,
Holland) system. Samples were initially gold coated using a
K550X sputter coater (EMITECH, UK) and subsequently
scanned using an acceleration voltage of 5.0 kV at a working
distance of approximately 10 mm.
5.9. NMR spectroscopic self-association studies
1H NMR spectra were recorded as a function of theophylline
concentration in the solution. Experiments were performed
in methanol-D4, chloroform-D, acetone-D6, dimethyl sulfox-
ide-D6, deuterium oxide, acetonitrile-D3 and formic acid-D2
concentration region from nearly saturated solutions (1.0 MThis journal is © The Royal Society of Chemistry 2015in formic acid-D2, 0.050 M in methanol-D4, 0.015 M in ace-
tone-D6, 0.10 M in dimethyl sulfoxide-D6, deuterium oxide,
chloroform-D and acetonitrile-D3) to 1 μM solutions was cov-
ered. Ground anhydrous theophylline form II was used to
prepare the most concentrated solution in each solvent and
the rest of the solutions were prepared by subsequent dilu-
tion. Additional samples, where an excess amount of ground
theophylline was added to deuterated solvents, were prepared
to simulate suspensions similar to that examined in SMPT.
The mass of theophylline added was 120% of the mass neces-
sary to prepare saturated solution in the respective solvent.
An analytical balance (±0.1 mg) and micropipettes (±1 μL)
were used for solution preparation. NMR spectra of prepared
solutions were recorded right after solution preparation, and
repeated after 1 and 2 weeks. NMR tubes of prepared solu-
tions were closed with lids and sealed with parafilm. Samples
were stored at 20.0 ± 0.5 °C between measurements.
1H NMR spectra were recorded on a Bruker Avance
DRX 300 MHz spectrometer using residual solvent as an
internal standard. NMR spectra were recorded at 26.8 ± 0.5 °C
(300.0 ± 0.5 K).
Theophylline 1H chemical shifts were allocated by 1H-13C
HSQC according to literature assignments.81 1H-13C HSQC
experiments were carried out using the standard Bruker pro-
gram hsqcetgpsi2.82,83
5.10. In situ monitoring of crystallization process
Two drops (~0.07 mL) of saturated theophylline methanol,
acetone, acetonitrile, chloroform, water and formic acid solu-
tions from solubility determination experiments (section 5.4)
were placed on a FTIR spectrometer liquids plate and spectra
of the solution were continuously recorded during solvent
evaporation/theophylline crystallization. Each FTIR spectra
showed the average of 16 co-added scans, recorded in 75 s.
For acetone solution 4 co-added scans (recorded in 17 s) were
averaged. Spectra were recorded until three continuous spec-
tra were identical and no peaks of solvents were visible. The
experiment with each solvent was repeated in triplicate.
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